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1 INTRODUCTION 
The pandemic of the Human Immunodeficiency Virus (HIV) still represents a global 
challenge, although the United Nations Millennium Development Goal aiming to stop and 
begin to reverse the spreading of this disease by 2015, can be achieved. The last United 
Nations report presented a reduction in new infections and deaths resulting from HIV (UN 
2012). According to the last World Health Organization (WHO) report, the fight against 
HIV/AIDS is turning from an emergency to a long-term, sustainable response of delivering 
HIV services (WHO 2011). The major step was taken in 1996 with the combination of three 
antiretroviral molecules to a Highly Active Antiretroviral Therapy (HAART), which 
significantly extended life expectancy (Autran, Carcelain et al. 1997). Furthermore, 
therapeutic access is recommended and free of charge for people living with HIV (PLWHA) 
who reach a CD4-lymphocytecount under 350 cells/mm3 (WHO 2006). 
Currently, UNAIDS report a world count of PLWHA of34 (31.4 – 35.9) million of whom 23.5 
(22.1 – 24.8) million are living in Sub-Saharan Africa. The coverage of people in need of 
HAART has risen to 54% in countries of low and middle income (UNAIDS 2012). 
 
1.1 Problem Statement and Aims 
Natural products can provide a low-priced and sustainable strategy to stabilize the condition 
of PLWHA until they are entitled to HAART and additional support when the patients 
undergo lifelong therapy (Kuete 2010; Van Tienen, Hullegie et al. 2011). One natural 
nutrition supplement is an alga called Arthrospira platensis (Spirulina). Present on all 
continents, research, production, and commercialisation of this alga have risen in the last 20 
years. The use of spirulina in the cure of various diseases is a focus of interest. 
Research carried out in Asia and North America focused on its functional activity. Studies on 
animal models showed activation and mobilization of lymphocyte cells and regulation of 
transmitter proteins (Hayashi, Katoh et al. 1994; Qureshi, Garlich et al. 1996; Mao, J et al. 
2000). In vitro, aqueous extracts of spirulina containing polysaccharides and calcium (Ca-SP) 
have been found to capture numerous enveloped viruses, including herpes virus, 
cytomegalovirus, influenza, and HIV,  and prevent humans from infection (Hayashi, Hayashi 
et al. 1996; Ayehunie, Belay et al. 1998; Rechter, Konig et al. 2006). Those results and the 
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increasing production world widesss position Spirulina as a potentially valuable nutritional 
supplement (Belay 2002). Spirulina is currently sold – even to PLWHA – as a supportive 
treatment. 
The suggestion that Spirulina could act against viruses such as HIV is used for 
commercialisation of the supplement as a therapeutic agent. Furthermore, publications 
presenting algae as a natural equivalent to the chemical HAART indicates the need to collect 
comprehensive information about the effect of algae in patients infected with HIV (Teas, 
Hebertb et al. 2004; Thanh-Sang and Se-Kwon 2010). 
Point four of a WHO statement explains “there is a proliferation in the marketplace of 
unproven diets and dietary therapies with exploitation of fears, raising of false hopes, and 
further impoverishment of those infected and affected by HIV and AIDS” (WHO 2005). This 
observation shows the imperative need to elucidate the real effect of natural preparations 
such as spirulina that are already in use by PLWHA. 
1.2 Human Immunodeficiency Virus (HIV) 
The agent of the disease called Acquired Immunodeficiency Syndrome is HIV. The virus is a 
member of the lentivirus family, part of the retroviruses. The diversity of the virus in 
Cameroon is one of the highest in the world (Sharp and Hahn 2011). The viral history seems 
to be much older than commonly presumed, although it is known that indigenous 
populations of the Congo forest have gained mutations showing resistance against the most 
virulent type HIV-1 (Zhao, Ishida et al. 2012). In 2006, a relationship between the 
chimpanzee simian immune virus (SIV) and the pandemic sub-group major HIV-1 was found 
(Keele, Van Heuverswyn et al. 2006). The HIV viruses show a large diversity of types and 
subtypes. They can be divided in two types: HIV-1 and HIV-2. HIV-1 is more virulent and 
more common worldwide than HIV-2. The most prevalent type in Cameroon is HIV-1 at 80%. 
The major subtype M of HIV-1 is the most virulent subtype. The HIV-1 subtypes O and N 
represent only 1-5% of the infections in the country (Fonjungo, Mpoudi et al. 2000). HIV-2 is 
mostly present in western Sub-Saharan Africa. The subtype 2 stands for a direct infection 
from SIV sooty mangabeys (Lemey, Pybus et al. 2003). 
An HIV infection is a long, progressive decrease of the immune system. The clinical course of 
the infection is determined by a decrease in CD4 cells. A study of an urban African cohort 
found a mean time lapse of 7.6 years between infection and manifestation of the disease 
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(Zwahlen 2008). In Africa, the majority of PLWHA have no access to or still have no need for 
a lifelong antiretroviral therapy. In order to achieve a sustainable answer to HIV/AIDS and to 
reverse HIV spread by 2015, further patient services need to be implemented, structural 
barriers removed, and prevention, treatment, and care optimized (WHO 2011). 
 Diagnosis 
The infection with HIV is diagnosed by the presence of antibodies against the viral antigen in 
the blood. In case of a positive ELISA test, a western blot is done for direct detection of the 
virus. This method is highly specific, detecting the gp120 protein on the viral envelope. To 
confirm or discover discordance, a second blood sample is taken. Again, an ELISA is 
conducted, and the positive result is again re-confirmed via western blot (WHO 2006). 
The major markers for documenting the progress of the infection is the number of CD4 cells 
and the viral load (CDC 1987). The lymphocytes expressing the epitope CD4 are host cells for 
the virus. Their number declines, inducing a loss of cell-mediated immunity due to the 
intracellular multiplication of the virus. After the primary infection, the course of the 
infection is characterized by a long, stable phase that can last up to 10 years (Zwahlen 2008). 
The decline of CD4 lymphocytes can be progressive over the duration of the infection or 
come to an abrupt decrease after stagnation before the AIDS phase.  
The impairment of immunity in the asymptotic pre-AIDS phase has still not been completely 
elucidated. However, immunity loss is related to the number of CD4 cells, which is also the 
indicator for monitoring and evaluating the therapy (Mellors, Munoz et al. 1997). The 
threshold of a CD4 cell population below 350 cells per mm3 has been designated as the start 
for HAART therapy by the WHO. CD4 fluctuation in a patient over a day can be important 
and needs to be assessed by an additional marker (Hughes, Stein et al. 1994). CRP and CD38 
have been postulated as monitoring markers for the stage of the infection or the effect of 
the therapy (Graham, Baeten et al. 2007; Nixon and Landay 2010). 
Several studies have implemented the CD38 expression on CD8 cells as an intervention 
efficiency marker (Wilson, Ellenberg et al. 2004; Gil, Martınez et al. 2005; Ondoa, Dieye et al. 
2006). An expression of CD38 is discussed in the literature as additional data for 
documenting the course of the infection. However, CD38 is considered to have only a minor 
relationship to the recovery of CD4 cells (Steel, John et al. 2008; Rosso, Fenoglio et al. 2010). 
Research on apes and their immune adaptation to SIV have shown that an immune system 
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can cope with a viral infection with no clinical outbreak (Klatt, Silvestri et al. 2012). 
Furthermore, ongoing research of asymptomatic carriers, called elite controllers, confirm the 
relationship of a non-detectable viral load and a low active immune system (Kamya, Tsoukas 
et al. 2011). 
1.3 Relation between Infection and Nutrition 
The link between nutrition and progression of the infection has been drawn as a vicious 
circle (Tomkins A and F. 1989). Infections have been shown to cause higher energy demand 
due to the activation of the immune system (Scrimshaw, Taylor et al. 1968). As the infection 
affects a large spectrum of physiological functions, especially the immune system, it is not 
only associated with an increasing energy demand but also with a decrease and imbalance of 
micronutrients in the blood. Micronutrient deficiencies have been documented at different 
stages of the HIV infection (Tang, Graham et al. 1997; Fawzi 2003; Tang, Lanzillotti et al. 
2005). Deficiencies of several micronutrients have been shown to be associated with 
accelerated disease progression, increased mother-to-child transmission, increased genital 
shedding of HIV and increased mortality (De Pee and Semba 2010). One proposed link 
between nutrition and infection is the antioxidant status (Schwarz 1996). Increased 
consumption of fruits and vegetables over three months exerted beneficial effects on the 
systemic redox balance and immune activation parameters such as CD38+/CD8+-cells in HIV-
infected persons (Greenspan 1994; Gil, Martınez et al. 2005). 
Moreover, studies in the United States have shown that woman and minority groups tend to 
a lower dietary intake than advisable according to the Recommended Dietary Allowance 
(RDA). This especially affects some vital nutrients such as vitamin A, vitamin C, vitamin E, 
vitamin B6, iron, and zinc (Woods, Spiegelman et al. 2002). The RDA is the level of intake 
considered adequate to meet all nutrient needs for nearly all (95%) healthy persons (Board 
2000). Furthermore, there is some evidence that micronutrient intakes at the RDA level may 
be insufficient for HIV-infected individuals since low micronutrient statuses have been 
reported in HIV-infected adults (Baum, Shor-Posner et al. 1992). The international 
recommendation is an increase of dietary energy intake of 10% for asymptomatic and 20 to 
30% for symptomatic HIV-infected persons; micronutrients should be consumed according 
to the RDA (WHO 2003).  
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The direct relation between nutrition, metabolic complications, and HIV infection has 
promoted nutrition to become a central part of care for PLWHA. The place of nutrition in the 
HIV challenge has been recently redefined by the American Dietetic Association, which 
advocates individualized care to optimize the nutritional status (Fields-Gardner 2010). 
Therapeutic nutrition is generally accomplished through nutrient supplementation in order 
to prevent or compensate for micronutrient deficiencies. Studies about supplementation 
with vitamin A, B complex, C, or E have shown effects on people living with HIV, which are 
presented here in table 1.1. 
The importance of well-balanced nutrition in the case of infections is well documented and 
part of international recommendations. An major problem in HIV infection is the appearance 
of malnutrition (UNAIDS 2001). The infection implements a burden on the nutritional status 
of PLWHA. In the case of a pre-existing nutritional deficiency, as often seen in sub-Saharan 
Africa, people suffer from the double burden of HIV and malnutrition (WHO 2005). 
Moreover, the spreading of HIV in sub-Saharan Africa remains related to socio-economic and 
wealth access inequality, which’s are also key factors in nutritional status. 
Efforts have been undertaken to fight emergency malnutrition with a focus on HIV as shown 
by the international agencies UNAIDS and WFP cooperating in the Food and Nutrition 
Technical Assistance project “FANTA-2”(WFP 2007; WFP 2011).  
Vegetable products present a diverse and equilibrated composition of nutrients. Besides 
their nutritional value, herbal products also contain bioactive compounds such as phenol 
and diverse antioxidants. These natural antioxidants are expected to have a better 
bioavailability and a greater protective efficiency than synthetic nutrient products 
(Greenspan 1994; Preziosi, Galan et al. 1998). The consumption of fruits and vegetables has 
also been related to the microbiota of the gut (Greenspan 1994; Gil, Martınez et al. 2005; 
Serrano, Goñi et al. 2007; Schmidt, Ribnicky et al. 2008).  
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TABLE 1.1 ESSENTIAL NUTRIENT EFFECTS ON PEOPLE LIVING WITH HIV 
 Nutrients Effect Reference 
Retinol and 
carotenoids 
(vitamin A) 
-Maintenance of epithelial integrity 
-Enhanced monocyte differentiation and function 
-Improved neutrophil function 
-Increase in C-reactive protein during infection 
-Increase in T cell counts 
Transmission and pregnancy outcomes 
-Low serum vitamin A increases risk of mother-to-child 
transmission of HIV. 
-Low maternal vitamin A increases risk of low birth 
weight. 
-High intake of vitamin A increases vaginal and breast 
milk viral shedding. 
(Coutsoudis, Kiepiela et al. 
1992) 
(Mehta and Fawzi 2007) 
(Semba, Caiaffa et al. 1995) 
(Ross 2012) 
(Burns, FitzGerald et al. 
1999) 
(Fawzi, Msamanga et al. 
2004) 
(Villamor, Koulinska et al. 
2010) 
Bvitamins 
-Use of B complex vitamins was associated with reduced 
progression to AIDS in South African adults. 
-High intake of vitamin B6 was associated with improved 
survival. 
-Low serum vitamin B12 associated with more rapid 
progression of HIV disease in homosexual men. 
(Tang, Graham et al. 1996) 
(Kanter, Spencer et al. 1999) 
(Tang, Graham et al. 1997) 
Tocopherol 
(vitamin E) 
-Improved neutrophil phagocytosis 
-Lymphocyte proliferation 
-Increased IL‐2 production 
-Increased natural killer cell cytotoxicity 
-Reduced production of inflammatory cytokines such as 
TNF, IL‐6 
-Higher serum vitamin E is associated with a one-third 
lower risk of progression to AIDS in HIV-infected 
homosexual men. 
-Supplementation in association with HAART is more 
effective in reducing viral load.  
(Beharka, Redican et al. 
1997) 
(Wang and Watson 1994) 
(Pekmezci 2011) 
(Spada, Treitinger et al. 
2002) 
(de Souza Junior, Treitinger 
et al. 2005) 
(Tang, Graham et al. 1997) 
Ascorbic acid 
(Vitamin C) 
-Improved T and B lymphocyte proliferative responses 
-Reduced concentration of pro-inflammatory cytokines, 
including IL‐6 
-High dose can reduce steady-state indinavir plasma 
concentrations 
(Hemila 1997) 
(Slain, Amsden et al. 2005) 
 
 
The use of herbal medicine is traditionally deep-rooted in Africa. The coverage of African 
traditional medicine is widespread, and patients often mix traditional and Western medicine 
(Peltzer and Mngqundaniso 2008). The application of local herbal products can be a part of 
medical treatment, especially in the context of low-income countries (Atawodi 2005; 
Nikiéma, Djierro et al. 2009; Nkengfack, Torimiro et al. 2012). Herbal products have some 
advantage over synthetic products because of their diverse composition, their local 
production, and their common acceptance (Schmidt et al. 2008). UNAIDS has released 
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guidelines to formalise a collaboration between modern medicine and traditional healers in 
the Sub-Saharan African context (King 2006). For example, African plants have been 
investigated in the context of a new cancer treatment (Sawadogo, Schumacher et al. 2012). 
Various plants used in the care of PLWHA have been described. The implementation of 
traditional plants, for example the “African potato” (Hypoxishemero callidea) and an l-
canavanine extract from Sutherlandia frutescens during the infection resulted in better 
absorption of nevirapine (Brown, Heyneke et al. 2008). The consumption of plant food also 
results in the intake of phytosterols, which have beneficial effects in some diseases and 
especially influence the immune response (Bouic and Lamprecht 1999). One major class of 
biologically active compounds are the polyphenols, which exert anti-inflammatory and 
immune-modulatory function (Cuevas, Saavedra et al. 2013). Plants used in the healthcare of 
PLWHA are presented in table 1.2. 
 
TABLE 1.2: PLANTS AND THEIR EFFECTS ON HIV PATIENTS 
PLANT Effect Reference 
Garlic 
-Reduces levels of saquinavir (protease 
inhibitor medication) 
(Sussman 2002) 
Aloe Vera 
-Lowers blood glucose in diabetics 
-Reduces blood lipid in hyperlipidaemia 
-Might be effective against herpes and 
psoriasis 
-Might promote wound healing 
(Vogler and Ernst 1999) 
Curcumin 
-Anti-tumour, anti-inflammatory, and anti-
infectious activities 
-Antiviral activity, HIV-1 integrase inhibition 
(Mazumder, Raghavan et al. 
1995); 
(Sharma, Gescher et al. 2005); 
(Hatcher, Planalp et al. 2008) 
Ginseng 
-Slows CD4 T cell depletion 
-Antifungal, antiviral effect of ginseng protein 
(Sung, Kang et al. 2005) 
(Ng and Wang 2001) 
Tea Tree 
-Effective against fuconasolzole-resistant 
oropharyngeal candidiasis 
-Antimicrobial  
(Vazquez and Zawawi 2002) 
(Carson, Hammer et al. 2006) 
Hysope -Antiviral HIV activity of polysaccharide (Gollapudi, Sharma et al. 1995) 
St. John’s Wort 
-Treatment of depression 
-Lowers nevirapine in the blood 
(Linde, Berner et al. 2005) 
(Piscitelli, Burstein et al. 2000) 
Neen -Anti-retroviral effect of leaf extract (Udeinya, Mbah et al. 2004) 
Propolis -Anti-candidose (Martins, Pereira et al. 2002) 
Sutherlandia 
frutescens 
-Antibacterial and antioxidant (Katerere and Eloff 2005) 
 
The WHO long ago recognized the need for research and regulation of herbal therapies 
(WHO 1989). Scientific efficiency and safety studies are vital for the broader implementation 
of herbal products. The registration of adverse events related to the consumption of herbal 
products improves the way these products are used and thereby improves patient safety. In 
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order to achieve both, the WHO started an international drug monitoring program on 
‘pharmacovigilance’, in which observations under herbal medicines can be reported (UMC 
2011).  
 Spirulina 
The current study focused on one old natural supplementation candidate: Arthrospira, two 
major species of which are consumed by humans; A.maxima and A. platensis (Asp). A 
common designation is ‘spirulina’. Asp is a photosynthesizing cyanobacterium (originally part 
of blue-green algae) that grows under bright sunshine, high temperatures, and alkaline soil 
conditions. Originating from the regions around Lake Chad (Chad-Cameroon-Niger) and Lake 
Texcoco (Mexico), Asp is consumed by the local Kanembou population in Chad and was 
considered a high-quality food by the Aztecs in former times (Farrar 1966; FAO 2008). Owing 
to the absence of a cellulose membrane, spirulina presents its nutrients with a high 
bioavailability and is rich in high-quality proteins, lipids, vitamins, minerals, and biologically 
active substances(Kulshreshtha, Zacharia et al. 2008). An early interest in spirulina was based 
on the iconic ‘single cell proteins’ (Clement, Giddey et al. 1967). This interest increased, and 
research on its production was conducted in the 1970s. Since the expected protein gap in 
human nutrition lost the attention of researchers, Asp was also relegated to the background. 
At the same time, the National Aeronautics and Space Administration  selected 
Arthrospira as a diet for its long-term space travel program, CELSS (Mahasin 1988). 
Arthrospira has diverse biological activities and effects on nutritional outcomes. Clinical 
observations among undernourished children in Burkina Faso (Simpore, Zongo et al. 2005) 
and among elderly people in Korea (Park, Lee et al. 2008; Selmi, Leung et al. 2011) presented 
spirulina as a possible food supplement to increase the dietary quality of populations in 
need. Recent reviews have drawn attention to Asp’s therapeutic effects, such as reducing 
blood cholesterol, enhancing antioxidative capacity, and strengthening the immune system 
(Deng and Chow 2010; Ravi, De; et al. 2010). 
Several investigations with Asp have been conducted on PLWHA in Africa. The first was 
studying malnourished HIV-infected children in Burkina Faso. Its showed a higher rate of 
nutritional recovery as well as an improvement in immunological variables in children 
receiving Arthrospira (Simpore, Pignatelli et al. 2007). In Bangi, data of a controlled study on 
out patients suggested that Arthrospira could be a strong candidate for a nutritional 
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supplement. However, this study could not prove any effect of Arthrospira on the course of 
the infection (Yamani, Kaba-Mebri et al. 2009). Critics wrote about this study: “they did not 
test body composition nor viral load and failed to demonstrate any benefits of direct 
improvement on immune response due to their limited experimental protocol” (Azabji, 
Dikosso et al. 2011). A more recent randomized single blind nutritional supplementation 
study conducted in Cameroon on undernourished patients starting HAART reported a 
significantly higher improvement in CD4 cells under Arthrospira supplementation in contrast 
to soy beans (Azabji, Ekali et al. 2011). 
1.4 Context 
The present intervention focuses on Cameroon with an HIV seroprevalence of 5.3%. It is the 
Central and West African country with the highest rate of HIV (UNAIDS 2010). This country is 
called “little Africa” and is known for its great diversity in climate, geography, religion, and 
populations consisting of 230 ethnic groups. This heterogeneity also impacts the regional 
HIV seroprevalence with 1% in the northand 10.6% in the south. The same report shows a 
difference in the HIV prevalence between the two megacities, Douala and Yaoundé, which 
are the home of 20% of the total population of the country: Douala has a HIV prevalence of 
4.6% and Yaoundé one of 6.4%. The capital city also registers a gender difference of 8.8% for 
women and 3.9% for men (National institute of Statistic 2011). This gender difference can be 
found throughout the continent: HIV prevalence in women in Africa stands at 58% of all 
cases (UNAIDS 2012).  
Since 2007 and free access to HAART medication in Cameroon, the number of patients under 
HAART has increased exponentially, reaching one of the highest rates in the sub-region. It 
reached 58% of the HIV-infected population eligible to receive HAART in June 2008 
(Loubiere, Boyer et al. 2009). The national number of patients treated was 17,156 at the end 
of 2005 and peaked at 89,455 at the end of 2010 representing a therapeutic coverage of 
38% of infected people (CNLS 2011).  
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1.5 Study Objectives 
The current study focused on spirulina as a functional food that strengthens the immune 
system of patients infected with HIV. It also sought to answer the question of whether 
spirulina could improve the nutritional status of patients not yet under antiretroviral 
therapy.  
- The main objective of the RCT is to evaluate Arthrospira p. by measuring the change 
in CD4 lymphocyte count compared to a placebo from baseline for up to three 
months. 
- The second objective is to document the effect of Arthrospira p. on the following 
nutritional status markers: albumin, iron anaemia, and body weight. 
- HIV infection is known for its deleterious effects on infected people. Therefore, the 
study will explore the course of three disease outcomes of an HIV infection at three 
different time points, i.e. at baseline, three months and six months. The three 
outcomes include the immune status, the CD8/CD38 cell ratio, and the frequency of 
opportunistic infections.  
- The total antioxidant status of the Asp group will be compared to that of the placebo 
group. 
11 
2 Methods 
2.1 Study Design 
The study was an experimental, prospective, and longitudinal intervention performed as a 
three-month randomized double-blind and placebo-controlled intervention (Intervention I), 
followed by a three-month open-label extension period (Intervention II), see Figure2.1.  
 
FIG. 2.1 FLOW CHART OF THE STUDY 
Supplements A and B were used during the randomized control on HAART-naïve patients. 
Supplementation C was exclusively composed of Asp and was used for all patients after the 
RCT was completed. The figure represents the four interventions with RCT composed of Sup 
A and B for three months, the long-term intervention, and crossover composed of the two 
intervention arms from baseline to six months. 
Screening: 
♀, HIV+, HAART- 
Sup. B 
Sup. A Sup. C 
Sup. C 
Baseline: 
0 months 
Intervention I: 
3 months 
Intervention II: 
6 months 
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In order to answer the research question, the RCT was carried out on pre-HAART patients. 
After screening, the three-month RCT with pre-HAART patients started. Each participant was 
randomly allocated either to group A or group B (see §2.4). 
The placebo for the control group contained an equal amount of protein and energy as the 
intervention product Asp (see §2.6). After three months, the randomized study ended. 
During the prolongation in the open label period, only Asp was distributed to the patients 
involved in the RCT in two different six-month intervention profiles; the ‘crossover’ 
originated from the placebo group, and the ‘long-term’ arose from the Asp exposure group. 
In order to continue the study in the open label period, the pre-HAART patients had to stay 
HAART naïve; this meant resuming with a CD4 greater than or equal to 350 cells/mm3. In 
case of a lower count, the participant was immediately excluded from the study and referred 
to a physician in order to start with HAART. During the prolongation period the former 
randomized distribution between the RCT groups was not continued. 
In addition to biomedical monitoring and the supplement bags, all participants were 
reimbursed for their travel expenses to the study site. The patients were asked to come and 
pickup their supplement bags every four weeks. The bags contained 30 daily blisters with ten 
pills each, 30 condoms, a pen, and one information leaflet (see appendix). The latter 
contained intervention information and a table on which the patient was asked to write 
down the number of pills taken per day and any concomitant events emerging on that day. 
The table helped the patient write down remarks and helped control compliance. Condoms 
were distributed in agreement with the patients and in accordance to the inclusion criteria 
to avoid pregnant participants. 
 Sample Size Calculation 
CD4 cell count is the primary outcome of this study. The sample size calculation was based 
on the assumption of patients (P) with a CD4 count increase of more than 100 
cells/mm3after three months compared to the baseline. The benchmark of 100 CD4 
cells/mm3 was based on previous field studies in Cameroon (Bourgeois, Laurent et al. 2005). 
Null hypothesis:  P1 (intervention group) = P2 (control group). 
Sample size tables were used to estimate the value of the sample size. 
These were our parameters: 
Ratio intervention group/control group=1;  precision = 0.05; Zα= 1.645 
At a power of 93%, 35 subjects per group (Asp and Placebo) were needed. 
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2.2 Ethical Considerations 
The intervention was conducted according to the World Medical Association Declaration of 
Helsinki (WMA 2008). The research proposal was reviewed and approved by two 
independent ethical committees: the ethical clearance committee of the Faculty of Medicine 
of Justus Liebig University, Giessen, Germany, and the National Ethics Committee of 
Cameroon (n°131/CNE/SE/2010 on 16 July 2010 in Yaoundé). 
 Informed Consent 
After a positive screening based on age, proof of HIV infection, BMI, and existing contact 
data, the study information was read to the patient in one of the two official languages of 
Cameroon: French or English. In addition to a discussion during the reading, the intervention 
was set into a general context (Corneli, Sorenson et al. 2011). A hardcopy of the information 
was distributed to the patient, and a sufficient amount of time for possible feedback was 
offered. Patients who could not write or had problems understanding were always 
accompanied by a literate family member (brother, husband, mother, or sister). Once the 
patient had signed the informed consent statement, a screening with data collection on the 
medical history and the actual CD4 cell count was performed. 
All original data and informed consent statements are kept under strict closure at the 
Institute of Nutrition at the University of Giessen, Germany. A digital copy is in the 
possession of the principal investigator in Cameroon. 
 Trial Funding 
The trial was mainly supported by an unrestricted grant from greenValley GmbH, Berlin 
Germany.  
Furthermore, OCEAC/PPSAC contributed as a founding and partner agency for Central Africa. 
The study was presented at the OCEAC/PPSAC meeting in N´Djamena in June 2010 to share 
data on the effect of spirulina on HIV-infected patients.  
 Institutional Review Board 
The project was carried out under the combined supervision of Prof Dr med. Michael B. 
Krawinkel (Institute of Nutritional Sciences – International Nutrition, University of Giessen, 
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Germany) and Dr med. Marcel Azabji (Department of Physiological Sciences, Faculty of 
Medicine and Biomedical Sciences, University of Yaoundé, Cameroon).  
In Cameroon, Dr Azabji was the principal investigator who supervised all steps of the project. 
Clinical data were managed by Ndazem Djenabou, a medical student from the team of Dr 
Azabjiat the Faculty of Medicine of Yaoundé. Francois Emakam and Frank Winter carried out 
the study’s field work and collected the patient and laboratory data. Both belonged to the 
working group on International Nutrition in Giessen. The following institutions were involved 
in the project: 
The ‘Hôpital du Jour’, the health unit for HIV/AIDS patients from the Central Hospital of 
Yaoundé. The current director of the unit is Dr Charles Kouanfack. The analysis of the clinical 
and biochemical markers was carried out at the Centre Pasteur Cameroun Laboratory of 
Virology by Frank Winter under supervision of Dr Jude Kfutwah. 
Statistical analysis was guided and supervised by Dr Rolf-Hasso Bödeker at the Institute of 
Medical Statistics, University of Giessen, and Dr Johannes Herrmann at the Institute of 
Nutritional Sciences, University of Giessen. 
2.3 Eligibility & Enrolment Criteria 
The study population was limited to voluntarily participating individuals. Only patients 
registered in the study health centres could be contacted and invited to participate. Contact 
was established via telephone for the pre-HAART patients. Recruitment for the randomized 
pilot study was achieved by searching through patient files, focusing on the years 2008 to 
2010. The inclusion criteria were applied during register research and at the screening.  
All patient files were screened for the following criteria: female, not under HAART, age 
between 18 to 49, and availability of a phone number. Potential patients were contacted by 
phone and invited to the office for a pre-screening consultation at the HDJ. All participants 
meeting the inclusion criteria during the enrolment period participated voluntarily. 
Participants were then recruited via convenience sampling. At the screening, the medical 
staff asked for informed consent as noted in § 2.2. Before the patient signed the consent 
form the study physician had to exclude any other chronic disease or any existing or planned 
pregnancy and make sure that the participant understood the upcoming study well. After 
signing the informed consent, the screening checklist was filled in (see appendix). The HIV 
infection, pregnancy, BMI measurement, CD4 T cell count, and any medication taken were 
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verified. First, body weight and height were measured with subsequent calculation of BMI. If 
BMI was under 26 kg/m², the patient was invited to perform a CD4cell measurement. For 
inclusion at this stage, the count had to be higher than 350 cells/mm3.  
Inclusion criteria:  
female, confirmed HIV infection, age 18 to 49 years, BMI below 26 kg/m², known medical 
history, and CD4 T cell count between 350 cells/mm3 and 600 cells/mm3. 
 
Exclusion criteria were as follows: male, under any antiretroviral therapy, pregnant or 
planned pregnancy, breastfeeding, initiation of an antioxidant vitamin therapy, any 
opportunistic infection requiring intensive medical care, intractable diarrhoea (at least six 
liquid stools daily). 
2.4 Randomization 
Each study patient received an ID number composed of four digits and two letters. The first 
two numbers were based on the recruitment chronology; the last two numbers related to 
the year of birth, followed by the initials of first and family name.  
For randomization of the pre-HAART patients, all ID numbers were entered into a MS Excel®-
file in chronological order. Two equal population groups, A and B, were defined and put in 
front of a generated random number through the Excel® formula “=rand()”. The decrease 
ordering of the random numbers resulted in the randomization list. 
2.5 Blinding 
The blinding was achieved by identical packaging of both supplemented products provided 
by greenValley GmbH, Berlin, Germany. The capsules were dark green, opaque, with no 
visible difference between the placebo and the Asp supplement. The patients and the 
medical personnel directly involved were blind about the products delivered to them. Pills 
were labelled A or B and distributed in blister packages to the participants. The blisters were 
labelled with ‘A’ or ‘B’. For the open-labelled phase, pills were labelled with ‘C’. 
All supplements were kept in a dry dark room near the hospital at room temperature. Every 
morning, the bags were taken to the office where the distribution and data collection were 
conducted. During the intervention no breaking of the blinding occurred. 
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2.6 Intervention & Placebo Product 
A five-gram supplement per day distributed in 10 pills containing 500 mg each is the dose 
considered adequate for study purposes. The pills were opaque green. The investigational 
product was 100% Arthrospira platensis powder provided by EARTHRISE® from California, 
USA. This producer applies ecological farming methods, highly automated harvesting, and 
respects strict hygiene regulations (ISO 9001:2008). The applied drying method through 
spraying Asp in a heat chamber guarantees the best possible preservation of all heat-
sensitive nutrients, pigments, and enzymes without using preservatives or stabilizers 
(Earthrise, 2009). The Asp provided for the study was standardized on iron and phycocyanin. 
For the randomized control study, a placebo was manufactured by HERBAMED Co. 
Euskirchen, Germany. The placebo had the same amount of protein and energy as the 
supplied Asp. The protein content was measured on the basis of a quantity of 500 mg of Asp 
Lot-No.14141. The energy calculation was based on 500 mg of Asp powder in 100 mg HPMC 
caps. The placebo was a mix of 362.57 mg of pea protein isolate Pisane F9 mix with 160 mg 
of Dextrans EMDEX. This results in 8.9 KJ or 2.1 Kcal per pill containing 310 mg protein. 
TABLE 2.1 NUTRITIONAL COMPOSITION OF THE INTERVENTION AND PLACEBO PRODUCTS 
Macronutrient 
composition 
Arthrospira p. 
(500mg per pill) 
Placebo 
(500mg per pill) 
Energetic value 8.9 kj; 2.1 kcal 8.8 kj; 2.1 kcal 
Protein 310 mg 310 mg 
Carbohydrate 77.5 mg 186 mg 
Lipid 35.5 mg 4 mg 
The supplement or placebo was swallowed in the form of pills, distributed in one blister for a 
daily intake of 10 pills. It was recommended to ingest the pills after a meal, preferably five 
pills after breakfast and five pills after lunch. 
2.7 Data Collection 
Observations of each patient included an assessment made at the beginning, then monthly, 
and at the end of each supplementation period (see table 2.2). 
Before the study began the screening group data was provided from the medical register, 
interviews, physical exam, and if required, a CD4 cell count was ordered at the HDJ 
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laboratory hospital. A blood sampling for the CD4 cell count was carried out for patients who 
could not present a CD4 count less than three months old at the screening. The method 
applied in the hospital laboratory was considered for HAART entry, and the results were 
valid as study inclusion criteria. Furthermore, diurnal variations are known to be found in 
CD4 counts, sometimes increasing during the day (Malone, Simms et al. 1990). A special 
focus was to set the sampling at similar times. The goal was to mitigate the diurnal cycle 
variation. Obtaining blood samples from fasting subjects would have been more appropriate 
for achieving higher reproducibility of the results. However, due to ethical reasons, the 
project decided to spare the participants the need to show up on an empty stomach. 
During the intervention, at baseline, and after three and six months, anthropometric 
measurements and blood samples were taken. The monthly visit focused on observations, 
safety, distribution, and ingestion of supplements. 
TABLE 2.2 ASSESSMENT TIMETABLE 
 Screening Baseline RCT Open-labelled 
Study month -1 0 1     2     3 4      5    6 
Informed consent 
Medical history 
Physical exams 
 
 
 
 
 
 
 
 
 
 
 
 
Effectiveness:     
Blood variable 
Body weight 
24h recall 
QoL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Safety:     
Adverse events     
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2.8 Measurement Methods 
Outcome variables measured in the current study were anthropometric markers and blood 
variables of two groups: immuno-virological and biochemical markers.  
 Immuno-Virological Variables 
HIV infection is defined by the strong predictors of disease progression and outcome. The 
gold standard used as an inclusion criterion for the initiation of HAART is the CD4 cell count. 
Furthermore, the CD38 expressions on lymphocyte cells and the viral load were measured. 
The flow cytometer and viral load measurements were performed at the laboratories of 
virology of the CPC, under the supervision of Dr Kfutwah and conducted by Frank Winter, 
respecting good laboratory practice. 
The FACS count from Becton Dickinson is the standard method in HIV monitoring of the CD4 
cell count. The CPC is the reference laboratory in Cameroon. The samples were analysed 
according to protocol with the use of an electronically calibrated pipette of 50 µl from 
Beckman. The calibrated range is CD4: 1 to 2,000 cells/µl; CD8: 1 to 2,000 cells/µl; CD3: 1 to 
3,500 cells/µl. The quality controls of sensitivity and precision were achieved by the standard 
IMMUNO-TROL and IMMUNO-TROL Low. The sensitivity is +/- 61 cells/mm3 for CD3 cells for 
the low level, of +/- 36 cells/mm3 for the CD4-cells, and +/- 21 cells/mm3for CD8 cell. 
CD38 expression is performed to describe the effect of an intervention or medication on 
immune activation that relates to infection evolution(Steel, John et al. 2008).Measurements 
of CD38 antigen expression were obtained with COULTER EPICS XL/XL-MCL®. The following 
antibody combination was used: PE-CD3 and PE/Cy5-CD4 from Biolegend®, Flurescein Iso 
Thio Cyanate, and FITC-CD38 from eBioscience®. The results were read with the CXP® 
software connected to the COULTER EPICS XL/XL-MCL®. This showed the result of the 
lymphocyte population in total blood. The results were expressed as %CD8, CD38 of CD8 
lymphocytes (%CD38-CD8), and as %CD4, CD38 of CD4 lymphocytes (%CD38-CD4). 
The viral load is a direct count of viral particles via one-step reverse transcriptase PCR in 
plasma. For the current study, plasma was stored at -80°C until the end of the intervention. 
To avoid methodical fluctuation, samples were handled chronologically for each patient 
during the same run. Viral RNA was extracted from the plasma using the QIAamp® Viral RNA 
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Mini extraction kit for medical diagnoses. The principle was a lysation to RNase’s free 
condition. Then the RNA was isolated with an RNA carrier and purified with a silica gel-based 
membrane with selective RNA-binding properties. The purified RNA was free of protein, 
nucleases, and other contaminants or inhibitors. 500 µl of clear plasma was concentrated 
through a spin of 17,000 g for 30 min. 360 µl of supernatant was removed before adding the 
lysis buffer and transferring it into the column. The elution was in 60 µl QIAamp® buffer 
before storing the stable RNA at -20°C. The load-extracted RNA amount was 10 µl per qPCR 
reaction. The PCR was achieved during the 24 hours following the extraction by using a 
medical diagnosis kit from Biocentric, Generic HIV charge Viral®. The diagnosis kit was 
developed by the Agence National de Recherche sur le SIDA (ANRS) for a quantification of 
HIV-1. The absolute quantification was done with a standard curve of 5 points with a 1log 
dilution, implementing a one-step retro-transcription PCR master mix. The measurements 
were done on a 7500 Real-Time PCR System from Applied Biosystems©. The results were 
calculated in MS-EXCEL® and expressed in viral Log10 and copies/ml, regarding the validated 
diagnostic protocol of the Centre Pasteur. Non-detectable viral load at baseline, a virological 
serotyping, was performed with an ELISA test to determine the HIV type. 
HIV serotyping is done through ELISA. The ELISA test is usually performed for patients not 
responding to HIV-1 quantification in order to confirm infection with the HIV virus by 
identifying an HIV-2 type. The ELISA test was developed by the clinical biology unit of CHU 
Rouen. The technique is based on the variation of two glycoprotein epitopes of the virus 
envelope, the region gp41/IDR (transmembrane) and gp120-V3 (external loop). These two 
epitopes allow one to discriminate type HIV-1 and HIV-2 and would also determine HIV-1 
subtypes (M,N,O,P). For the current study, ELISA was performed by the trained personnel of 
the Centre Pasteur on a serum volume of 10µl. 
 Biochemical Outcomes 
C-reactive protein is the most accurate marker for the acute immune response phase. It is 
used to screen for infections and inflammatory injury/diseases. C-reactive protein was 
measured via a chemiluminescence-immunometric assay on an IMMULITE 2000®. The 
required volume was 5 µl serum. The results were available within four hours. 
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Total Antioxidant Capacity: The anticoagulant blood tubes were centrifuged and aliquoted. 
300 µl serum were frozen at -80°C. To avoid handling and methodological fluctuation, 
samples were analysed chronologically per patient in duplicate in the same run. The mean of 
the two measures was taken as the value. Samples for each patient were put side by side 
from time 0, time 3, and time 6 months (if available) for meltdown. After the quantity 
needed had been sampled, the serum was conserved at -80°C as a serum library at the 
Centre Pasteur Cameroon for one year. The total antioxidant status (TAOS) was quantified by 
using the research ABTS assay kit CS790 from Sigma® for 96-wellplates. ABTS (2, 2’-azino-di-
(3-ethylbenzthiazoline sulfonate) was incubated five minutes with metmyoglobin and 
hydrogen peroxide to produce the radical cation ABTS•+. It has a stable blue colour. 
Antioxidants added to the sample suppress colour production according to their 
concentration. The absorption was correlated with the trolox standard curve and expressed 
µM relative to the trolox standard. The measurement range was 45 –420 µM. Samples were 
diluted if needed by a factor of ½ with assay buffer. The sensitivity of the test was measured 
by the variation on the 5 trolox standard curve. The sensitivity is +/- 8µM. The serum 
reaction input was 10 µl of serum. The endpoint absorption was read at 405 nm on the 
micro plate reader, Dynex Technology® MRX Version 2.02, USA. 
Further biochemical variables were measured in the biochemistry laboratory of the CPC on 
the sampling day from the same serum tube. The following analyses were performed with 
the biochemical analysis system Vitros 250® using the following methods: 
Albumin is a un-glycosylated plasma protein playing a major role as a carrier and by 
maintaining osmotic pressure. The concentration was determined directly by building the 
albumin-bromocresol green complex. The measurement was achieved via 
spectrophotometry at 630 nm. The sample volume was 5.5 µl of serum. The method range 
was 10–60 g/l with an accuracy of 0.9 g/l. 
Serum iron measures the transferrin-bound and free-circulating iron in the blood. About 
30% of the iron in the body is bound to transferrin protein, and a small amount is solubilised 
in the serum. Iron concentration was determined by liberating iron from transferrin under 
acidic pH. The measurement was read at 600 nm. The sample volume was 10 µl of serum. 
The method range was 0.5– 14 mg/l with an accuracy of 0.5 mg/l. 
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Cholesterol is an important component in the hormonal systems of the body for the 
synthesis of bile, steroid hormones, and vitamin D. It plays a role in membrane fluidity. It can 
be synthesized by the body or comes from animal foods. Cholesterol concentration was 
determined by enzymatic catalysed hydrolysis of cholesterol through a final oxidation of a 
colorant. The measurement was analysed to be 540 nm. The sample volume was 10 µl of 
serum. The method range was 0.5– 3.25 g/l with an accuracy of 0.027 g/l. 
Plasmatic triglyceride concentration is related to the balance of nutritional input and storage 
of the lipid in the body. The concentration was determined via enzymatic catalysed 
hydrolysis of triglyceride through a final oxidation of a colorant. The measurement was read 
at 540 nm. The sample volume was 10 µl of serum. The method range was 0.11– 5.93 g/l 
with an accuracy of 0.036 g/l. 
Urea is synthesized in the urea cycle from the oxidation of amino acids. Urea is eliminated 
from the body through the kidney in the urine. Urea concentration was determined via 
hydrolysis of urea to ammoniac, which reacts with an ammoniac indicator. The measure was 
achieved at 670 nm. The sample volume was 10 µl of serum. The method range was 0.02– 
1.2 g/l with an accuracy of 0.007 g/l. 
Creatinine is a breakdown product of creatine phosphate in muscles and is usually produced 
at a fairly constant rate by the body (depending on muscle mass). Creatinine concentration 
was determined via hydrolysis of creatinine through a final oxidation of a colorant, 
leucoderivative. The measure was established to be 670 nm. The sample volume was 10 µl 
of serum. The method range is 0.5– 1.4 g/dl with an accuracy of 0.5 g/dl. 
 Blood Cell Count 
Blood cell counts were handled on EDTA blood and analysed with the Sysmex XT-1800i 
NFS®. This instrument performs haematology analyses according to the hydrodynamic 
focusing (DC detection) flow cytometry method (using a semiconductor laser). Flow 
cytometry, using a semiconductor laser, analyses physiological and chemical characteristics 
of cells. The hydrodynamic focusing method improves blood count accuracy and 
reproducibility. Abnormal numbers of blood cells were observed under the microscope to 
exclude haematological malignancies. No malignancies were observed or detected. 
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Haemoglobin is measured via extinction. 
 Anthropometric Measurements 
Weight and height of the patients were measured after the interview. This procedure was 
carried out by the same medical student throughout the entire study. Patients with light 
clothes and without shoes were asked to stand on a standing-weighing machine, SECA® with 
a kilogram scale to the nearest 0.1 kilograms. The researcher read the weight appearing on 
the display and recorded it onto the chart of the patient. Respondents were asked to stand 
upright and in front of a standing board with a centimetre scale. The researcher used a ruler 
to equate the respective height and read the scale above the patient’s head. Body height 
was measured to the nearest 0.5 cm. The measured weight and height of the patients were 
used to calculate their BMI, (kg/m2). For that purpose, the patients’ heights were converted 
into meters. 
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TABLE 2.3 MARKERS MEASURED IN THE STUDY 
Variables Method Range; Accuracy Normal values* 
CD4 
FACScount from Becton 
Dickinson 
1–2,000 cells/mm3; 
+/- 36 cells/mm3 
500–1,600 cells/mm3 
Viral load RT-PCR >50 copy/mm3 <50 copy/mm3 
CD8-CD38 
COULTER EPICS XL/XL-
MCX 
0–100%; +/- 1% < 30% 
CRP  
Immunometric assay on 
an IMMULITE 2000® 
0–400 mg/l; 0.1 mg/l <6 mg/l 
TAOS ABTS ELISA 
15–1,000 µM; 
+/- 8 µM 
~1,000 µM 
Albumin 
Colorimetric measure 
with bromocresol green 
10–60 g/l ; 
+/- 0.9 g/l 
35–50 g/l 
Haemoglobin Photometric measure 
0.0–30.0 g/dl; 
+/- 0.1 g/dl 
11.1–16.8 g/dl 
Erythrocyte Discriminator 
0.00–99.99 Tera/l; 
+/- 0.02 Tera/l 
3.5–5.5 Tera/l 
Iron 
2 points enzymatic 
measure 
0.5–14 mg/l ; 
+/- 0.5 mg/l 
0.5–1.5 mg/l 
Cholesterol Colorimetric measure 
0.5–3.25 g/l ; 
+/- 0.027 g/l 
1.8–2.8 g/l 
Triglyceride Colorimetric measure 
0.11–5.93 g/l ; 
+/- 0.036 g/l 
< 1.5 g/l 
Creatinine 
2 points enzymatic 
measure 
0.05–1.4 g/dl ; 
+/- 0.05 g/dl 
0.5 g/dl- 1.4 g/dl 
Urea Colorimetric measure 
0.02–1.2 g/l ; 
+/- 0.007 g/l 
0.1–0.5 g/l 
* Reference value from the CPC, Yaoundé, 2010 
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2.9 Concomitant Events & Therapy 
During the monthly monitoring appointments, the patient was asked if any change had 
occurred during the past four intervention weeks. The discussion referred to a flyer filled out 
by the patient. The flyer mentioned the number of pills, concomitant events, and severity 
per day. The concomitant events were scaled as not at all, a little, as usual, a lot, and 
enormous. The proposed concomitant events were as follows: appetite, fatigue, 
nausea/vomiting, cough (divided into dry and spit), abdominal pain, and dejection (divided 
into diarrhoea and constipation). The physician filled the clinical register where the occurred 
concomitant events were registered and, if possible, diagnosed; the start and end dates 
were mentioned, and the action undertaken (view appendix). 
The involvement in the intervention did not impose any medical restriction except for the 
intake of antiretroviral medication. A therapy affecting the main outcome could be the 
intake of steroids, cortisone, or dexamethasone. Immunosuppressive medications are not 
part of the standard therapy for people with an immunodeficiency syndrome. It is 
prescribed, for example, in cases of heavy malaria outbreak. Dexamethasone is usually taken 
at the beginning of the hospitalization to minimize the risk of encephalitis and to protect the 
blood-brain barrier from an acute inflammation that would lead to the parasite appearing in 
the brain (van de Beek, Farrar et al. 2010). Any patient taking this therapy was excluded, and 
it was mentioned as a co-medication. Anyone hospitalized due to an accident or tuberculosis 
was also noted as excluded for co-medication. The patients were also excluded from 
intervention in cases of pregnancy or the start of HAART. Other study dropouts were caused 
by the patient herself due to consensual withdrawal or travelling. 
2.10 Compliance 
A follow-up of the intervention compliance was implemented through daily self-reporting on 
the flyer by the patient. The patient was asked to document her daily intake of pills; general 
condition on that day;  appetite;  tiredness; events such as headaches, abdominal pains, and 
vomiting; and the dejection texture. There were 28 days between the meetings, and 30 daily 
portions were distributed. A compliance break was established by a delay of more than two 
days to the monthly monitoring meeting without reason. At each meeting, the patient and 
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the personnel in charge discussed the flyer. The number of pills was checked by counting the 
intake mentioned on the flyer and cross-checked by asking how many pills were left. 
A 24/7 hotline ensured prompt management of complaints. In the case of severe complaints, 
the patient was invited to the office to see the medical staff. All information and measures 
were meant to build a trusting relationship between the medical personnel and the patient. 
No written protocols were made during the personal discussions or phone calls. Only 
medical data were summarized in the patient file, and the patient flyers were filed. 
Furthermore, no blood sampling was done during an acute malaria crisis. In such a case, the 
patient was asked to come back one week later. Additional pills were given to the patient to 
cover the time gap. 
2.11 Quality Control 
The intervention was conducted by three persons, each of them having specific 
responsibilities. Francois Emakam coordinated the patient meetings, designed the 
questionnaires, and conducted the 24-hour recalls. He was the only person with access to 
the participant list with their names and phone numbers. Furthermore, he managed the 
hotline during the intervention. Dr Djenabou conducted all anthropometric measurements, 
filled in the medical history file on the basis of the hospital data, and conducted 
conversations with the patients. She handed out the supplement and the results of the 
blood analysis. She was in direct contact with the principal investigator, Dr Azabji, who was 
responsible for good clinical practice. The blood sampling was taken by a nurse of the HDJ 
under the supervision of Frank Winter. He was responsible for the analyses of the blood 
samples as well as the logistic part of the intervention. 
The HDJ is 100 meters away from the CPC. The HCY and the CPC are in the so called ‘île de la 
santé’, or ‘health island’ in Yaoundé. In there the best possible electricity and water supplies 
were guaranteed. 
The collected data complied with high-quality standards. The anthropometric measurements 
were performed with strict regard to the initial description by the same person throughout 
the entire intervention. The materials were used exclusively for this study and were stored 
as described. All laboratory analyses were done at the Centre Pasteur Cameroon in a 
controlled environment in accordance with good laboratory practice. Samples were analysed 
immediately after the laboratory had received them. If an automaton was in maintenance or 
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any reactive was missing, the blood sampling was not performed and was delayed until all 
tests could be processed. Tests results were collected a day later and controlled on 
likelihood. The laboratory results were printed in two copies, one for the study file and one 
that was handed out with an explanation to the patient by the clinic personnel. The patients 
were identified by their intervention ID number. This way the laboratory data could only be 
linked to the patient by the clinic personnel in charge. The data was managed by the same 
personnel from the beginning until the end of intervention. Data input was done in duplicate 
by an external study secretary using the software Epidata®. The database generated by 
Epidata® was controlled on plausibility by the statistician in charge of the study. No analyses 
were performed before the database was closed. 
2.12 Data Analysis 
The analysis of the collected data was done after the database had been checked and closed 
by the working group for medical statistics of the Department of Medical Information 
Technology in the Medical Faculty of Giessen. The double data entries were performed with 
Epidata® software. The two generated databases were compared. Discrepancies were 
corrected. The complete database was then transferred to SPSS® for analysis. 
 Efficacy Outcomes 
The main objective was to determine whether a three-month supplementation of five grams 
of Arthrospira p. is superior compared to a placebo with regard to the infection marker 
CD4+lymphocyte and the viral load count. Furthermore, the blood immune activation, 
inflammatory, and nutritional markers of the two RCT groups were compared. The immune 
activation outcome was based on the CD38-CD8 cells. Inflammation was defined by the C-
reactive protein concentration level. The ratio of concomitant events occurring over the 
intervention was documented. Outcomes related to nutrition were body weight, albumin, 
TAOS, anaemia status, iron, lipid status, and the elimination status. The outcome changes 
were interpreted through cut points as follows: 
For the immuno-virology aspect, a stabilization or increase in CD4 cells and a lowering of the 
viral load combined with a CD4 cell increase can be regarded as a positive effect. Patients at 
these stages show a loss of CD4 cells bound to a high viral load (Mellors, Munoz et al. 1997; 
Lima, Fink et al. 2009). The endpoint is a decline in the effect of antiretroviral medication 
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with a gain of 100 CD4 cells/mm3 in three months and a 1 log lowering of the viral load 
during the same time (Bourgeois, Laurent et al. 2005).
 Supplementation of Asp results in an increase of CD4 cell count by 100 cells/mm3
 Supplementation of Asp results in a lowering of 1 log of the viral load 
The immune system reacts to pathogensviaCD38 up regulation on CD8 lymphocytes. 
Research shows that an increased CD38 expression is related to an increased risk of AIDS 
(Mocroft, Bofill et al. 1997). At this stage, stabilization or lowering can be considered 
beneficial for the patient (Tilling, Kinloch et al. 2002). 
 Supplementation of Asp results in a lowering of the immune activation, CD38-CD8 T cell 
Inflammatory aspect 
The inflammatory marker depends on the presence of an inflammatory process going on in 
the body. C-reactive protein can also be a marker for an aggravation of the infection during 
the AIDS stage (Feldman, Goldwasser et al. 2003). This marker is not linear but exponential 
when inflammation is present. The CRP value is normally <6 mg/l in adult patients. For a 
better visualization, the inflammation status was dichotomised into yes or no.
 Supplementation of Asp results in a CRP level under 6 mg/l 
Concomitant events were documented by the medical register created for each patient. The 
rates of concomitant events were handled per symptom frequency shown during the period. 
The events were categorised into headache, gastrointestinal events, diarrhoea, malaria, 
opportunistic infection, respiratory infection. 
 Supplementation of Asp results in an absence of outbreak of concomitant events 
Nutrition outcomes 
The bodyweight measurement during the study was one indicator of nutritional intake and 
disease progression. The pre-HAART period is often characterized by a decrease in body 
weight (CDC 1987). A decrease can be due to intake problems and increased energy needs 
during the infection.
 Supplementation with Asp and placebo results in body weight stabilization or increase 
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The total antioxidant capacity of the serum (TAOS) is related to the infection by a decrease, 
which is related to an increase in oxidative stress (Suresh, Annam et al. 2009). The oxidative 
balance is disturbed by infection progress. Pre-HAART patients are characterized by low 
TAOS (Coaccioli, Crapa et al. 2010). An increase in the antioxidative potential is to be 
considered a positive outcome. 
 Supplementation of Asp results in an increase in TAOS 
The serum albumin level is considered a good predictor of the severity of the HIV disease in 
individuals who are not taking antiretroviral therapy and can also indicate the extent of a 
patient’s response to HIV treatment (Graham, Baeten et al. 2007). Furthermore, the value 
gives information about the patient’s nutritional and hydration status. Albumin is the most 
abundant protein in blood serum, normally ranging between 35 and 50 g /dl. 
 Supplementation of Asp results in stabilization of plasma albumin (at normal value) 
Anaemia is defined as a condition in which red blood cells and consequently their oxygen-
carrying molecule haemoglobin insufficiently meet the body’s physiological needs (WHO 
2008). Anaemia was defined by a haemoglobin (Hb) value lower than 11 g/dl (WHO 2011). 
Normal haemoglobin values in adult women ranges between 11 and 16.9 g/dl. The 
supplementation hypothesis on haemoglobin concentration is the following: 
 Supplementation of Asp results in a stable Hb concentration 
Furthermore, red blood cell count (RBC) is used in the current study to measure the effect of 
the intervention on the cell’s synthesis and erythropoiesis. RBC has a major influence on Hb 
and anaemia. The normal erythrocyte rang value is 3.5 to 5.5 Tera/l.
Supplementation of Asp results in a stable amount or increase in erythrocyte cell count 
The measure of total serum iron is related to the free iron in the body and is bound to 
dietary intake. It is also related to chronic inflammation and infection (Wessling-Resnick 
2010). Normal values in adult women range between 0.5 to 1.5 mg/l. 
Supplementation with Asp improves serum iron concentration. 
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Lipid profile is defined in the study by total cholesterol (TC) and triglycerides (TG), which 
are important markers in the course of HIV infection. The interaction between the two 
markers is a TC decrease and a TG increase, which stands for HIV-related complications (El-
Sadr, Mullin et al. 2005). Further disturbances in the lipid profile are outcomes of HAART 
medication. The pathology of lipodistrophy is related to an HIV infection and especially to 
HAART. The cut-off points used in the current study to determine lipodistrophy were TC≥2 
g/l and TG ≥ 1.50 g/l (NCEP 2002). A lowering or stabilization of these variables is considered 
a good effect of the intervention. Normal cholesterol values for adults are between 1.8– 2.8 
g/l; for triglyceride, normal values are under 1.5 g/l or 1.69 mmol/l; TG values over 2 g/l are 
considered elevated.
 Supplementation of Asp has a stabilizing effect on cholesterol and triglyceride (at normal 
values) 
Renal function is compromised due to an HIV infection, which can lead to nephropathy 
(HIVAN). Urea and creatinine serum are used to estimate renal function through the 
glomerular filtration rate (eGFR). The eGFR is estimated through the modification of diet 
renal disease (MDRD) formula chronickidney disease epidemiology collaboration published 
in May 2009 (Levey, Stevens et al. 2009). The formula is adjusted for black women and 
accurate to the serum creatinine concentration, blood urea concentration, and albumin 
concentration in the blood. 
eGFR= 170 x serum creatinine -0.999 x age-0.176 x urea-0.17 x albumin0.318x 0.762 (woman) x 1.18 
(black) 
eGFR is expressed in ml/min 
Renal failure is determined by eGFR<60ml/min and serum creatinine >2 g/dl. Furthermore, 
the serum concentrations are documented and analysed independently from each other and 
put in relation to the eGFR. The serum urea measurement is a common indicator for renal 
function, dehydration, and protein-rich food. Normal values for adult women are between 
0.1– 0.5 g/l. Measuring serum creatinine is a common indicator for renal function. A rise in 
blood creatinine level is observed only in cases of marked damage to functioning nephrons.
 Supplementation of Asp results in no change in the urea and creatinine presence in serum 
and a normal eGFR 
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 Statistics 
The statistic approach defined first the populations involved in the intervention. The 
characteristics of the populations were age, height, DDS, marital status and education level. 
The populations’ characteristics were compared for the pre-HAART at baseline between 
compliant and excluded. The intervention results start with a description of the compliance, 
where the exclusion reasons were summarized by population and over the intervention 
time. 
The study efficiency outcomes were analysed in three different approaches.  
- In the RCT intervention the outcomes were compared in terms of superiority of Asp 
compared to placebo. 
- The long-term intervention focused on the evolution of the outcomes over six 
months of Asp supplementation. 
- The crossover intervention profile analysed the difference between the placebo and 
Asp occurring in the same population. 
The efficacy outcomes were analysed inside each group and compared to the other groups 
for each intervention approach. The focus was on the changes occurring during the 
intervention. To describe the evolution of each variable, the difference between the start 
and the end of the intervention was calculated. Accordingly the results for one outcome in 
the RCT intervention are defined by three values: a baseline, the three-month point, and the 
difference between baseline and three months. The six-month intervention follows the 
intention to document a long-term exposure to Asp. For this, the group was only defined by 
the baseline, three-month, and six-month values. A further purpose of the crossover 
intervention was to compare the change occurring during placebo supplementation to the 
change occurring during the Asp supplementation. The group was documented by two 
values, change under placebo and the change occurring during the Asp. 
Further correlations were achieved in order to describe and relate the change in initial value 
that occurred during the intervention. 
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TABLE 2.4 STATISTICAL APPROACH PER INTERVENTION 
 
Baseline 
Three 
months 
Difference 
3 months –
baseline 
Six 
months 
Difference 6 
months – 3 
months 
Main 
statistical 
test 
Pilot-RCT X X X   
Mann 
Whitney 
Long-term X X  X  
Friedman 
ANOVA 
Crossover X  X  X 
Wilcoxon 
rank 
X stands for a description of the value as mentioned below. 
 
All variables of the intervention groups were summarized and analysed with the patient set 
that finished the intervention, called the full analyses set (FAS). Variables were described as 
mean (standard deviation) and/or median (interquartile range; IQR) and 
minimum/maximum. For qualitative variables, the absolute and relative frequencies of the 
categories were computed as a percentage. 
For the RCT intervention, the superiority of Asp to the placebo was checked by testing null 
hypotheses: “There was no difference in the variable level for patients treated with 
Arthrospira p. compared to the placebo: µAsp =µPlacebo”. The superiority of Asp to the placebo 
was demonstrated if the p value (2 sided) was less than 0.05 (significance level), and the 
0.95confidence interval lay entirely to the right of (higher than) 0. The assumption of 
independence was achieved for the RCT with the trial construct. All analyses performed 
inside each group on the same population fulfilled the assumption of data dependence. 
The choice of the statistical test was made in order to have a comprehensive and common 
analysis over the entire study. For this purpose, the same test form was chosen for all 
statistical analyses in the study. As the number of patients in each group finishing the study 
was less than 30, the non-parametric tests are to be considered more consistent (Kitchen 
2009). The Mann-Whitney U test was used (comparison of two proportions) when the 
assumption of independence was valid. Wilcoxon ranks were used when the variables were 
analysed inside the same population, and the assumption of dependence was achieved. In 
the case of repeated measurements, as in the case of the long-term intervention, the 
analyses were performed with the Friedman one-way ANOVA. If the ANOVA result was 
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significant, a post hoc analysis was conducted based on three Wilcoxon rank tests between 
the three sampling points: baseline – three months, three months – six months, and baseline 
– six months. The correction for multiple testing was applied for post hoc tests through 
Bonferoni correction. The significance level was adjusted to the number of tests as follows: p 
value multiplied by the number of tests, in the present case three. The effect magnitude of 
all statistical tests performed in the study was reported by the effect size r. The variable ‘r’ 
was calculated with the following formula (z/√n). R shows the importance of an effect 
related to the observation population. 
 Analysis Population 
o Statistical Population Set 
The intervention population could be divided in three statistical population sets: the safety 
population, the full analysis set, and the per-protocol population. They were defined as 
follows: 
The full analysis set (FAS) was a subset of the safety population including all randomized 
patients who received at least one supplementation dose and who had at least one 
assessment of the primary parameter after randomization, the baseline population. 
The per-protocol (PP) population included all patients in the FAS without any major protocol 
violation. Patients were analysed according to the intervention they received. Major 
protocol violations were an intake of less than 504 caps during the 12 weeks (168x3; 28x6 = 
168 because 6 caps a day represents the minimal doses). If the patient took less, she was 
included in the FAS. Moreover, between the sample time 0 and the sample time 12 weeks, 
the day limit should not be over 98 days (12x7 plus 14 days, since more caps were 
distributed for 6 extra days). If the intervention time was over this limit, the patient was 
included without adding a supplement in the FAS, not in the PP. The intake of 
immunosuppressive medication such as steroids, cortisol, and dexamethasone was also a 
criterion for exclusion from the PP. 
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 Intervention Groups 
The intervention population was a per-protocol population. This population was involved in 
a three-month randomized control trial followed by an open-labelled intervention of three 
months, which could mean an intervention duration of six months. The randomization at 
baseline divided the pre-HAART population into two comparable groups, Arthrospira and 
placebo. The patients who wanted to continue the open-labelled intervention had to fulfil 
the baseline inclusion criteria and, especially, had to not be eligible for HAART (CD4 > 350 
cells/mm3). The randomization between the groups was abrogated for the open-labelled 
period. The groups achieving six months of intervention could not be compared to each 
other; comparisons could only be carried out within the individual OLI groups. The analyses 
were achieved on the population as follows: 
The randomized control intervention, patients were given placebo for 12 weeks against 
Arthrospira for 12 weeks. 
In the long-term exposure group, patients were supplemented for 24 weeks with 
Arthrospira. 
The patients supplemented for 12 weeks with placebo and 12 weeks Arthrospira were part 
of the crossover group in the open-labelled analyses. 
 Software 
Data entry was achieved and controlled by Epidata. The database was imported to SPSS 
version 20.0 (SPSS, Chicago, IL) for statistical evaluation.
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3 Results 
3.1 Timeframe of the Trial 
The randomized controlled study included a total of 73 participants after screening 516 pre-
HAART patients between June and September 2010. The study was finished in December 
2010 with 58 participants. Of those 58, 36 continued for the following three months of 
exclusive Asp supplementation in the open-label intervention until March 2011. Thirty 
patients accomplished the six-month intervention. 
3.2 Recruitment Summary 
The screening results on patient files were estimations. The percentage of patients’ files not 
under HAART was between 8 and 16% of all files checked. The sex ratio was approximately 
one man to six women. The diagram of recruitment below shows the recruitment steps and 
the intervention with the patients effective. 
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weeks) 
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FIG 3.1: THE DISPOSITION OF THE PATIENT GIVES AN OVERVIEW OF PATIENT HANDLING DURING THE STUDY 
The data were collected during screening, baseline, after three months, and after six months. The 
dropouts were divided into two categories: health issues/adverse event and social events/unset 
response. The 2indicates the supplementation groups during the open-labelled intervention. 
 
The repartition in the statistical populations was achieved in the safety population, full 
analysis set, and per protocol. 
- The safety population consisted of 73 pre-HAART patients grouped into two groups, 
36 participants in the placebo group and 37 in the Asp group. 
- The full analysis set included 30 participants of the placebo and 28 of the Asp group. 
- The per-protocol population included 14 placebos of the placebo group and 17 of the 
Asp group. 
- The open-labelled intervention (OLI) stands for the patients known to have taken at 
least three months of Asp supplement. The 2indicates the pre-HAART groups during 
the open-labelled intervention. 
3.3 Exclusion and Compliance Analysis 
 Exclusion Reasons 
Exclusion reasons were divided into five categories: 
1. Reaching the endpoint of CD4 <350 cells/mm3, thereby having to start HAART 
2. Starting a relevant co-medication as heavy medication therapy, for example 
tuberculosis or a hospitalization 
3. Withdrawal of consent 
4. Lost to follow-up 
5. Pregnancy 
Reasons for exclusion varied between the placebo and treatment group during the RCT. Ten 
placebo patients were eligible for HAART compared to five out of the Asp group. The rate of 
withdrawal of consent and the lost to follow-up were similar in all groups. Over an 
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intervention time of six months, the same exclusion rate was reached in both pre-HAART 
groups. Twenty-three out of 36 patients in the placebo group did not complete six months of 
intervention, as with 19 out of 37 patients in the Asp group. That results in a dropout rate of 
63% and 51% in the placebo and Asp group, respectively. 
 
FIG 3.2 HISTOGRAM OF THE DROPOUT REASONS PER GROUP OVER THE STUDY 
The histogram shows the dropout reasons by effective in each group, the pre-HAART with the 
mentioned placebo and Arthrospira. 
The pre-HAART study population participated in a six-month intervention and was the 
subject of the RCT intervention in the first three months. The chronology was divided into 
three periods: the two intervention periods and the period in between. 
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FIG. 3.3 REASONS FOR EXCLUSION AT DIFFERENT INTERVENTION PHASES 
The diagram presents the exclusion reasons over the intervention. The dropout frequencies are 
represented by the coloured areas. The “n” stands for the total drop out on the total population 
given in percentage. 
 
During the RCT, the exclusion rate reached 20%.The highest dropout (38%) was present, 
when participants finished the RCT and started with OLI. Here, the two major exclusion 
reasons were the start of a HAART therapy with 55% and withdrawal of consent with 27%. 
During OLI the dropout decreased to 16%. The main reasons were the start of HAART 
medication or relevant co-medication. 
 Variable Analyses 
The variable and patient information was analysed; those who were excluded during the 
intervention were compared to those who had completed a six-month intervention. These 
analyses included exclusively pre-HAART patients. 
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TABLE 3.1 MARITAL & EDUCATION LEVEL OF EXCLUDED AND COMPLIANT 
 Excluded 
n=43 
Compliant 
n=30 
Variables 
Frequency 
(Patient) 
Percent 
(%) 
Frequency 
(Patient) 
Percent 
(%) 
Marital status 
single 37 86 29 96.7 
married 6 14 1 3.3 
Level of education 
primary & secondary 39 90.7 23 76.7 
university & tertiary 4 9.3 7 23.3 
 
TABLE 3.2 INFLAMMATION & ANAEMIA IN EXCLUDED & COMPLIANT 
 Excluded 
n=43 
Compliant 
n=30 
Variables 
Frequency  
(Patient) 
Percent 
(%) 
Frequency  
(Patient) 
Percent 
(%) 
Inflammation 
normal 37 86 26 87 
inflammation 6 14 4 13 
Anaemia 
normal 27 62 22 73 
anaemia 16 37 8 27 
 
66% of the anaemic patients at baseline did not complete the intervention. The presence of 
an acute inflammation at baseline did not seem to have any relation to the exclusion. 
Furthermore, more highly educated persons completed the study than less educated 
persons. The same was true for unmarried women. 
The variable comparison between the exclusion and six-month compliant patients was 
significantly different for RBC: r=.23, p=.041, and haemoglobin: r=.24, p=.037. An overall 
better health status could be found in the patients who concluded the intervention. The 
median immune activation, CRP, triglyceride, cholesterol, and urea were smaller in the 
compliant group than in the exclusion group. In contrast, BMI, CD4, TAOS, haemoglobin, 
iron, and albumin were higher. 
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3.4 Randomized Control Intervention 
 Study Population Characteristics 
The RCT deals with the pre-HAART patients who completed three months of 
supplementation. The following analyses were made with regard to the fully analysed 
population. Variables defining the population in terms of age, education, marital status, and 
anthropometric values are presented here. 
TABLE 3.3 RANDOMIZED INTERVENTION GROUPS, CONSTANT VARIABLES 
 Placebo n=30 Arthrospira n=28 
Variables Mean (SD) Median (IQR) Min-Max Mean (SD) Median (IQR) Min-Max 
Age (year) 31.3 (8.0) 33 (25–36) 18–48 30.2 (7.9) 27 (25–36) 19–47 
IDDS 4.8 (1.7) 5 (4–6) 1–8 5.3 (1.6) 5 (4–6.5) 2–8 
Height (m) 1.62(0.06) 1.64(1.58–1.66) 1.48–1.75 1.63(0.06) 1.62(1.59–1.67) 1.53–1.73 
Weight (kg) 57 (6) 57 (55–62) 46–70 58 (7) 57 (53–62) 48–73 
BMI (kg/m2) 22 (2) 22 (20–23) 17–26 22 (2) 22 (20–23) 18–26 
 
The placebo group had a median age of 33 (25– 36) years compared to 27 (25– 36) years for 
the Asp group. The IQR were the same for both groups, and the median difference was not 
significant: r=.07, p=.513. Height was equal in the two groups, being approximately 1.63 
(0.06) meters, r=.08, p=.944. 
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TABLE 3.4 MARITAL STATUS & EDUCATION LEVEL BETWEEN THE GROUPS 
  PLACEBO ARTHROSPIRA TOTAL 
REASONS 
FREQUENCY 
(PATIENT) 
PERCENT 
(%) 
FREQUENCY 
(PATIENT) 
PERCENT 
(%) 
FREQUENCY 
(PATIENT) 
PERCENT 
(%) 
MARITAL 
STATUS 
SINGLE 21 70 24 86 45 77 
MARRIED 2 7 1 3 3 5 
DIVORCED 
& 
WIDOWED 
7 23 3 11 10 17 
TOTAL 30 100 28 100 58 100 
EDUCATIO
N 
LEVEL 
PRIMARY 
&SECONDAR
Y 
26 87 23 82 49 84 
TERTIARY 
&UNIVERSIT
Y 
4 13 5 18 9 16 
TOTAL 30 100 28 100 58 100 
 
 Primary Objective 
The primary objective was to assess the effect on the infection markersCD4 cells count and 
viral load. 
 Lymphocyte CD4 
The CD4 variables were not normally distributed. The applied tests were non-parametric. 
The CD4 cell count at baseline between placebo and Asp was not significantly different: 
r=.04, p=.744 (Appendix Table 10.5). After 12 weeks of intervention, the placebo and the Asp 
supplement did not differ significantly from each other: r=.01, p=.901. Within the two 
groups, the CD4 cells count decreased significantly, for placebo -52 (-112– -16) cells/mm3: 
r=.67, p<.001, and for the treatment group -66 (-111–-20) cells/mm3 for Asp: r=.61, p<.001. 
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FIG 3.4 BOX PLOT OF T LYMPHOCYTE CD4 DIFFERENCE DURING THE RCT 
The box plot represents the median and the IQR of the difference occurring during the 12 weeks of 
RCT. The zero line represents the baseline value. The crosses stand for the mean. 
 Viral Load 
For the serum viral load, no significant difference could be reported between the groups; at 
baseline: r=.14, p=.262 and after 12 weeks intervention: r=.03, p=.774. Within the groups, 
the changes were insignificant for placebo: r=.18, p=.329 and Asp: r=.13, p=.501. One patient 
in each group displayed had confirmed infection with HIV-2 subtype, not detectable by the 
applied quantification method. Furthermore, three patients, two in the placebo group and 
one in the Asp group, showed an undetectable viral load after three months (see table 10.6 
in appendix). 
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FIG 3.5 BOX PLOT OF VIRAL LOAD DIFFERENCE DURING THE RCT 
The box plot represents the median and the IQR of the difference occurring during the 12 weeks of 
RCT in the placebo and Asp groups. The zero line represents the baseline value. The crosses stand for 
the mean. 
 Secondary Objective 
The immuno-inflammatory profile included the CD8 lymphocyte presenting the antigen 
CD38, the inflammatory marker CRP, and the adverse events recorded. 
 Immune Activation 
The assessment of the CD38-CD8 expression at baseline showed no significant difference 
between Asp and placebo: r=.08, p=.513. After the RCT period, the groups did not differ from 
each other: r=.04, p=.732. Within the groups, Asp median decreased by -1.3% (-5.8– 2.0) and 
-0.9% (-4.17– 1.56) for placebo. However, the decreases were not statistically significant, 
respectively Asp: r=.24, p=.185 and placebo: r=.18, p=.327. The effect sizes were small to 
very small for the immune activation decrease in placebo and Asp. The small decrease 
difference that occurred during the RCT correlated with the baseline CD8-CD38 value: Rho=-
.325, p=.01 (see table 10.7 in appendix). 
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FIG 3.6 BOX PLOT OF CD8-CD38 DIFFERENCE DURING THE RCT 
The box plot represents the difference occurring during the RCT in the placebo and Asp groups. The 
horizontal line stands for no change over the intervention. The cross represents the mean. Stars and 
dots stand for outlying patients. 
 C-Reactive Protein 
C-reactive protein has an exponential expression with high fluctuation. It occurs in strong 
outline influence (see graph below). CRP variable was dichotomized into active inflammation 
and no inflammation. At baseline, the clinical inflammation rate was 10% in both groups. 
After the intervention, the placebo group had an inflammation rate of 20% compared to 18% 
in the Asp group. The effect sizes of the CRP concentration variation in the groups were very 
small, only a few patients showed high fluctuation: inside the placebo group r=.18, p=.325 
and r=.06, p=.374 inside the Asp group. 
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FIG 3.7 BOX PLOT OF C-REACTIVE PROTEIN DIFFERENCE DURING THE RCT 
The box plot shows the difference occurring during the RCT in the groups. Three outlying placebo 
patients had an increase over 10 mg/l and are not shown, neither are two patients with a decrease 
over 40 mg/l. Two outlying patients from the Asp group had a decrease 40 mg/l and are not shown 
on the box plot. 
 
In the following table the inflammation was dichotomized between normal and presenting 
an active inflammation. The inflammation status was described by a cut-off point for the CRP 
concentration over 6 mg/l. 
TABLE 3.5 INFLAMMATION OUTBREAK DURING RCT 
 Placebo n=30 Arthrospira n=28 Total 
 Inflammation CRP n % n % n % 
Baseline Normal 27 90 25 89 52 90 
> 6 mg/l  3 10 3 11 6 10 
After 12 Normal 24 80 23 82 47 81 
weeks > 6 mg/l  6 20 5 18 11 19 
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 Concomitant Event 
The concomitant event incidences were documented on the basis of the population that 
finished the RCT intervention, for the full analysis population of the RCT (see table 10.9 in 
appendix). Each placebo patient had a concomitant event incidence of 0.7. An Asp patient 
showed an incidence less than half of a concomitant event over the same time period. A 
total of 33 events occurred during the pilot RCT intervention, a third of which can be 
attributed to malaria. 
 
 
FIG 3.8 INCIDENCE OF THE CONCOMITANT EVENTS DURING THE PILOT RCT 
Patient frequencies of the events are noted by the number. 
 Third Objective 
The variables described below were nutrition-related outcomes of the RCT intervention. 
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 Body Weight 
Body weight was measured at baseline and after the RCT intervention (see table 10.10 in 
appendix). At baseline the groups were not significant: r=.02, p=.889. After 12 weeks of 
intervention, the placebo and the Asp supplement did not differ from each other: r=.05, 
p=.697. The differences occurring during the intervention in each group, placebo 0.6 (-0.1– 
2.9) kg and Asp 0.5 (-0.3– 1.6) kg, were not significant: r=.21, p=.105. Body weight increased 
significantly in the placebo group: r=.52, p=.005 but not in the Asp group: r=.12, p=.517. 
 
 
FIG 3.9 BOX PLOT OF BODY WEIGHT DIFFERENCE DURING THE RCT 
The box plot represents the difference occurring during the 12 weeks of RCT in the placebo and Asp 
groups. The horizontal line stands for no difference between baseline and 12 weeks. The cross 
represents the mean. 
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 Total Antioxidant Status 
Both groups had a similar TAOS value at baseline: r=.14, p=.269. After 12 weeks, the groups 
significantly differed: placebo 336 (275– 373) µM, Asp 387 (320– 430) µM: r=.30, p=.023. The 
difference occurring during the intervention between the groups was highly significant: 
placebo -22 (-64– 19) µM; Asp 56 (1– 98) µM: r=.51, p<.001. The change inside the groups 
was also significant, with an increase in the Asp group: r=.51, p=.007 and a decrease in the 
placebo group: r=.48 p=.008 (see table 10.11 in appendix). 
 
FIG 3.10 BOX PLOT OF TAOS DIFFERENCE DURING THE RCT 
The box plot represents the difference that occurred inside the groups over three months, with the 
mean as a cross. The zero line stands for no difference between baseline and 12 weeks. The dots 
represent outlying patients. 
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 Albumin 
Both groups had the same albumin concentration at baseline: r=.01, p=.938. After 12 weeks 
there was no significant difference between the groups: r=.03, p=.796. The difference that 
occurred during the intervention was also not significant between the groups: r=.07, p=.595. 
However, the decrease within the groups was statistically significant: placebo -1.5 (-4.0– 1.0) 
g/l: r=.39, p=.034 and Asp -3 (-4– 0) g/l: r=.42, p=.026. The effect size stood for a medium 
lowering in both groups (see table 10.12 in Appendix). 
 Anaemia 
The table below represents the anaemia incidence per group, at baseline and after the RCT 
intervention. The anaemia was defined as haemoglobin< 11 g/dl. 
TABLE 3.6 ANAEMIA IN THE RCT GROUPS 
 Placebo n=30 Arthrospira n=28 Total 
Anaemic, Hb 
Frequency 
(Patient) 
Percent 
(%) 
Frequency 
(Patient) 
Percent 
(%) 
Frequency 
(Patient) 
Percent 
(%) 
Baseline Normal 18 60 21 75 39 67 
Anaemic 12 40 7 25 19 33 
After 12 
weeks 
Normal 15 50 16 57 31 53 
Anaemic 15 50 12 43 27 47 
 
The absolute number of anaemic patients increased over the intervention in both groups 
from 12 to 15 patients in the placebo group and from 7 to 12 patients in the Asp group. The 
relative proportion of anaemic patients at baseline was 40% in the placebo compared to 25% 
in the Asp group. After the RCT intervention, the proportion was 50% in the placebo group 
compared to 43% in the Asp group. 
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 Haemoglobin 
TABLE 3.7 HAEMOGLOBIN 
 Placebo n=30 Arthrospira n=28  
Haemoglobin 
(g/dl) 
Mean(S
D) 
Median 
(IQR) 
Min-Max Mean(SD) 
Median 
(IQR) 
Min-Max 
U-test 
(p=) 
Baseline 11.4 (1.9) 11.9(10.5–12.8) 5.7–14.6 11.9 (1.4) 11.9(11.1–12.9) 8.9–14.8 .3 
After 12 
weeks 
10.8 (1.7) 11.1(9.1–12.2) 7.6– 14.5 11.6 (1.5) 11.8(10.6–12.5) 9.1–14.8 .07 
Difference -0.6 (1.2) -0.8(-1.3– -0.2) -2.7– 3 -0.3 (1.1) -0.3(-0.7–0.0) -4.2–2.5 .07 
Wilcoxon (p=)  .003*   .031*   
*p<.05 
Both groups had similar haemoglobin values at baseline: r=.12, p=.371. The groups did not 
differ significantly after 12 weeks of intervention: r=.24, p=.073. The difference occurring 
between the groups was not significant: placebo -0.8 (-1.3– -0.2) g/dl and Asp -0.3 (-0.7– 0.0) 
g/dl: r=.24, p=.071. However, the decreases within each group were significant for Asp: 
r=.40, p=.031 and for the placebo group: r=.54, p=.003. 
 Erythrocyte Count 
The randomized groups had the same count of erythrocytes at baseline, r=.04; p=.773 (see 
table 10.13 in appendix). The groups did not differ significantly from each other after 12 
weeks of intervention: r=.06, p=.663. The change occurring during the intervention was not 
significant between the groups: r=.21, p=.109. The decrease within both groups was 
significant: placebo r=.68, p<.001 and Asp: r=.57, p<.002. The two groups had a large effect 
size for the decrease; the placebo group r=.68 was higher for a median decrease of -0.4 (-
0.5– -0.2) tera/l, compared to the Asp at an effect size of r=.57 and a median decrease of -
0.3 (-0.4– 0.0) tera/l. 
 Iron 
Both groups had a comparable iron concentration at baseline: r=.03, p=.795 (see table 10.14 
in appendix). The groups did not differ significantly after 12 weeks intervention: r=.10, 
p=.415. The differences occurring during the intervention between the two groups were not 
significant: r=.11, p=.402. The decrease inside the Asp group was not significant: r=.01, 
p=.949, nor was the decrease in the placebo group: r=.13, p=.480. 
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 Lipid Profile 
The variables below document the lipid profile of the patients involved in the intervention by 
the total cholesterol and the triglyceride concentrations (see tables 10.16 and 10.17). 
- Cholesterol 
The randomized groups had a comparable TC concentration at baseline: r=.05, p=.686. The 
groups differed but not significantly from each other after 12 weeks intervention: r=.21, 
p=.114. The group-internal difference over the intervention was not significant between the 
groups: r=.22, p=.101. The decrease within the groups was significant for Asp:-0.14 (-0.47– -
0.04) g/l: r=.55, p=.004but not for the placebo median -0.07 (-0.20– 0.06) g/l: r=.28, p=.113. 
The mean decrease was -0.20 (0.36) g/l for Asp and -0.08 (0.30) g/l for the placebo group. 
 
FIG. 3.11 BOX PLOT OF CHOLESTEROL DIFFERENCE DURING THE RCT 
The box plot represents the difference that occurred within the placebo and Asp groups over the 
intervention. The line stands for no change between baseline and 12 weeks. The dots represent 
outlying patients. 
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- Triglyceride 
The randomized groups had similar triglyceride concentrations at baseline: r=.05, p=.686. 
The groups differed but not significantly from each other after 12 weeks of intervention, 
r=.13; p=.286. The change that occurred inside the groups was not significantly different 
between the groups: placebo 0.07 (-0.16– 0.48) g/l, Asp 0.04 (-0.18– 0.2) g/l: r=.04, p=.72. 
The increase within the groups was not significant for Asp: r=.16, p=.407 and the placebo: 
r=.24, p=.188. 
 Renal Function 
The renal function in this study was defined by the serum creatinine, the serum urea 
concentration, and the calculated eGFR (see tables 10.-18. 10.19 and 10.20). 
- Urea 
Urea concentrations showed no significant difference at the beginning and over the 
intervention between the groups and within the groups. The randomized groups had similar 
urea values at baseline: placebo 0.19 (0.16–22) g/l and Asp 0.17 (0.13– 0.20) g/l: 
r=.20,p=.132. The groups did not differ significantly from each other after 12 weeks 
intervention: r=.13, p=.326. The changed urea concentration did not differ between the 
groups: r=.02, p=.882. The change within the groups was not significant for Asp: r=.03, 
p=.861 and the placebo: r=.02, p=.905. 
- Creatinine 
The randomized groups had identical creatinine concentration at baseline: r=.08, p=.527. 
The groups did not differ significantly from each other after 12 weeks intervention: r=.21, 
p=.097. The difference occurring over the intervention was significant between the groups: 
placebo 0.0 (-0.1– 0.1) g/dl, Asp 0.1 (0.0– 0.2) g/dl: r=.35, p=.008. The increase in the Asp 
group was significant: r=.59, p=.002. No change was observed in the placebo group: r=.12, 
p=.51. 
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FIG 3.12 BOX PLOT OF CREATININE DIFFERENCE DURING THE RCT 
The box plot represents the difference occurring during the RCT in the placebo and Asp groups in mg 
per litre. The zero line stands for no difference between baseline and 12 weeks. The crosses 
represent the mean. 
 
- eGFR 
The eGFR for the randomized groups did not differ significantly from each other at baseline: 
r=.12, p=.35. After 12 weeks the elimination ratio changed for placebo and Asp but not 
significantly between the groups: r=.15, p=.256. The differences occurring over the period 
were0.01 (-6.73– 4.62) ml/min for placebo: r=.04, p=.992 and -7.31 (-17.2– 0.95) ml/min for 
the Asp group. The groups differed significantly from each other: r=.32, p=.016. The change 
within the Asp group was significant with a large effect size: r=.55, p=.004. 
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3.5 Open Label Intervention 
The OLI treatment had two separate interventions: the long-term intervention and the 
crossover for the pre-HAART population. The variables for population characteristics are 
presented together for both intervention arms. Additionally, the inflammation and anaemia 
ratio as the concomitant events in the involved intervention arms are compared to each 
other at the beginning of the chapter. The results are regrouped into tables, one table for 
immuno-virological markers and four tables for nutrition-related markers (weight, TAOS, 
albumin, anaemia outcomes, lipid profile, and renal function tables). The results are 
summarized by median, IRQ, and minimum-maximum. The variables are presented in 
absolute values at each sampling point for the long-term intervention. The crossover 
compares the difference during the two three-month supplementation periods. 
 Population Characteristics 
The crossover group had a median age of 34 (26– 36) years compared to 25 (23– 30) years of 
the long-term group. The IDDS was smaller in the crossover group, having a median of 5 (4– 
6) index points, than in the long-term group, having a median of 6 (5– 6) index points. Height 
was equal in all groups with approximately 1.63 (1.59– 1.67) m. 
TABLE 3.8 MARITAL STATUS & EDUCATION LEVEL DURING OLIL 
  Crossover Long-Term 
Variables Frequency 
(Patient) 
Percent 
(%) 
Frequency 
(Patient) 
Percent 
(%) 
Marital 
status 
Single 8 61 15 88 
Married 1 8 - - 
12 Divorced & 
Widowed 
4 31 2 
Total 13 100 17 100 
Education 
level 
Primary 
&secondary 
9 69 14 82 
Tertiary 
&university 
4 31 3 18 
None at all - - - - 
Total 13 100 17 100 
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 Inflammation 
The inflammation status was dichotomized inactive inflammation with a CRP over 6 mg/l. 
Presented for each intervention arm at the three sampling time points. 
TABLE 3.9 INFLAMMATION STATUS PER GROUP 
 Crossover Long-Term 
Inflammation 
CRP > 6 mg/l 
Frequency 
(Patient) 
Percent 
(%) 
Frequency 
(Patient) 
Percent 
(%) 
Baseline 
Normal 11 84.6 15 88.2 
Inflam. 2 15.4 2 11.8 
Three 
months 
Normal 12 92.3 14 82.4 
Inflam. 1 7.7 3 17.6 
Six 
months 
Normal 11 84.6 16 94.1 
Inflam. 2 15.4 1 5.9 
 Anaemia 
The Hb concentrations were dichotomized into anaemic and non-anaemic patient sat a 
cutoff point of Hb<11g/dl. 
TABLE 3.10 ANAEMIA PREVALENCE DURING THE INTERVENTION 
 Crossover Long-Term 
Anaemia 
Prevalence 
Frequency 
(Patient) 
Percent 
(%) 
Frequency 
(Patient) 
Percent 
(%) 
Baseline 
Normal 9 69.2 13 76.5 
Anaemia 4 30.8 4 23.5 
12 
weeks 
Normal 9 69.2 9 52.9 
Anaemia 4 30.8 8 47.1 
24 
weeks 
Normal 8 61.5 9 52.9 
Anaemia 5 38.5 8 47.1 
 
The table above shows an increase of the overall number of anaemic patients over the 
intervention. The crossover group had only an increase of one patient who became anaemic. 
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The number of anaemic patients in the long-term supplemented group doubled during the 
intervention from four to eight patients. 
 Long-Term Intervention 
The long-term group includes 16 patients who were on Asp supplementation for six months. 
The Friedman one way ANOVA test was applied to document the changes between baseline, 
12, and 24 weeks. A post hoc test was applied and subsequently three Wilcoxon rank tests. A 
correction by Bonferroni through the multiplication of the p-value by the number of tests 
was achieved. 
o Immuno-Virological Marker 
The immuno-virological variables consisted of CD4 cell count, the viral load, and the CD38-
CD8 expression. 
TABLE 3.11 IMMUNO-VIRAL OUTCOMES OF THE LONG-TERM INTERVENTION 
 
CD4 (cells/mm3) Viral Load (log10) 
CD38-CD8 
Lymphocyte (%) 
Long-term 
n=17 
Median 
(IQR) 
Min-Max 
Median 
(IQR) 
Min-Max 
Median 
(IQR) 
Min-Max 
Baseline 440(427–559) 324–594 5.3 (4.8–5.8) 3.1–7.4 17.9(14.8–30.5) 11.5–46.9 
After 12 weeks 436*(340–502) 227–540 5.2 (4.8–5.9) 3.7–6.5 23.5(14.1–30.3) 10.4–40.4 
After 24 weeks 444(376–469) 261–586 5.3 (4.6–5.9) 2.8–6.5 18.7(14.6–27.3) 4.6–59.6 
*p<.05 
 
CD4 Lymphocyte 
The CD4 count showed a significant change over six months, X2(2)= 6.1, p=.046. Wilcoxon 
signed-rank tests were conducted to follow up the findings. CD4 count significantly 
decreased from baseline to 12 weeks, -64 (-104– -13) cells/mm³, r=.62, p=.03. It was 
followed by a non-significant increase between 12 and 24 weeks of 32 (-45–70) cells/mm3, 
r=.21, p>.99. Nine patients showed an increase compared to eight decreases between 12 
and24 weeks’ intervention. The decrease observed between baseline and 24 weeks was 
attenuated and not significant, r=.52, p=.09. 
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Viral Load 
Friedman’s ANOVA detected no significant change over the six-month intervention: X2 
(2)=0.82; p=.664. No post hoc test was applied. 
CD38-CD8 Lymphocyte 
The ratio increased from baseline to the 12-week assessment point and decreased again at 
24 weeks, from 18% (14.8– 30.5) to 23.5% (14.1– 30.3) after 12 weeks to end at 18.7% 
(14.6– 27.3). However, these changes were not statistically significant. The repeated ANOVA 
for non-parametric variables showed no significant change over the six-month intervention, 
X2(2)=1.412; p=.494, no post hoc test was conducted to go further. However, the data 
showed a decrease in the maximal activation values over the entire intervention from 47% 
to 40.5% and finished at 38%. 
o Nutrition Outcome Variables 
The following variables are related to the nutritional status of the patients. First the body 
weight, TAOS, and albumin are presented in one table, followed by the anaemia status, lipid 
profile, and renal function at the end of the chapter. 
 Body Weight, TAOS, Albumin 
The following part presents the body weight, serum TAOS, and albumin (see table 10.23 in 
appendix). 
Body Weight 
According to Friedman ANOVA, body weight changed significantly over the course of six 
months, X2(2)= 6.03, p=.049.During the first 12 weeks, median body weight increased by 1.2 
(-0.1– 1.7) kg, r=.41, p=.24. Over the following period from 12 to 24 weeks, body weight 
increased by 0.7 (-0.9– 1.5) kg, r=.27, p=.76. Thus, the overall increase was 1.5 (0.3– 3) kg, 
r=.49, p=.13. The low Friedman ANOVA score results in the post hoc test are not significant. 
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FIG 3.13BOX PLOT REPRESENTING BODY WEIGHT IN THE LONG-TERM INTERVENTION PER SAMPLING 
 
Total Antioxidant Status 
The TAOS outcome changed significantly over the six months, Friedman ANOVA, X2(2)= 21.5; 
p<.001 (see graph below). After 12 weeks the median TAOS increased by 85 (9– 130) µM, 
r=.59, p=.045. In the second period, the increase was 107 (32– 133) µM,r=.77, p=.003. The 
overall effect of Asp supplementation had an elevated effect size for a total increase of 198 
(88–254) µM, r=.85, p=.001. The correlation between the TAOS increase observed over the 
intervention and the baseline value was significant: Rho=-0.767, p<.001. 
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FIG 3.14 BOX PLOT REPRESENTING TAOS IN THE LONG-TERM INTERVENTION PER SAMPLING 
 
Albumin 
 
The Asp supplementation of 24 weeks significantly changed the albumin concentration, X2(2) 
=16, p<.001. The albumin decrease was significant over the six-month intervention with a 
high effect size: -4 (-8– -2) g/l, r=.77, p=.003. Between the two periods, the decrease was 
significant between 12 and 24 weeks and not significant between baseline and 12 weeks:-5 
(-6– 1) g/l, r=.58, p=.048 and -3 (-4– 0.0) g/l, r=.55, p=.069, respectively. 
 Hb, RBC, and Iron 
The following part presents the outcomes of haemoglobin concentration, red blood cell 
count, and iron concentration (see table 10.24 in appendix). 
The long-term Asp supplementation showed a significant effect on Hb over the six-month 
intervention: X2(2)= 6.48, p=.039. The applied post hoc test showed a significant decrease 
over the entire intervention over 24 weeks of -0.6 (-1.1– 0.0) g/dl, r=.63, p=.027. The 
decrease had a similar, non-significant extent during the two periods: for the first period-0.2 
(-0.7– 0.0) g/dl, r=.27, p=.24, and for the second period -0.3 (-0.8– 0.3) g/dl, r=.42, p=.78. 
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Regarding the minimal values at the three sampling times t0= 8.9 < t12= 9.1 < t24= 9.6 g/dl, 
an absolute light increase in values was observed. 
The RBC count showed also a significant change over the long-term supplementation: X2(2)= 
11.3, p=.003. The six-month decrease was significant: r=.80, p=.003. However, the main 
decrease occurred during the first intervention period of three months: -0.3 (-0.4– -0.1) 
tetra/l, r=.66, p=.028. The second period showed a slight increase for 7 out of 9 patients 
tested: 0.0 (-0.2– 0.2), r=.03, p> .99. 
But, there was no significant change in the iron concentration over the six-month Asp 
intervention. The Friedman ANOVA resulted in significant results, X2(2)= 0.222, p=.895. 
However, eight patients showed an increase, while seven had a decreased value. The 
median values showed an increase over the intervention from 0.7 to 0.9 mg/l. 
 Lipid Profile 
The following part presents the outcomes of the lipid profile, i.e. total cholesterol and 
triglyceride (see table 10.25 in appendix). 
Cholesterol significantly changed during long-term Asp exposure X2(2)= 7.731, p=.02. 
However, the post hoc test showed no significant change during the intervention with 
corrected p values. The highest effect size was registered during the first three months -0.13 
(-0.22– 1.53) g/l, r=.53, p=.09. The second period, from 12 to 24 weeks, showed no change: 
0.00 (-0.10– 0.23) g/l, r=.09, p>.99. The results of the overall intervention confirmed a small 
effect size: r=.26, p=.83 for a median decrease of -0.8 (-0.3– 0.11) g/l. 
 
The long-term intervention presented no significant change of the triglyceride concentration 
over six months X2(2)= 5.303, p=.07. In order to describe the variation, a corrected post hoc 
test was carried out. During the first three months, nine patients showed an increase: 0.02 (-
0.19– 0.18) g/l, r=.27, p>.99, followed by a decrease in 12 patients during the second three-
month period: -0.12 (-0.28– 0.0) g/l, r=.45, p=.193. The overall result was a decrease in 12 
patients, r=.37, p=.37. 
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 Renal Function 
The following part shows the assessed renal function variables creatinine and urea, with the 
subsequent calculated eGFR (see table 10.26 in appendix). 
Creatinine 
There was a significant change in creatinine concentration during the study, X2(2)= 17.8; 
p<.001. The post hoc test confirmed a significant increase during the first period: 1 (0– 2) 
mg/l, r=.63, p=.027, followed by a non-significant increase between 12 and 24 weeks: 1 (0– 
2) mg/l, r=.33, p=.519. The increase over the six-month intervention was significant with a 
high effect size: 2 (-1– 3) mg/l, r=.80, p=.003. 
 
 
FIG 3.15 BOX PLOT REPRESENTING CREATININE IN THE LONG-TERM INTERVENTION PER SAMPLING 
The long-term intervention had no significant effect of the urea over the six-month 
intervention: X2(2)= 0.215, p=.898. The fluctuation was +/- 0.01 g/l of urea. 
There was a significant change of the eGFR during the intervention: X2(2)= 13.765, p=.001. 
The first period had a significant decrease of -0.1 (-20.6– -2.3) ml/min, r=.64, p=.024, where 
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as the second period had one of-6.4 (-9.5– 0.7) ml/min, r=.48, p=.150. Overall, there was a 
significant median decrease of -14.3 (-20.1– -6.81) ml/min, r=.84, p=.003. 
 Crossover Intervention 
The crossover group included patients who were on placebo for three months, followed by a 
three-month Asp supplementation. As the population is dependent, the differences 
occurring during each period were compared via the Wilcoxon rank test. 
o Immuno-Virological Marker 
The following marker describes the immunological status with CD4 lymphocytes, the CD38 
expression on the CD8 lymphocytes, and the viral load see table 10.27). 
CD4 Lymphocyte Count 
The Wilcoxon rank test showed no significant difference in the CD4 median between the two 
periods: r=.20, p=.46. Both presented a decrease of -33 (-87– 14) cells/mm3 during the 
placebo period compared to a decrease of -14 (-71– 131) cells/mm3 during the Asp period. 
However, seven patients presented a positive and six a negative evolution of the CD4 after 
the implementation of Asp. 
 
FIG. 3.16 BOX PLOT REPRESENTING THE CD4 DIFFERENCE OCCURRING IN THE CROSSOVER POPULATION DURING 
THE TWO SUPPLEMENTATION PERIODS: PLACEBO AND UNDER ASP 
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The VL decreased over the six-month intervention by -0.4 (-0.6– -0.2) log10. However, the 
difference between the two periods was not statistically significant: r=.13, p=.65. The 
tendency of a decrease seemed more accurate when Asp was given, placebo 0.0 (-0.4– 0.2) 
log10 and Asp -0.2(-0.4– 0.1) log10. 
 
CD38-CD8 Lymphocyte 
There was no significant difference between the placebo and Asp treatment period: r=.26, 
p=.35. The intervention yield with placebo was -2.4% (-11.3– 0.4) and Asp of 0.0% (-11.2– 
3.5). However, the expression of CD38 on the lymphocytes tended to decrease over the 
entire intervention by -7.64 % (-16.1– 2.4). 
o Nutrition Outcome Variables 
The following variables are regrouped per outcomes or relationship. 
 Body Weight, TAOS, Albumin 
The following part presents body weight, TAOS serum variables, and albumin concentrations 
(see table 10.28 in appendix). 
Weight 
There was a significant difference in body weight change between both periods: r=.67, 
p=.015. The changes consisted of an increase of 0.4 (0.2– 2.5) kg during the placebo 
compared to a decrease of -1.1 (-2– 0.2) kg during the Asp period. 
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FIG. 3.17 BOX PLOT REPRESENTING THE BODY WEIGHT DIFFERENCE OCCURRING IN THE CROSSOVER POPULATION 
DURING THE TWO PERIODS: PLACEBO AND UNDER ASP 
 
Total Antioxidant Status 
The changes in TAOS values differed significantly between the two periods: r=.80, p=.004. 
During the placebo period, the median decreased by -54 (-103– 00) µM, compared to an 
increase of 67 (44– 243) µM after Asp implementation. 
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FIG. 3.18 BOX PLOT REPRESENTING THE TAOS DIFFERENCE OCCURRING IN THE CROSSOVER POPULATION DURING 
THE TWO PERIODS: PLACEBO AND UNDER ASP 
 
Albumin 
The occurring albumin changes between the two periods did not differ significantly from 
each other: r=.37, p=.484. The two periods showed the same tendency with median 
decreases of -2 (-5– 0) g/l during the placebo and 0 (-4– 1) g/l during the Asp period. 
 Hb, RBC, Iron 
The following part presents: haemoglobin concentration, red blood cells count, and iron 
concentration (see table 10.29). 
There was a significant difference in the haemoglobin concentration between the placebo 
and Asp periods: r=.54, p=.05. There was a decrease of -1.1 (-1.3– -0.5) g/l during the 
placebo in contrast to an increase of 0.2 (-0.7– 1.0) g/l during the Asp period. 
 
The change in RBC significantly differed between placebo and Asp: r=.82, p=.004. During the 
placebo period, the RBC decrease was -0.4 (-0.5–-0.3) tetra/l. In contrast, during the Asp 
supplementation, there was an increase of 0.3 (-0.2– 0.4) tetra/l. 
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The analyses of the iron difference registered during the two periods resulted in a non-
significant difference between the periods: r=.09, p=.726. The data showed a larger spread 
for the placebo 0.0 (-0.3–0.3) mg/l and alight increase of 0.1 (-0.1– 0.2) mg/l during the Asp 
period. 
 Lipid Profile 
Cholesterol 
There was no significant difference between the placebo and Asp period: r=.03, p=.917. 
Median TC decreased during the placebo period by -0.06 (-0.18– 0.0) g/l, and increased 
by0.05 (-0.15– 0.14) g/l in the Asp period (see table 10.25). 
Triglyceride 
Triglycerides did not differ significantly between the placebo and Asp group: r=.27, p=.328. 
However, there was an increase of 0.07 (-0.16–0.57) g/l during the placebo period compared 
to a decrease of -0.24 (-0.36–-0.08) g/l in the Asp period. 
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 Renal Function 
The variables below define the renal function for the present intervention, i.e. by serum 
creatinine, serum urea concentration, and the calculated eGFR (see table 10.26). 
The creatinine changes occurring during the two periods did not differ significantly from 
each other: r=.48, p=.083 (see figure below). However, creatinine remained the same during 
the placebo period compared to an increase after the Asp period: 0 (-2– 1) mg/l and 1 (0– 3) 
mg/l, respectively. 
Creatinine 
 
FIG. 3.19 BOX PLOT REPRESENTING THE CREATININE DIFFERENCE OCCURRING IN THE CROSSOVER POPULATION IN 
THE TWO PERIODS: PLACEBO AND UNDER ASP 
Urea 
There was not significant change in urea concentration in the two periods: r=.08, p=.263. The 
placebo period resulted in a decrease of -0.02 (-0.05– 0.01) g/l and the Asp supplementation 
period resulted in a low change of 0.0 (-0.02– 0.07) g/l.  
D
if
f. 
C
re
at
in
in
e 
(g
/l
) 
  
68 
The change of eGFR in both periods did not differ significantly but showed a high effect size 
in the periods: r=.51, p=.064. The placebo period resulted in an increase of 2.7 (-6.3– 4.6) 
ml/min. During Asp supplementation the eGFR decreased by -4.9 (-18.9– 0.1) ml/min. 
3.6 Resumption of the Intervention 
The different interventions were resumed by outcome for a better comparison. The effect 
size and the tendency have been summarized in the table below. The tendency was 
mentioned when it overstepped the variable method accuracy. 
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TABLE 3.12 TENDENCY AND EFFECT MAGNITUDE BY VARIABLE AND SUPPLEMENTATION 
D = decrease; S = stable; I = increase; * = significant 
r = effect size 
 RCT Long-term Crossover  
Variable Plac1 
n=28  
Asp1 
 n=30  
Asp1bis 
n=17 
Asp2 
n=17 
Plac1bis 
n=13 
Asp2bis 
n=13 
Variable 
Accuracy 
CD4 
D* 
r=.67  
D* 
r=.61 
D* 
 r=.62 
S 
r=.21 
D 
r=.44 
S 
r=.07 
36 
cells/mm3 
VL 
S 
r=.18 
S 
r=.13 
S 
r=.18 
S 
r=.00 
S 
r=.22 
D* 
r=.66 
 
CD38 
S 
r=.18 
D 
r=.24 
I 
r=.23 
S 
r=.05 
D 
r=.45 
D 
r=.24 
+/- 1% 
Weight 
I* 
r=.52 
I 
r=.12 
I 
r=.41 
I 
r=.27 
I 
r=.42 
D 
 r=.33 
+/- 0.1 kg 
Alb 
D* 
r=.39 
D* 
r=.42 
D 
r=.55 
D* 
r=.58 
D* 
r=.59 
I 
r=.22 
+/- 0.9 g/l 
TAOS 
D* 
r=.48 
I* 
r=.51 
I* 
r=.59 
I* 
r=.77 
D 
r=.49 
I* 
r=.88 
+/- 8 µM 
Hb 
D* 
r=.54 
D* 
r=.40 
D 
r=.27 
D 
r=.42  
D* 
r=.63 
I 
r=.17  
+/- 0.1 g/dl 
RBC 
D* 
r=.68 
D* 
r=.57 
D* r=.66 
S 
r=.03 
D* 
r=.88 
I 
r=.48  
+/- 0.02 
Tera/l 
Iron 
S 
r=.13 
S 
r=.01 
S 
r=.16 
S 
r=.19 
S 
r=.13 
S 
r=.19 
+/- 0.5 
mg/l 
TC 
D 
r=.28 
D* 
r=.55 
D 
r=.53 
S 
r=.09 
D 
r=.34 
S 
r=.01 
+/- 0.027 
g/l 
TG 
I 
r=.24 
S 
r=.16 
I 
r=.27 
D 
r=.45 
I 
r=.30 
D 
r=.48 
+/- 0.036 
g/l 
Creat 
S 
r=.12 
I* 
r=.59 
I* 
r=.63 
I 
r=.33 
S 
r=.24 
I* 
r=.65 
+/- 0.05 
g/dl 
Urea 
S 
r=.02 
S 
 r=.03 
S 
r=.03 
S 
r=.11 
D 
r=.38 
S 
r=.17 
+/- 0.007 
g/l 
eGFR 
S 
r=.04 
D* 
r=.55 
D* r=.64 
D 
r=.48 
I 
r=.09 
D* r=.67  
70 
4 Discussion 
This section is divided into three main parts. The first part debates the population involved 
and the findings of the intervention with regard to the main objectives, i.e. the effect on the 
immune virology outcomes, inflammation, and concomitant events frequency, as well as the 
effect on the nutrition markers. The discussion continues by comparing the findings of 
existing Asp supplementation among HIV patients to current studies on PLWHA in sub-
Saharan Africa. In part three the general practice of supplementation will be discussed, 
followed by the conclusion and the outlook sections for the present study. 
4.1 Debate of the Results 
Spirulina is assumed to have antiretroviral and immunity-enhancing properties (Hayashi, 
Hayashi et al. 1996; Rechter, Konig et al. 2006; Teas and Irhimeh 2012). Therefore, the 
current study assessed the effect of an Asp supplementation on pre-HAART HIV-infected 
women. The main objective was to investigate the effect on CD4 lymphocyte count. Two 
groups, one Asp group and one placebo group, received five grams per day of supplement or 
placebo, respectively, for three months. 
With regard to CD4 lymphocytes there was no significant difference between the groups 
before and after the supplementation. However, more than half of the patients showed a 
decrease of more than 50 cells/mm3. An increase was observed in 8.6% of all patients 
involved in the RCT. An increase of 100 CD4 cells was achieved by one patient in each group. 
Those two patients did not mention having taken any antiretroviral medication. Thus, the 
assumption that Arthrospira platensis has an effect on CD4 lymphocytes could not be proved 
in the present randomized control trial over three months. Since spirulina is sold on the 
public market with the mention of therapeutic effects, we recommend avoiding this 
mention. 
 Target Population 
Cameroon was the focus of this study due to the high rate of HIV infection for the region and 
mainly because spirulina is consumed in the country. Furthermore, the country is becoming 
a growing market for functional food. For example, in the Cameroonian megacities Douala 
and Yaoundé, spirulina is already sold as nutraceutical along with local concoctions and 
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Chinese natural medicine. The focus is on women’s response to the infection ratio inequity 
because two thirds of PLWHA in Yaoundé are women. But more important for the success of 
this pilot trial, women in low and middle income countries were described as having better 
health awareness (UNAIDS 2012). 
Yaoundé, the country capital, is a diverse city in terms of ethnic and socio-economic groups. 
Recruitment was performed in four different health care centres. These were the modern 
hospital of “La Caisse” from the Cameroonian health insurance (CNPS), the public HIV care 
unit in the popular urban area of Biyem-Assi, the HIV care unit in the religious hospital of 
Djoungolo, and the largest HIV care unit of the city in the central hospital, the ‘Hôpital du 
Jour’. The study intended to recruit a representative group of the female HIV-infected 
population being monitored in Yaoundé. The eligibility criteria mentioned in §2.3, specify 
that the patients be in a stable phase of their infection, with no specific ongoing or upcoming 
medication intervention. These criteria followed the purpose of minimizing interferences on 
the marker set measured in the study. 
 Protocol Deviation 
While elaborating the proposal, the health centre in Cameroon started a HAART whenever 
the CD4 cell count of the patients got below 250 cells/mm3. At the beginning of 2010, the 
national council in Cameroon (CNLS 2010), in line with international guidelines, raised the 
HAART start-up point to 350 CD4 cell/mm3 (WHO 2009). To maintain the CD4 cell window of 
250 CD4 cell/mm3 chosen for the study, an elevation of 100 from 500 to 600 CD4 cell/mm3 
was decided for the inclusion criteria. 
During the recruitment screening, a total of 80 blood tests to document CD4 cell count were 
carried out at the HDJ hospital laboratory. Fourteen tests presented a CD4 cell count under 
350 cells/mm3, resulting in HAART eligibility. From the total of 80 blood tests, 41 were over 
the inclusion limit of 600 CD4 cells/mm3. For the 25 recruited patients, the CD4 values were 
measured at different days in a time lapse of two weeks maximum between them and at 
two different laboratories, the hospital laboratory, and for the baseline at the CPC, those 
values did not significantly differ from each other, Wilcoxon rank test r= .02; p= .842 (see 
table below). Patients were included after their screening test results. In case the baseline 
CD4 results did not match the fixed inclusion criteria, the patient was classified in the FAS 
population analysis set. 
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TABLE 4.1 CD4 CELL COUNT OF THE RECRUITED PATIENTS AT SCREENING IN THE HDJ AND AT BASELINE 
 Pre-HAART n=73 
CD4 
Cells/mm3 
Mean (SD) Median (IQR) Min-Max 
Screening, 
HDJ 
455 (72) 446 (390–515) 350–595 
Baseline; CPC 463 (119) 449 (397–558) 139–815 
 
A further inclusion criterion measured was BMI. No person present at the screening showed 
signs of acute undernourishment, defined by a BMI <18.5 kg/m2. The median BMI of the 
recruited population was 22 (20 – 23) kg/m2. The screening data showed that approximately 
every second patient had a BMI over 23 and every fourth over 26 kg/m2. Thus, the inclusion 
criterion for BMI was increased from 23 to 26 kg/m². The present study’s inclusion criteria 
resulted in an exclusion of women with a BMI >26 kg/m2, rejecting acute overweight and 
obesity. 
 Compliance 
The intervention was divided into two supplementation periods of three months each. The 
compliance was handled in three phases: the two intervention periods and the phase 
between. 
During the first period the main exclusion reason with a rate of 53% was “lost to follow-up” 
out of an overall rate of 20%. At the end of the RCT period, 12 patients, representing 55% of 
the overall exclusion rate of 38% for this phase started with HAART. Starting with a HAART 
therapy remained the main exclusion criterion during the second intervention period (16% 
exclusion), with 41% of the exclusions. However, this dropout was part of the study design, 
related to the recruitment of pre-HAART patients with a CD4 cell count below 600 
cells/mm3. 
With regard to social variables, only one of the seven married women completed the study. 
Furthermore, the education level was higher among women who completed the study than 
those who dropped out. A higher educational level and being unmarried seemed to have a 
positive effect on compliance. Possible explanations could be the quotidian pressure due to 
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time-consuming family management and/or the lack of acceptance by the husband. For 
example in the current study, one husband announced by phone that his wife would not 
travel anymore to the study site. 
 Intervention Population 
The intervention population involved all participants who completed at least three months 
of intervention. The study population is defined as being adult women living with HIV. The 
main focus of the study was on patients that had not started an antiretroviral therapy, 
presented a CD4 count lower than 600 cells/mm3, and had a BMI below 26 kg/m2. The pre-
HAART patients were randomly distributed into two groups, the Asp and placebo groups, 
and were supplemented for three months (RCT). After the first three months of intervention, 
an additional three months of exclusive Asp supplementation followed (OLI). Here, one 
group continued to get the Asp supplement, thus representing the long-term Asp 
supplementation group, while the former placebo group was now given Asp 
supplementation as well, and changed its name to the crossover group. 
Before starting the OLI, patients who met the criteria for starting HAART therapy based on 
their CD4 count were encouraged to start the therapy and stop the nutritional intervention. 
Patients who wanted to stop the nutritional intervention could do so at any time. 
To interpret the data of the 36 patients who achieved the six-month OLI, the prerequisites 
are as follows: the population is to be considered responsive to the intervention, and the 
results of the OLI group can only be discussed as they relate to the previous outcome 
conclusion of the RCT. 
In the present discussion, the RCT outcomes are related to the long-term intervention. At 
the end of the chapter the crossover group is discussed separately. 
 Variable Consideration for Spirulina 
The analyses were achieved by focusing on the first three months between the two groups 
in order to document the superiority of Asp against the placebo (Asp n=28, placebo n=30). It 
should be noted here that there were no significant differences in blood and immune 
markers between the two groups at baseline. The discussion handles each outcome 
individually. 
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 CD4 Lymphocyte 
As already mentioned, the main outcome of the study is to document the CD4 lymphocyte 
count difference between the two groups during the RCT. The two groups did not differ and 
presented the same tendency. With regard to the effect size, a small non-significant 
difference between the groups placebo r=.67 versus Asp r=.61 can be illustrated by the mean 
difference, placebo -65.2 (86.2) cells/mm3 versus -55.7 (71.4) cells/mm3 for the Asp. An 
effect size over .5 stands for a large effect, and it has to be assumed that the decrease 
concerns most of the involved patients in both groups. As the difference was not significant, 
the interpretation is that the study showed no difference between the two products on this 
variable over the given time. 
The long term Asp intervention (n=17), confirmed that  CD4 cells decrease during the first 
three months with a large effect size of r=.62. However in the following period, nine patients 
registered an increase of their CD4 cells. This results in a median increase of 32 (-45– 70) 
cells/mm3 defined by a small effect size of r=.21. The increase in the second period could not 
compensate for the precedent lowering as shown in the scatter plot below. 
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FIG.4.1 SCATTER PLOT WITH DOUBLE Y-AXIS SHOWING THE CD4 VALUES OF THE LONG-TERM GROUP 
The hashed black line is the origin line, the blue lozenges and line represent the three-month 
intervention (y=0.86x+ 10.8) with an effect size of R2=.52. The green dots and line represent the six-
month intervention (y=0.69x+ 99.5) with an effect size of R2=.69. Over the first three months, a 
median decrease was observed, illustrated by the blue line, followed by a slight increase after six 
months represented by the green line. 
 
To interpret the intervention effect, it is important to consider the specificity of the long-
term study population. As mentioned, this population has to be considered as pre-selected 
due to the fact that they had accomplished a six-month intervention. Moreover, the 
accuracy of the measuring method is 36 cells/mm3. As the observed change stays within the 
method accuracy, the result is so hard to relate to the supplemented product. The 
assumption that a nutritional product such as Asp can affect the immunological progress was 
not proved. The interpretation of the CD4 lymphocyte count in relation to infection 
evolution and to the specific population will be done in “Discussion in Context” §4.2. 
 Viral Load 
An antiretroviral effect was documented by examining the blood’s viral load. The presently 
used VL quantification method is restricted to the HIV-1 type virus. The study did not test for 
a double infection with both HIV-1 and HIV-2. However, two patients showed no VL value 
and were tested positive for HIV type 2, one in each group, and could not be considered for 
this outcome. 
As expected, the VL at baseline was high with 5.5 (4.3– 6) log10, 315,000 (20,000– 
1,000,000) copy/ml. Such high values are common among pre-HAART patients with 
progressing immunodeficiency (Sabin, Devereux et al. 2000). The HIV-1 viral load did not 
significantly change over the RCT period, neither in the Asp nor in the placebo group (no 
difference between the group difference, r=.03, p=.774). Three outlier patients (over 2 
standard deviations from the median) showing a VL decrease over the intervention indicated 
no medical intakes, but an intake cannot be excluded. The patients were asked about self-
medication, but the use of street medicine made a proper recording very difficult. 
The long-term intake of Asp did not present any significant change on VL value. The value 
seemed to decrease slightly, but the changes appeared to be within the methodological 
fluctuation range. 
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 Immune Activation 
The immune activation profile is defined by the expression of the protein CD38 on CD4 and 
CD8 lymphocytes and on monocyte cells. In the current study, the expression showed strong 
correlations between the CD38 expression on CD4 and CD8 cells at baseline: Rho=.64, 
p<.001, and a correlation at baseline between CD38 expression and higher viral load: Rho= 
.47, p<.001, but no correlation to CD4 count. According to the literature, the activation is 
reported by the expression of CD38 antigen on the CD8 lymphocyte (Liu, Cumberland et al. 
1997). 
During the RCT, the ratio of CD8 cells expressing CD38 showed a slight decrease in both 
groups. However, it did not differ between the groups (r=.04, p=.732). The decreases inside 
the groups were non-significant but seemed to affect more patients in the Asp group (r=.24; 
p=.185) with a median decrease of -1.3% (-5.8– 2.0) as opposed to the placebo group (r=.18; 
p=.327) with -0.9% (-4.2– 1.6). An overall group analysis showed that the immune activation 
effects registered during the intervention were influenced by the initial activation level. The 
differences occurring correlated significantly with the absolute values at baseline: an initial 
high baseline value allowed a higher decrease (Rho= -.325, p= .010). Moreover, among seven 
patients presenting a CD38-CD8 expression over 40%, five had concomitant events. Due to 
the low number of patients with high immune activation and the lack of data on the 
vigorousness of the events, it is not possible to quantify the dependency between the two 
observations. In reverse, the concomitant events do not seem to be related to a high 
immune activation, as only five cases of concomitant events could be registered for a total of 
24 patients with a high immune activity. 
During the long-term intervention, the immune activation fluctuated from an initial baseline 
value of 18.0% (14.8– 30.5) to 18.7% (14.6– 27.3). However, the absolute percentage of 
CD38-CD8 lymphocytes for the patients stayed below 30%. The scatter plot below 
documents that no increase was observed. Regarding these results, it can be assumed that 
the Asp intervention did not increase the expression of CD38 on lymphocytes. 
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FIG 4.2 SCATTER PLOTOF T-CD8- CD38% WITH DOUBLE Y-AXIS PRESENTING THE LONG-TERM PATIENTS OVER 
THE SIX-MONTH ASP INTERVENTION. 
The blue lozenges represent the first three-month supplementation summaries in the blue regression 
line (Y= 0.691X + 6.83), R2=.61. The green dots stand for the value after an Asp supplementation of 
six months, summaries in the green regression line (Y= 1.057X -0.124), R2=.68. The blue lines 
between the points stand for a decrease, and the red line that stands for an increase of the CD38 
expression on CD8 cells. The numbers are resumed in the table below and stand for the patients over 
an activation of 30% CD38. 
Number 
or * in 
graph 
Concomitant events 
Inflammation or an aemia 
status 
1 Diarrhoea Inflammation and Anaemia 
2 Malaria in period 1 Normal 
3 Fatigue in period 1 Anaemia 
4 Fatigue in period 1 Anaemia 
5 Malaria in period 2 Inflammation and anaemia 
6 - Anaemia during period 1 
7 - Inflammation at baseline 
* Malaria or fatigue Normal 
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The graph shows that patients with immune activation increase were linked to concomitant 
events, inflammation, and/or anaemia. 
 Concomitant Events 
The outbreak of concomitant events can be an indicator for the patients’ vulnerability. In the 
present study, concomitant events were documented during the monthly monitoring visits 
(see §3.9). The patient flyer was checked for recorded events and documented by the 
physician in the patient file. The documentation of events by the patients was not 
necessarily related to disease. The crossed concomitant events were cross-checked by the 
physician based on a consultation. Additionally, the physician recorded any medication 
taken. 
The results showed a higher proportion of concomitant events in the placebo (70%) than in 
the Asp (43%) group. However, opportunistic infections such as candidoses and sona, were 
very low in both groups. One must consider that the appearance of severe concomitant 
events or the intake of some medication could lead to exclusion. The concomitant events 
must be considered in combination with the exclusion reasons. Infection-related exclusion 
reasons were: “start of HAART” and “start of relevant concomitant medication.” Overlapping 
the AIDS-related concomitant events with AIDS-related exclusions at the end of the RCT 
summarizes the progression of AIDS status on the population over the first period. The 
placebo group had three cases of AIDS-related events and no related exclusion. The 
Arthrospira p. group had five exclusions due to starting HAART or starting co-medication but 
no AIDS-related events. The intervention products did not differ between the groups with 
regard to AIDS progression over the three-month intervention. 
During the OLI, the three main events were malaria with a prevalence of 23%, 
gastrointestinal symptoms with 16%, and diarrhoea with 13%. The possible relationship 
between malaria and an Asp supplementation will be discussed in the context of iron 
supplementation in malaria-endemic areas in part §4.2. The prevalence of gastrointestinal 
symptoms and diarrhoea observed over the long-term intervention could be due to the 
digestive clash of Asp. However, a comparison of the event frequency between placebo and 
Asp in the RCT present the same rate for gastrointestinal symptoms and diarrhoea in both 
groups. Furthermore, the implementation of Asp in the crossover did not show an 
enhancement of those digestive events. No relationship seemed to exist between the 
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product and gastrointestinal symptoms or diarrhoea. However, due to the small occurrence 
of concomitant events, it is difficult to rule out or conclude a relationship between the 
supplement and events. It can be maintained that the study confirms the US safety analysis 
on the lack of relationships between the supplement and adverse events (Marles, Barrett et 
al. 2011). 
 Inflammatory Outcomes 
The inflammation marker CRP is an exponential variable, with a normal level under 6 mg/l, 
crossing this level in case of acute inflammation. The C-reactive protein concentration 
showed no significant increase in either of the two RCT groups. The effect can be described 
as follows: the data range condensed for the Asp (r=.06) while it spread out for the placebo 
group (r=.18). The absolute number of patients with acute inflammation increased from 
three in each group at baseline to six in the placebo and five patients in the Asp group after 
12 weeks. The increase in the absolute number of patients presenting an inflammation 
status could be due to opportunistic and/or parasitic infections. 
Overall, six out of eleven patients with inflammation suffered from anaemia. The scatter plot 
below shows the inflammation represented by the CRP on the Hb concentration with 
additionally reported malaria cases. Plasmodium is a red blood parasite exacerbating 
anaemia and the innate immune system (Perkins, Were et al. 2011). Seven out of eleven 
presenting an inflammation had malaria symptoms, and most of them were anaemic. The 
relationship will be brought into context in part 4.2. 
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FIG. 4.3 SCATTER PLOT REPRESENTING HAEMOGLOBIN CONCENTRATION OF THE CRP CONCENTRATION AT 12 
WEEKS OF INTERVENTION. 
The vertical line represents the cut-off point CRP= 6 mg/l; all patients on the right hand side had an 
active inflammation, in total 11. The horizontal line stands for the anaemia cut-off point at Hb= 11 
g/dl; 21 patients were below this line. The star shows patients who developed malaria over the 
period. 
In the long-term intervention, one to two cases of active inflammation were observed per 
group. The result corroborates the assumption regarding the comparison of patients 
compliant with the six-month intervention with excluded patients, that the patients of the 
six-month intervention had a better health status. 
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 Nutritional Outcomes 
The following markers are indicators of general health status by describing nutrition 
metabolic outcomes. Every metabolic variable stands in a multi-causal relationship to the 
body, the environment, and the infection. They are indirect markers of the infection and are 
assessed to document health complications associated with HIV infection. Some are 
postulated to become alternative clinical predictor markers of the infection course. 
Weight 
The intervention did not aim to increase body weight but to ameliorate the quality of 
proteins and implement anabolic nutrients. The energetic gain from a five-gram daily 
supplementation with Asp or placebo was negligible. The daily intervention added 21 
calories. The total daily recommendation for an HIV-infected women is 2.4 kcal (Emmanuel 
2006). The supplement thus represented 1% of total energy supply. The three grams of 
protein in capsules comprised 5-6% of the recommended 50 grams of protein intake per day. 
The hypothesis implies that the intervention would have a marginal effect on weight gain, 
independent of the product, Asp, or placebo. 
The present intervention results showed a weight increase with large size effects inside both 
groups (placebo, r=0.5 and Asp, r=012). The groups showed no difference between them 
(r=.05, p=.697). The increase is not product related, and since it is not expected at this 
infection step, it seems to be related to involvement in the intervention. A more detailed 
explanation will be given in section 4.2. 
The long-term Asp exposure group confirmed the weight effect with a constant significant 
increase of 1.5 (0.3– 3) kg over the six-month intervention (r=.49, p=.049). The major 
increase occurred during the first period with an effect size of r=.41. The registered weight 
evolutions over six months can be considered a stabilization of body shape. 
Total Antioxidant Status 
The TAOS measure represents the body’s own antioxidant potential present in the blood 
serum (Mariken, Dallinga et al. 2004). The method used is a robust detection of the capacity 
of the sampled serum to reduce ABST. The measurement of total antioxidant serum capacity 
was reported to provide an integrated index as opposed to a simple summation of 
measurable antioxidants (Ghiselli, Serafini et al. 2000). The changes occurring in the two RCT 
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groups differed significantly: r=.51,p<.001. The placebo group presented a decrease of -22 (-
64– 19) µM, which is consistent with the infection progression as described in the literature 
(Coaccioli, Crapa et al. 2010). The increase observed in the Asp group was 56 (1– 98) µM. The 
effect sizes registered for both trends were high with r=.51 for the increase in the Asp group 
and r=.48 for the decrease in the placebo group. Thus, Asp supplementation showed a 
positive effect on the antioxidative potential and seemed to be superior to the placebo. 
Furthermore, the increase shows a dependency on the initial TAOS baseline value. The 
increase in the Asp-supplemented group was negatively correlated with the baseline values 
Rho= -.436, p=.02. This dependence may support the effect of Asp that restores the 
antioxidant balance. 
Long-term Asp exposure confirmed the results of the RCT. The TAOS value showed a 
continuous improvement. The increase was documented by a very large effect size between 
baseline and six months with a median increase of 198 (88– 254) µM, r=.85. The effect size 
was larger in the second period in comparison to the first one. It could be assumed that the 
supplementation effect increases with the intervention time. The correlation with the initial 
baseline value provided similar results to the RCT, namely a strong significant negative 
correlation, Rho= -.767. The scatter plot below presents the long-term progression of TAOS. 
The value of 450 µM where the regression lines cross each other may show the normal 
lower limit of total antioxidative capacity. However, the mechanism behind rehabilitation on 
TAOS of Asp remains unclear and demands further research. 
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FIG. 4.4: SCATTER PLOT REPRESENTING TAOS WITH DOUBLE Y-AXIS PRESENTING THE LONG-TERM PATIENTS OVER 
THE SIX-MONTH ASP INTERVENTION. 
The blue lozenges represent the first three-month supplementation, the green dots the value after 
six months of Asp supplementation. The regression lines are not representative, R2 of .12 for the blue 
line and R2= .021 for the green line, but resume a tendency that occurred during the periods. 
Albumin 
The blood marker albumin was studied as a prediction marker for an advancing infection 
resulting in AIDS; albumin is expected to slide below the normal value (Graham, Baeten et al. 
2007). At baseline, the study observed a normal to high albumin concentration for almost all 
patients involved in the study: 50 (47– 52) g/l. Both groups had a significantly lower albumin 
level after three months: placebo r=.39, p=.034 and Asp r=.42, p=.026. In the long-term 
population, albumin decreased even more strongly in the second period over six months 
with -4 (-8– 0.2) g/l, with a magnitude of r=.77. The effect seemed to intensify with 
supplement duration. However, as the placebo presented the same tendency as the Asp 
group, the outcome can be ascribed to the environment and not related to the product (see 
table 10.1). One explanation could be that the baseline measurement took place during the 
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heavy rain season (mean rainfall 293 mm) when the patients maybe did not feel thirsty and 
were more likely to be dehydrated as opposed to the second sampling during the dry season 
(mean rainfall 19 mm), which could be a reason for a more accurate hydration at the end of 
the RCT. Differences in hydration between the two samplings could be responsible for the 
ensuing albumin reduction. 
Haemoglobin/Erythrocyte 
An abnormality in red blood cells and their oxygen-carrying protein, haemoglobin, is called 
anaemia (WHO 2011). The determination of anaemia through the Hb cut-off was adjusted to 
the study population. In the present study, Hb-relevant population factors were adult 
women, not pregnant, living at an altitude under 1,000 meters, non-smoking, and African 
(Sullivan, Zuguo Mei et al. 2008). Thus, the cut-off was Hb< 11 g/dl (WHO 2011). The CPC 
defines the normal haemoglobin range for adult women in Cameroon to be between 11 and 
17 g/dl. A significant decrease was observed in both groups over the RCT. In the placebo 
group, the median difference was twice as high as in the Asp group. The effect magnitude 
showed significant Hb lowering for a large number of placebo patients r=.54, p=.003, 
compared to a medium effect size of r=.40, p=.03 in the Asp group. Regarding this result, an 
effect of Asp against Hb lowering could be presumed. There was a significant negative 
correlation for the study population between the baseline values and end assessment, Rho=-
.288, p<.05. Thus, the higher the baseline value, the higher the decrease. 
Parallel to the Hb decrease, RBC decrease also occurred in both groups (Asp: r=.57, p=.002 
<placebo: r=.68, p=.001). The slight, non-significant difference between the two groups with 
regard to RBC was of 0.1 tetra/l (r=.21, p=.109). As haemoglobin is the major protein in RBC, 
the present results corroborate each other. An advanced explanation could be that the RBC 
count lowers and pulls down Hb concentration. With regards to haematocrit, the total RBC 
volume in the blood (see appendix), the two groups differed significantly from each other 
(r=.31, p=.039). The placebo RBC volume decrease was compared to a constant haematocrit 
value for the Asp group. The result is consistent with a study of senior patients in which the 
RBC count decreased while haematocrit and Hb increased (Selmi, Leung et al. 2011). The 
study concluded that spirulina may counteract anaemia in senescence. 
The clinically relevant status of anaemic patients increased by five for Asp and three in the 
placebo groups. In the long-term intervention, the number of anaemic patients doubled 
from four at baseline to eight after the intervention. The increase in the absolute number of 
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anaemic patients can be explained in relation to inflammation, see §4.2. Furthermore, the 
Hb concentration decreased significantly over six months from 12 (11.4– 13.7) g/dl to 11.6 
(10.4– 12.6) g/dl, p=.039, with a large effect size of r=.63. 
Focusing on the outlier patients, the major decreases in Hb and RBC were related to malaria 
or AIDS symptoms. In contrast, the strongest Hb increases were related to medication as 
antibiotic therapy with Cotrim or Bactrim. These results strengthen the importance of a 
nutritional intervention as only an adjunct therapy in case of a major disease incidence. 
Iron 
In the current study, iron is an indicator of acute iron availability depending on diet and 
health state. The measurements of iron in the serum determine available iron in the blood 
(Chemistry 2013). During the RCT intervention, no significant changes were registered 
between and within the groups. The two groups presented the same median decreasing 
tendency of -0.1 mg/l (r=.11, p=.40). The effect sizes inside the groups were r=.01 for Asp 
and r=.13 for placebo. But the groups differed on the lower values. A low iron status at 
baseline seemed to limit a further decrease. Focusing on low iron concentration, an Asp 
versus placebo intervention seems to be better at preventing a large iron decrease. The 
number of patients did not permit us to run any statistical test besides a description of the 
value. The placebo had a 25%IQR value of -0.3 mg/l with a minimum of -0.9 mg/l, and Asp 
had a 25%IQR of -0.15 mg/l with a minimum of -0.5 mg/l. 
Regarding the long-term supplementation, the increase in iron was not significant, but it 
showed a high effect size: r=.49. As mentioned before, the long-term population was a 
healthy selected population, which may explain why there was no further significant change 
in iron levels. 
Lipid Profile 
The two lipid markers, TG and TC, represent the main fatty acids stored in the blood (Cox 
and Garcia-Palmieri 1990). A comparison of the lipid profile at baseline between compliant 
and excluded patients showed that excluded patients tended to have higher TG and 
cholesterol values than compliant patients. With regard to this result, it could be supposed 
that low TG and TC are more common in a stable infection. 
During the RCT, the total cholesterol concentration decreased significantly in the Asp-
supplemented group: -0.14 (-0.47– -0.04) g/l, p=.004 with a large effect size of r=.55. In the 
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placebo group, cholesterol also decreased significantly with a small effect size for the 
variation: r=.28. The same effect of lowering TC was documented in both groups, but the 
affect was more accurate for patients in the Asp group than in the placebo group, (placebo 
r=.28 <Asp r=.55). The regression line in figure 4.5 shows that the decrease was higher 
among patients with initially high cholesterol levels. 
 
FIG 4.5 SCATTER PLOT OF THE TOTAL CHOLESTEROL DIFFERENCE IN THE BASELINE TOTAL CHOLESTEROL 
CONCENTRATION THAT OCCURRED DURING RCT 
The black dots stand for the Asp group and the white for the placebo. The fat black line is the Asp 
regression line (y=-0.585x+0.721) R2=.43. The fat hashed line is the placebo regression line (y=-
0.527x+0.749) R2=.39. 
 
In the present study, a relationship between triglyceride increase and cholesterol decrease 
was observed. The tendency combining the two markers is resumed below in the scatter 
plot. Almost 82% of the Asp patients showed a decrease in TC as opposed to 60% among the 
placebo group. Most patients (60%) showed an increase in TG. The combination of lowering 
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TC and increasing TG is present in half of the patients (Asp: 57%; placebo: 40%). The two 
groups differ only in their cholesterol change. Resuming the changes in the lipid outcomes, 
for Asp a TC decrease with a stabilization of TG and for the placebo group a small decrease in 
TC and a small but non-significant TG increase could be established. 
 
FIG 4.6 SCATTER PLOT OF THE CHANGE THAT OCCURRED DURING THE RCT IN CHOLESTEROL AND TRIGLYCERIDE 
AMOUNTS 
The black dots stand for the Asp group and the white for the placebo. The patient distribution over 
the diagram is documented by the percent of cases expressing the tendency. The numbers are the 
total case tendency, in the parentheses the first number stands for the placebo group followed by 
the Asp percentage in bold. 
 
The Asp effect on the lipid profile was consistent in the long-term intervention. In the first 
period, TG and TC decreased with high effect sizes: TC r=.53, TG r=.45. In the second period, 
TC stabilized at 1.28 (1.21– 1.51) g/l. The combination of the supplementation and ongoing 
infection may be one explanation for the lowering TC level. The meaning of a low TC will be 
discussed in context (see §4.2). Over the total intervention time of six months, 12 patients 
out of 17 registered a non-significant decrease in TG -0.06 (-0.26– 0.04) g/l, with a medium 
effect size of r=.37. The lack of a TG increase could present a beneficial effect during the 
course of an HIV infection. 
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Renal Function 
The purpose of this measurement was to see if the intervention with an Asp supplement 
burdened renal function. Renal activity is measured indirectly by way of serum creatinine 
and urea concentration and is summarized by the estimated globular filtration rate. 
Serum creatinine alone is a weak marker for renal function (Levey, Perrone et al. 1988). The 
serum values should be constant over time (Perrone, Madias et al. 1992). Factors that 
influence creatinine serum concentration are a rich protein dietary intake, and/or increased 
intense physical activity, and/or a change in filtration capacity of the kidneys (Perrone, 
Madias et al. 1992; King and Levey 1993). The normal value for the serum creatinine 
concentration for women is between 0.7– 1.2 g/dl. Above 1.5 g/dl, the serum creatinine 
concentration is considered abnormally elevated. During the RCT period, creatinine showed 
a significant increase in Asp-supplemented patients of 0.1 (0.0– 0.2) g/dl, with a high effect 
size of r=.59 as opposed to the placebo, where creatinine remained constant 0.0 (-0.1– 0.1) 
g/dl. The creatinine difference between the two protein-rich products was significant with 
an effect size of r=.35, p=.008. However, as both median values for the Asp group at baseline 
0.7 g/dl and follow-up 0.75 g/dl were still below the cut-off of 1.5 g/dl, no clinically relevant 
action was taken. 
Urea is an excretion product of protein ingestion (O'Connor and Summerill 1976). As both 
intervention products of the RCT are rich in protein, even if the absolute protein amount 
were supplemented, representing 5% of the daily requirement, urea concentration would 
not change within the two groups over time and would not differ. An additional five grams of 
protein per day had no effect on nitrogen metabolism and the elimination product urea. 
The estimated GFR is calculated and summarizes renal activity including creatinine, albumin, 
and urea serum concentrations, as well as the age factor. A chronic renal disorder is reached 
at the cut-off point of eGFR <60 ml/min and a serum creatinine >2.0 g/dl. All patients 
participating in the RCT study had a low eGFR at baseline 57.6 (50.3– 69.0) ml/min, which 
can be related to a high albumin concentration. For the Asp patients, the eGFR was affected 
by an increase in creatinine and decrease in albumin that resulted in a low eGFR after the 
intervention. The eGFR value significantly decreased in Asp-supplemented patients by -7.3 (-
17.2– 0.95) ml/min, with a large effect size of r=.55. There was no change in the placebo 
group. The renal burden seemed to be related to the Asp product. 
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For the patients involved in the long-term Asp supplementation, the creatinine 
concentration increase did not rise further after the first three months from a median 
baseline value of 0.7 (0.6– 0.7) g/dl to 0.8 (0.7– 1.0) g/dl. The serum creatinine was constant 
and equal to the creatinine production, representing 1-2% of the body’s creatinine pool 
(Perrone, Madias et al. 1992). It can be assumed that the intake of Asp elevated the body’s 
creatinine pool and thereby creatinine production and the serum creatinine level. An 
assessment of the fat-free mass of the patient via bioimpedence would have been helpful in 
describing the change in creatinine serum. Furthermore, measuring creatinine uraemia could 
have permitted the exclusion of filtration alteration by the nephron. A dose-dependent 
analysis is needed in order to explore the effect in more detail. In summary, an increase in 
creatinine was related to the Asp supplementation product, which was not the case for urea 
concentration. 
 Crossover Group 
There were only 13 patients in the crossover group. Thus, the interpretation of the results 
has to be done with caution. In the crossover group, patients first took the placebo for three 
months, followed by Asp. The presently named “crossover” group diverges from the usual 
appellation, as it includes a placebo control intervention on the same patients. This group 
should be considered selected because all participants could end the six-month intervention 
without starting HAART. 
Focusing on the immune marker, the stable CD4 cell count over the first three months could 
be linked to the generally good health presented by compliant patients. There was no 
significant change between the two periods. However, the noted difference was an 
attenuation of the CD4 decrease from -33 (-87– 14) cells/mm3 during the placebo to -14 (-
71– 131) cells/mm3 in the period under Asp. Half of the patients showed a positive 
development of their CD4 cell count after the implementation of Asp. 
The viral load did not change significantly during the placebo supplementation period. 
However during the Asp one, the viral load tended not to decrease significantly, with a 
median of-0.2(-0.4– 0.1) log10.Since both changes occurring on the immuno-virological 
marker were not significantly different between the two periods, it has to be assumed that 
the measurements were marker variations and did not define a product-related tendency, 
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thereby confirming the lack of effect described in both of the other studies designed to run 
in parallel. 
As to the immune activation, CD38-CD8, both periods showed tendencies to decrease. The 
overall decrease effect of -7.64% (-16.1– 2.4) was significant: r=.67, p=.048. The main 
decrease occurred during the first period under placebo: r=.45 > r=.24, compared to the Asp 
period. Furthermore, high CD38-CD8 levels at baseline may have been attributed to an 
adverse event such as malaria. The decrease in CD38-CD8 during the intervention can be due 
to Asp supplementation or the intake of antimalarial medication or antibiotics. No clear 
causal relationship could be drawn. 
Nutrition Outcomes 
In the crossover group, the change in body weight significantly differed between placebo 
and Asp periods: p=.015. In the placebo period, body weight increased by 0.4 (0.2– 2.5) kg 
compared to a decrease of -1.1 (-2– 0.2) kg in the Asp period. The switch between the two 
periods affected most of the patients, documented by a large size magnitude, r=.67. The 
implementation of Asp seemed to affect body weight, which was not the case in the other 
interventions. Events related to a weight decrease such as diarrhoea or gastrointestinal 
symptoms did not increase after the start of Asp supplementation. None of the patients 
mentioned any disturbance after changing from placebo to Asp. 
Albumin tended to differ between the two periods. The albumin concentration in the 
crossover group continually decreased over six months from -2 (-5– 0) g/l during the placebo 
to 0 (-4– 1) g/l under Asp. As mentioned previously, the different seasons during which the 
samplings were conducted seemed to influence the hydration status of the patients and thus 
may have influenced albumin concentration. However, a clear relationship between change 
in body weight, albumin concentration, and placebo or Asp could not be drawn. 
TAOS outcome documented well the switch between the two products: r=.80,p=.004. The 
decrease registered under placebo was followed by an increase in capacity under Asp. 
Furthermore, the effect on TAOS confirmed the previous results. 
Regarding anaemia, the patients showed a median decrease in Hb concentration of -1.1 (-
1.3– -0.5) g/dl during the placebo period against an increase of 0.2 (-0.7– 1.0) g/dl during Asp 
supplementation. The difference between the two intervention periods was significant, 
p=.05, with a medium effect size of r=.54. RBC had the same significant development as Hb, 
with a decrease during the placebo period followed by an increase during the Asp 
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supplementation period: r=.82, p=.004. These results were also seen in the RCT. In regards to 
the effect size, it can be assumed that the effect of Asp is higher on the erythrocytes than on 
haemoglobin (r=.82> r=.54). 
Iron concentration did not significantly increase over the entire intervention in the crossover 
groups. Asp implementation did show a slight, non-significant improvement in iron 
concentration of 0.1 (-0.1– 0.2) mg/l. The effect is analogous to the long-term group, which 
showed a continuous improvement in iron median concentration of 0.1 mg/l every three 
months. The lack of significant change may be due to the small number of patients. 
Total cholesterol values did not change significantly in either period. Triglyceride values 
tended to change differently between the two periods. The present intervention showed an 
increase of TG during the placebo of 0.07 (-0.16– 0.57) g/l and a decrease during the Asp 
period of -0.24 (-0.36– -0.08) g/l. The difference between the two periods was not significant 
p=.328. However, during the supplementation of Asp, eight out of 13 patients showed a 
decrease in TG. 
The difference in serum creatinine between the two periods was not significant but 
presented a medium effect size of r=.48, p=.083 for an increase of 0.1 (0.0– 0.3) g/dl after 
the implementation of Asp. The urea concentration, as observed previously, did not differ 
between the two periods. As noted before, the creatinine clearance affected the eGFR value 
calculated. The difference between the two periods was not significant but had a large effect 
size of r=.51, p=.064. The eGFR decreased by -4.9 (-18.9– 0.1) ml/min during Asp 
supplementation. 
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4.2 Discussion in Context 
 Population Definition and Study Restriction 
The study population was defined by the inclusion criteria: HIV-infected females from 18– 49 
years of age with a BMI <26 kg/m3 and CD4 count below 600 cells/mm3. The aforementioned 
criteria were chosen to focus on a homogenous population of women at reproductive age, 
without overweight and presenting a low immunity. The women were also distinct in that 
they were being treated at the health care centre in Yaoundé. 
The last population census documented that women in Yaoundé were aware of 
supplementation and fortification practices; 45% of child-bearing women took vitamin A, 
93% iron supplementation, and 96% consumed fortified food (National institute of Statistic 
2012). Even if this awareness is essentially associated with pregnancy care, it has to be 
considered that the selected study population was sensitive to supplementation due to 
being women at childbearing age and in contact with the health centre. 
Furthermore, the recruitment confirmed a higher proportion of women than men being 
registered in the health centre of the capital. This confirms the known difference in infection 
prevalence among gender, 8.8% for women compared to 3.3% among men. The gender 
prevalence discrepancy in case of young people between 20 to 24 years is even higher, being 
of 3.4% for women and 0.7% for men (National institute of Statistic 2011). One speculated 
reason for the gender difference may be the practice of “sponsoring,” where senior men 
offer to take care of young student girls in exchange for unprotected sexual intercourse 
(Abega and Magne 2006). An additional explanation for the predominance of women in 
health centres are the additional screening carried out in case or assumption of pregnancy, 
in addition to a voluntary screening. The opening of a registered file in an HIV health care 
unit is only possible with a confirmed positive HIV test and patient agreement. 
The file ratio concerning pre-HAART patients was in the range of8 to 16% of all files checked 
in the health centres between 2008 and 2010. Furthermore, contact information of pre-
HAART patients was often missing. The consultation and opening of a file must be paid by 
the patient, around 5,000 FCfa (7.50 euros). The half-yearly monitoring visit costs 3,000 FCfa 
and takes at least two to three days (Mbanya, Sama et al. 2008). Pre-HAART monitoring is 
very rarely done. An explanation could be the lack of symptoms at the early infection stage. 
The time between sero-conversion and the beginning of antiretroviral therapy can take 
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years. An estimation made among an urban African cohort resulted in a time of 7.6 years 
(Zwahlen 2008). For pre-HAART persons living with the virus who are otherwise healthy, it 
seems to be difficult to foresee the outcomes and consequences of their HIV infection. 
Furthermore, it is difficult to check the correctness of any personal data provided by the 
patient. The ratio of wrong phone numbers in the pre-selection was 41% of 474 patients’ 
files. These facts help explain the high number of files screened, patients contacted, and low 
response rate. 
The social outcomes of the recruitment undermine the specificity of the pre-HAART period in 
the HIV infection, especially for urban women. A low rate of patients in a relationship has 
been pointed out by Fabienne Marcellin. She studied delay reasons for the first consultation 
after HIV diagnosis in Cameroon. One significant reason for a woman to have a medical 
monitoring delay of at least six months was because she was in a relationship (Marcellin, Abe 
et al. 2009). Following the same argumentation, the care provided by the intake of a daily 
therapy such as HAART allows family planning and increases the rate of married women 
living with HIV (Myer, Carter et al. 2010). The period of time between infection and entering 
HAART care seems to be characterised by a low married rate, also shown in this present 
study. 
A main consideration of this study is that the patients involved were all people with at least 
primary education. The result is related to a high level of literate people in the country 
(UNICEF 2010). Yaoundé has the lowest rate of female illiteracy in the country with 1.6% 
versus 33.9% for rural areas (National institute of Statistic 2012). The question of health 
access for illiterate women remains open. A selection based on access to health was a 
prerequisite for the present study. 
A further concern for the implementation of the present results is the discrepancy between 
urban and rural women, which is also shown well in anaemia cases. The reported anaemia 
prevalence for Yaoundé is 46.9%, and it is 61.9% in rural areas (National institute of Statistic 
2012). Usually urban areas have lower anaemia rates due to better access to food, health 
care centres, prevention, and treatment possibilities. Compared to that, the study 
population had a lower anaemia rate, namely 32.5%. The study population is assumed 
already to have an awareness of health concerns and also the capability to look after them. 
This study also excluded an current development characterizing urban African areas: the 
transition to a Western lifestyle with a high fat and sugar-rich diet and low physical activity 
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(Popkin 2004). This nutrition transition is not considered in this study due to the exclusion of 
overweight patients. Median BMI of the study population was 22 (20– 23) kg/m2 and did not 
reflect the BMI of women living with HIV in Yaoundé. The last population count in Yaoundé 
in 2011 presented a mean BMI of 25.5 kg/m2 with 17.5% over a BMI of 30 kg/m2 (National 
institute of Statistic 2012). The statistic showed that the more educated and wealthier the 
woman were, the higher their BMI was (National institute of Statistic 2012). In 2011 Lissock 
et al. described metabolic obesity in urban and rural Cameroonians and found an even 
higher obesity rate in the urban population, BMI 29.6 (5.86) kg/m2 with high values in the 
lipid profile (Lissock, Sobngwi et al. 2011). The increased prevalence of obesity in African 
urban women has been shown to be recent and is becoming a severe public health problem 
for the Sub-Saharan countries (Villamor, Msamanga et al. 2006). At the time of the current 
study, no study documented an obesity problem among PLWHA in urban African areas. The 
addition of these new public health issues to chronic infection with HIV can lead to specific 
pathologies, such as lipodystrophy. No abnormal lipid profile was found in the study 
populations. Pathologies such as lipodystrophy are specific for advanced infection and 
HAART. The lack of this pathology could be related to the exclusion criteria of overweight. 
However, the health awareness presented by the patients willing to participate in a 
nutritional intervention could even be a stronger criterion. 
The following discussion of the effects is largely influenced by the selected population and 
restricts the conclusion to this defined population of urban women present in the health 
care units of Yaoundé. 
 Immuno-viral outcomes 
The HIV type screening in the study population could not exclude any co-infection of the two 
HIV types, but only two patients presented an exclusive HIV-2 infection. The virus diversity 
had no effect on the study outcomes, as the variables were reviewed through relative 
changes occurring during the period of the study. 
As documented in the current RCT, the two supplemented products (Asp and placebo) had 
the same effect, namely a decrease of over 50 CD4 cells. A precedent study associated a 
mean decrease of 55 cells/mm3 in CD4 cells with an increase of 1 log10 in the viral load 
(Lima, Fink et al. 2009). The steady state in the study of a VL over 5 log10 corroborates the 
expectation of a high viral peak present in the terminal, asymptomatic HIV phase (Sabin, 
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Devereux et al. 2000). A result in the selected population is that over the time most of the 
patients reached the mark of 350 cells/mm3 and started with HAART. The participant now 
could follow the intervention over six months and showed a non-significant CD4 cell 
increase. This may suggest an annihilation of the infection progression. The benefit of a 
nutritional supply can appear after a certain amount of time and individually depends on the 
body’s enforcement and metabolization. The lack of a short-term outcome of Asp on direct 
infection markers such as the viral load and CD4 cells can be interpreted as an absence of 
therapeutic effects in acute infection progress, but it cannot exclude an enforcement effect 
in the long term. However, the goal to document immune fortification effects could not be 
reach in the present study. This could be due to the dose of 5 grams per day, the three-
month timeframe, or the time point of the infection chosen with a high VL. 
Additionally, the antiretroviral properties described in vitro were also not confirmed by the 
study. In vitro the antiretroviral effect has been related to the property of the 
polycarboxylate chain complex with the Ca2+ ion, which catches the virus and isolates it from 
further interaction with cells (Rechter, Konig et al. 2006). In the current study, this mode of 
action may have been affected by the digestion processes. However, studies implementing 
Asp water extract described contrasting results such as a CD4 increase and a reduction in VL 
(Oben, Enonchong et al. 2007). The focus on an antiretroviral active extract remains an 
important outlook for future research on Asp. 
A further immune marker proposed to describe infection course could lead to a better 
understanding. Even if the literature mentioned more about the sensitivity analysis of CD8 
cell activation by quantifying the expression of CD38 proteins on the cells, CD8-
CD38bright(Tuaillon, Al Tabaa et al. 2009), the present laboratory did not allow the 
implementation of the enumeration and calibration to determine CD38bright. Only the 
percentage of CD38-CD8 cells was reported in the immune activation profile. The immune 
activation marker in this study corroborates the literature and presents an accurate 
correlation to the viral particle in the blood (Almeida, Cordero et al. 2007). Furthermore, the 
literature mentions that under HAART, immune activation seems negatively related to a CD4 
recovery (Hunt, Martin et al. 2003). The relationship between immune activation and 
immune recovery through CD4 in patients under HAART is complex and multi-causal. For 
example, the literature presents a favourable prognosis for the expression of CD38 for 
children and in contrast to that, a negative one for adults (Savarino, Bottarel et al. 2000). In 
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the pre-HAART stage for adults, a stabilisation or lowering of immune activation can be 
considered beneficial (Tilling, Kinloch et al. 2002). 
As all patients involved in the study present a stable immune activation, no relationship 
could be established between the supplements and immune activation. The restricted 
recruitment seems to be a more consistent reason for the stable immune activation 
registered for the participant. Furthermore, in regard to the OLI, all patients had a low initial 
immune activation, 22% (16– 40). CD38 expression did not vary significantly for patients 
involved over six months. The case description made in Fig 4.2 between high or increased 
immune activation levels and concomitant events help us understand the lack of change in 
this outcome. The reason seems to be that the recruited participants were in good condition 
in term of having no active immune reaction. 
A future study on selected patients presenting a high immune activation level would also 
allow researchers to reach a conclusion on the effect Asp has on immune activation. For 
example, a dietary micronutrient intake study on stationary patients detected an influence 
of the intervention on the immune activation decrease; the baseline CD38-CD8 was 60% (Gil, 
Martınez et al. 2005). The current study level under 30% CD38-CD8 activation represents a 
low level and cannot respond to an intervention with the goal of lowering the activation 
level. 
 Antioxidant Balance 
It is assumed that a general infection increases oxidative stress in the human body (Pace and 
Leaf 1995). Oxidative stress is defined as a disturbance in equilibrium between pro- and 
antioxidant molecules in the body. Pro-oxidants are molecules that have an odd number of 
electrons and act as free radicals. An efficient immune system needs pro-oxidants and 
therefore depends on oxidative equilibrium (Shils and Shike 2006). The level of oxidative 
damage is directly influenced by the extent of oxidative stress and the activity of the body’s 
antioxidant defence. This antioxidative defence line includes dietary and antioxidant 
enzymes, e.g. catalase and superoxide dismutase. These enzymes are over expressed during 
an HIV infection (Delmas-Beauvieux, Peuchant et al. 1996; Repetto, Reides et al. 1996). 
Among other factors, the activity of antioxidant enzymes is influenced by the intake of 
nutrients. One example is glutathione peroxidase (GPX), which requires selenium as a co-
factor for its activity and glutathione, a tripeptide, as a substrate (Stephensen, Marquis et al. 
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2007). In addition to its own antioxidant molecules, the animal body can assimilate 
nutritional antioxidant molecules such as carotenoid, tocopherol, and xanthin(Preziosi, Galan 
et al. 1998). The postulated nutrition model by Friis in 2006 for people suffering from 
acquired immunodeficiency syndrome relates nutrition to infection, as shown in the diagram 
below, but represents a more theoretical than practically proven concept (Friis 2006). One 
connection between nutrition and the immune system is the oxidative stress balance in the 
body. The preservation of this balance is a main issue for patients living with the virus. 
 
FIG. 4.7 NAIDS; NUTRITIONALLY ACQUIRED IMMUNODEFICIENCY SYNDROME FROM FRISS. 
MICRONUTRIENT INTERVENTIONS AND HIV INFECTION: A REVIEW OF CURRENT EVIDENCE 
Henrik Friis; Tropical Medicine and International Health 
Volume 11 no. 12 pp 1849–1857 December 2006 
 
Beside the indirect cause of a chronic infection, a direct relationship mediated by the protein 
NF-ƘB has been proposed between antioxidant status and HIV (Schreck, Rieber et al. 1991). 
The transcriptional factor NF-ƘB is regulated by oxidative stress, an elevation in stress 
stimulates the release of the factor (Gloire and Piette 2009). The key regulator protein in the 
case of low oxidative stress is bound to an inhibitor, I-ƘB, and forms a complex with NF-ƘB in 
the cytoplasm. However, the present study could not document a relationship between an 
increase in antioxidant status and a decrease in viral particles in the blood. Furthermore, the 
total antioxidant potential showed no correlation with any other variable measured. The lack 
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of a relationship with any auxiliary marker may be due to the lack of the power of the study. 
A previous supplementation study with known antioxidant vitamins such as tocopherol at 
800 mg/day plus ascorbic acid at 1 g/day has been shown to reduce oxidative stress and viral 
load of HIV-infected adults (Allard, Aghdassi et al. 1998). 
However, the present intervention periods proved the capacity of Asp to restore the 
antioxidant capacity in the serums. The negative significant correlation between the change 
in TAOS during Asp intervention and the TAOS baseline value showed that Asp was especially 
beneficial among patients with low antioxidative capacity (Rho= -.436, p=.02). The present 
trial does not allow one to relate the increase in TAOS to a defined group of antioxidants, 
which could have been especially improved via supplementation with Asp. The enforcement 
of patients with low antioxidant capacity still permits the hypothesis of an action on the 
body’s own antioxidative capacities such as the rehabilitation of the antioxidative enzymes. 
The enforcement of body serum micronutrients due to HAART is known (Jones, Tang et al. 
2006). An examination of the antioxidative status of advanced HIV patients not under HAART 
showed a dramatic decrease of carotenoids during the ongoing infection (Favier, Sappey et 
al. 1994). The β-carotenoids in Asp could balance the carotenoid decrease and thus stabilize 
antioxidant capacity. This may not the only explanation for the stabilisation of the 
antioxidant status and would need to be further evaluated and differentiate between the 
multitudes of components acting in this multi-causal mechanism. The present 
measurements do not allow further interpretation but corroborate the antioxidant potential 
of Asp. 
 Inflammation & Anaemia 
As mentioned, the spreading of HIV affects the immune system and the body’s overall 
health. This leads to an increased sensitivity to opportunistic infections. In the African 
context in particular, there is a large variety of opportunistic parasites: protozoa such as 
Plasmodium falciparum, bacteria such as Mycobacterium tuberculosis, fungi such as Candida 
albicans, and viruses such as the human cytomegalovirus. Focusing on Cameroon where the 
tropical forest represents a large part of the country, this serves as a storage basin for 
zoonotic diseases. According to literature, the Congo forest and its apes are the origin of a 
multitude of human parasites, for example for the most deadly malaria strain Plasmodium 
falciparum, which originated in West African gorillas, common in Cameroon (Liu, Li et al. 
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2010). Furthermore the African burden of malnutrition and low hygiene practices increases 
the co-infection rate and virulence of opportunistic diseases. Combinations of these factors 
amplify the spreading of HIV in the body and significantly reduce life expectancy and quality 
in infected people (Stillwaggon 2002). 
The first outcome of any infection is an augmented and prolonged inflammation reaction. 
One such inflammation messenger is the C-reactive protein, which is released by the liver to 
target altered self and alien molecules and activates the immune system (Du Clos 2000). The 
expression of C-reactive protein increases very rapidly in response to an acute inflammation. 
In HIV infections, CRP has been presented as an inexpensive biomarker related to infection 
outcomes such as mortality (Feldman, Goldwasser et al. 2003; Noursadeghi and Miller 2004; 
Drain, Kupka et al. 2007). The relationship to HIV is not a direct one. The marker is 
considered a surrogate (Nixon and Landay 2010).The impact of the inflammation marker as 
such is hardly reliable, especially in a limited intervention with a small sample size and short 
duration time. The serum acute phase proteins may facilitate the interpretation of serum 
nutrient concentrations (Thurnham, Mburu et al. 2008). One result of an inflammation is a 
low iron concentration in the blood. The iron pathway is co-regulated by the immune system 
and the inflammation in order to keep the free serum iron level low (Wessling-Resnick 
2010). The serum iron concentration depends on nutritional intake, the inflammation status, 
and the body’s storage. Thus, under inflammatory conditions, there is a diversion of iron 
traffic from the blood circulation via the sequestration of the macrophages and enterocytes 
and a reduction of iron absorption (Cherayil 2011). The present study corroborates this with 
a significant negative correlation between CRP and iron concentration (Rho=-.348, p<.05). 
The regulatory mechanism by reducing the disposability of iron for opportunistic bacterial 
infections was observed by Weinberg and called “nutritional immunity” (Weinberg 1974). 
This phenomenon results in iron-restricted erythropoiesis and can lead to the development 
of anaemia, termed ‘anaemia of chronic disease’(Weiss 2005). This mechanism may also 
influence the concentration of further essential metals such as zinc and manganese (Kehl-Fie 
and Skaar 2010). 
The abnormality in the red blood cells and their oxygen-carrying protein haemoglobin is 
expressed as anaemia. Anaemia can have various reasons such as individual, infection, or 
nutritional reasons (WHO 2008). Those reasons can depend on the population, as in the 
genetic emergence of thalassemia, or be related to iron deficiency, malaria, and other 
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parasitic infections such as hookworms, ascaris, and schistosomiasis, as well as cancer, 
tuberculosis, and HIV. Further micronutrient deficiencies such as vitamin A and B12, foliate, 
riboflavin, and copper can also result in low Hb (Claster 2002). 
The differentiation of anaemia types was not feasible within the context of this study. A 
common mutation of the RBC in Cameroon, thalassemia, raises the risk of anaemia. 
However, in the current study it remained constant, as the intervention results measured 
the change of Hb occurring over time. The present study showed no amelioration of Hb 
concentration or RBC count, but the variable decrease registered was less strong for the Asp-
supplemented patients in comparison to the placebo. The literature mentions an 
erythropoiesis mechanism, which may be influenced by Asp phycocyanin, namely by a 
release of the erythropoietin hormone (Khan, Bhadouria et al. 2005). The stable haematocrit 
value in the Asp group in the present study may be an indicator of the effect on erythrocytes 
in the blood. To document an erythropoiesis action, a period of four months would have 
been more appropriate due to the RBC lifetime of 120 days; however, the long-term 
supplementation documented a significant decrease of the two variables RBC and Hb. Those 
results seemed to show that in this study, Asp does not act on Hb. The effect of the 
implemented Asp doses did not seem to be sufficient to show a reliable effect over the 
chosen periods of time. 
The iron recommendation for the study population is a daily intake of 15 mg through the 
diet. The implemented Asp supplement contained 4.37 mg covering 1/3 of the RDA. Iron 
bioavailability of Arthrospira is poor and lies between egg and wheat (Kapoor and Mehta 
1992). As shown, the Asp iron supply effect on Hb was not significant, but the long-term six-
month exposure showed a non-significant improvement in iron concentration in the blood 
(r=.49). 
Independently from the supplement, an absolute increase of anaemic patients in both 
groups was registered. The relationship between anaemia and HIV has been described as 
being a predictor of mortality for HIV-infected women (O’Brien, Kupka et al. 2005). As 
mentioned before, another mortality predictor is acute inflammation. The present data 
showed a significant association between acute inflammation and anaemia, Pearson chi-
square X2(1)=7.08, p=.008. Anaemic patients had a 7.08 higher chance of having an 
inflammation than patients with no anaemia. The relationship between anaemia and 
inflammation was absent at baseline X2(1)=0.69, p=.404. An increase in anaemia over the 
101 
intervention time was probably due to inflammation and chronic disease. This increase 
seemed to represent the previously defined ‘anaemia of chronic disease’. Patients with 
severe anaemia showed a beneficial evolution of their Hb after receiving medication. 
Furthermore, the intake of medications was very low in the study groups and could not been 
considered a cofounder in statistical analysis. Anaemia of chronic disease could not be 
compensated by the nutrition supplementation and had to be treated medically. 
 Weight 
Body weight is a major and easily measurable indicator of infection progression. The pre-
HAART infection stage without medical or nutritional supply, according to the CDC’s 
expectation, is related to a body weight decrease (CDC 1987). A 10% weight loss over a short 
period of time is considered to be a reason to start an antiretroviral therapy (WHO 2005). 
Weight loss can have a number of reasons such as health, socioeconomic, psychological, 
and/or metabolic reasons. A chronic infection increases the energy demand due to the 
constantly active immune system. If this demand is not covered by an increase in nutrition, 
the body starts a catabolic process to supply the energy, which then leads to body weight 
loss (Grinspoon and Mulligan 2003). HIV infection can affect the production of hormones 
such as glucagon, insulin, epinephrine (adrenaline) and cortisol, which are involved in 
carbohydrate, protein, and fat metabolism (Young 1997). Elevated levels of these hormones 
contribute to weight loss and to the wasting syndrome. In addition to the metabolic activity, 
a form of anorexia due to deglutition problems is frequent in HIV patients and is often the 
start of rapid health alterations. 
In addition to an increased energy requirement, all essential nutrients have to be contained 
in a matching alimentation for infected people (WHO 2003). The macronutrients, especially 
protein with all essential amino acids, were present in both supplements. The difference 
between the two intervention products is the micronutrient content such as minerals, 
vitamins, and the secondary plant metabolites, which were present in Asp but not in the 
placebo. The intervention showed good results for the two products with regard to body 
weight stabilization and increase. The weight effect in the crossover group, where the 
implementation of Asp after the placebo showed a significant decrease between the two 
periods, has to be further investigated. The switch between the two products was not 
related to other markers, and the impacts on concomitant events or food intake were not 
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registered. Weight change during the intervention could also be due to new nutrition 
awareness created by involvement in the intervention. Furthermore, the presence of a 
nutritional counsellor in the HDJ health centre with the goal of creating awareness about a 
balanced diet has to be taken into consideration. Additional posters specifying country-
based nutritional guidelines complemented the counselling (Emmanuel 2006). Even if the 
intervention participants did not have to go through the waiting hall or were actively 
instructed, an influence on the food quantity could not be excluded. 
 Albumin 
A particular trait of the patients’ population involved in this study was a hyperalbuminaemia 
at baseline. A protein denaturation and hypoalbuminaemia would have been more likely 
expected in pre-HAART HIV patients (Salomon, de Truchis et al. 2002). The high albumin 
concentration over 50 g/l can have three main reasons: a high dietary protein intake, 
dehydration, or a retinol deficiency. After the RCT, both groups had a decreased albumin 
level, which was also true for patients of the long-term supplementation. The decrease was 
slightly more consistent in the Asp group during the RCT and continued over the long term. A 
possible reason may be an amelioration of a retinol deficiency by Asp. In this case, the supply 
of β-carotenoid from Asp ameliorates a low level of vitamin A and decreases the albumin 
concentration. Beta carotene is a precursor of retinol, which has a regulatory effect on 
albumin synthesis (Masaki, Matsuura et al. 2006). As the lowering effect was also present in 
the placebo group, a general explanation is needed. A possible reason related to all patients 
is probably a current dehydration state, which may be related to the high concentration at 
baseline. Dehydration is a known problem in relation to the disease. Some reasons for 
dehydration could be diarrhoea and/or no access to proper water. However, in the present 
study, there was a low rate of diarrhoea or having no access to water. The period during 
which the intervention was carried out coincided at the baseline with the rainy season and 
ended in the dry season for the RCT. The high albumin concentration registered could 
corroborate the state of dehydration at baseline. One assumption that would explain the 
general albumin level lowering over the intervention time is that light dehydration is more 
common during the rainy season than during the dry season. An argument would be that 
particularly in the dry season, attention given to proper hydration is more accurate than 
during the rainy season due to a stronger feeling of thirst in a warm environment. The intake 
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of water due to the ingestion of 10 caps a day can be an additional source of hydration that 
may have had an impact on the albumin concentration. However, no correlation between 
the absolute intake of pills and the albumin concentration was found: Rho=-.102, p=.469. 
Moreover, knowledge about the intake of protein-rich supplements and a sated feeling may 
also be able to influence the absolute protein intake not assessed in the intervention. The 
albumin evolution over the intervention can be multifactorial and due to the low power, no 
model could be tested in order to rank the effect of the different factors. 
 Lipid profile 
A burden related to a high lipid profile is coronary heart disease (CHD), which increases 
because of an industrial, processed diet and a sedentary lifestyle. Applying the NCEP cut-off 
point to detect an acute risk of CHD (TC >2.0 g/l and TG >1.5 g/l) (NCEP 2002), no patients 
involved in the study presented a risk of CHD. There was no elevated lipid profile among the 
participants. In another study among pre-HAART patients living with HIV in Yaoundé in 2010, 
subjects with CD4 >350 cells/mm3 had a mean TC of 2.39 (0.8) g/l and a TG mean of 1.57 
(0.12) g/l. This study by Nguema im did not mention the body weight of the patients 
(Nguemaim, Mbuagbaw et al. 2010). The absence of CHD risk in the Asp study is maybe 
related to the BMI of 22 (20– 23) kg/m², well documented by the general dependence 
between the lipid variables and the BMI (Carr, Emery et al. 2003). 
The relationship between TC and TG has been described for advanced HIV infection in pre-
HAART patients. Studies in Tanzania and Uganda showed that pre-HAART patients 
manifested an increase in TG and a decrease in TC (Buchacz, Weidle et al. 2008; Armstrong, 
Liu et al. 2011). An abnormal serum lipid profile described in pre-HAART patients, low 
cholesterol and high TG, seems to be related to CD4 values below 200 cells/mm3 (El-Sadr, 
Mullin et al. 2005). Furthermore, for the ongoing infection in pre-HAART patients, the 
expected lipid changes are a TC decrease and a TG increase without antiretroviral treatment 
(Shor-Posner, Basit et al. 1993; Constans, Pellegrin et al. 1994). Only the increase in TG has 
been associated with an increased risk of mortality in the case of initiating HAART (Ngu, 
Heimburger et al. 2010). The two groups differ only in their cholesterol change. The infection 
progression documented by the CD4 cells does not presently correlate with the cholesterol. 
The long-term Asp supplementation showed a stabilization of the TC value in the second 
period, which may show a regulatory effect of Asp on total blood cholesterol. The 
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cholesterol lowering registered in all Asp-supplemented groups has to be described further. 
However, more research with regard to the relationship between an Asp supplementation 
on cholesterol and infection progression on pre-HAART patients is needed. The comparison 
of the Asp effect to a well-documented cholesterol-lowering natural product such as bitter 
gourd could lead to a better description of efficiency. 
 Renal function 
The renal function documents the elimination mechanism of the body. The elimination 
molecules are creatinine and urea found in urine. Blood is filtered in the renal glomerulus. 
The estimation of the GFR is based on creatinine, urea, and albumin concentration in the 
blood. The renal unit nephron is affected by chronic infections and, in the case of HIV, can 
develop an associated nephropathy (HIVAN) (Herman and Klotman 2003). HIV infection 
impairs kidney function through a direct infection of the cells. The genetic mechanism and 
inclusion of the virus in the cells remains unclear, but some genetic predominance seems to 
play a role in the outbreak of HIVAN (Atta 2010). This pathology is the most common cause 
of chronic renal disease in HIV patients. A strong ethnic relationship has been documented; 
HIVAN mostly affects Africans (Bourgoignie, Ortiz-Interian et al. 1989). The screening of the 
present study population for nephropathy in adjusting the eGFR and creatinine value 
showed no case of HIVAN. In contrast, a study in Nigeria among 400 patients recorded a 38% 
prevalence of HIVAN. Renal disease was defined as serum creatinine above 1.5 g/dl. The 
mentioned risk factors were elevated age, low BMI, and low CD4 count (Emem, Arogundade 
et al. 2008). The lack of nephropathy in the current study has to be considered with regard 
to the inclusion criteria of an age between 18 to 49 years and the CD4 count over 350 
cells/mm3. A protective effect of these criteria against HIVAN could be the reason. 
The present intervention with Asp caused a creatinine increase, which was clinically not 
relevant. A study using 10 grams of Asp on HIV patients in the Central African Republic also 
reported a serum creatinine increase (Yamani, Kaba-Mebri et al. 2009). The present increase 
of 0.1 g/dl seemed to stabilize over six months, which could be due to an adapted 
elimination balance. The increase in creatinine blood level was not associated with an 
increase in serum urea. It could be concluded that an additional five grams of protein-rich 
supplement per day had no effect on N-metabolism. However, creatinine level has to be 
studied dose dependently. 
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4.3 Discussion of Nutrition Practices in HIV 
Benefits of nutrition supplementation, which delays the time to HAART and how it influences 
HAART, are currently discussed (Chandrasekhar and Gupta 2011). Furthermore, the new 
aging process of PLWHA is the result of the successful implementation of efficient HAART 
and needs innovative complementary medical management based on nutrition and physical 
activity (Somarriba, Neri et al. 2010). Nutrition, besides the disease, depends on multiple 
factors such as social, economic, environmental, psychological, and physiological ones. Each 
individual or group has special needs. Energy and nutrient requirements differ between men 
and women and vary with regards to age, the degree of physical activity, and climate 
conditions. According to these issues the American Dietetic Association highlights cross-
cutting criteria to define the nutritional status of people living with HIV: sex, age, disease 
progression, and treatment (Fields-Gardner 2010). Furthermore, the HIV pandemic presents 
different backgrounds in each region and country in the world. As a result, the epidemic and 
the care gain a social character due to higher infection prevalence in marginal groups such as 
homosexuals, prostitutes, socially rejected people, intravenous drug users, or people having 
undergone blood transfusion but also groups of workers such as truckers and miners. These 
contexts have to be taken into account for the care support and in particular for the 
nutrition advice and/or supplementation proposed. 
The African immunodeficiency context suffers from the prevailing burden of malnutrition. 
Pre-existing micronutrient deficiency has to be treated in addition to the infection burden 
(WHO 2005). Moreover, the burden of other infectious diseases such as malaria, hepatitis, 
and tuberculosis needs to be considered in the fight against immune deficiency (The Global 
Fund to fight AIDS 2001). The African HIV context also shows particular associated metabolic 
abnormalities such as iron deficiency anaemia, nephropathy, and lipodystrophy (O’Brien, 
Kupka et al. 2005; Manuthu, Joshi et al. 2008; Atta 2010). One main reason for iron 
deficiency in this region is related to malaria and other parasitic and bacterial infections 
(Weinberg and Moon 2009; Cherayil 2011). HIV-associated nephropathy (HIVAN), a collapse 
of the kidney function, is distinctive to African patients and patients of African descent 
(Bourgoignie, Ortiz-Interian et al. 1989). Finally, lipodystrophy is a redistribution of fat from 
subcutaneous regions to the visceral organs (Carr, Samaras et al. 1998). The syndrome is 
strongly related to the first HAART line and the use of protease inhibitors (Heath, Chan et al. 
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2002). A further burden on the lipid profile of the urban population in Africa is the transition 
to a fashionable Western lifestyle and nutritional behaviour (Pasquet, Temgoua et al. 2003). 
The major result is insulin-resistant diabetes related to nutrition transition and also appears 
as a complication in HIV infections and their HAART protease medication (Das 2011). 
Nutrition is part of the care of HIV patients. In addition to the recommendation for better 
alimentation, the practice of supplementation takes up a large part of the help and care 
given to the patients. Nutritional societies encourage the implementation of evidence-based 
use of oral nutritional supplements to fight malnutrition in order to reduce health care costs 
and achieve economic benefits (Stratton and Elia 2010).However, in particular since beta-
carotene and retinol efficiency trials with β-carotene, 30 mg/day, plus vitamin A, 25,000 IU, 
have shown to increase the risk of lung cancer among present and former smokers and 
workers exposed to asbestos (Omenn, Goodman et al. 1996),supplements have to be 
checked and validated in trials. The research has shown that a megadose of β-carotene 
increases serum levels of β-carotene 5 to 12 times higher than the normal physiological 
levels. At high doses, β-carotene has prooxidant effects (Palozza 1998).In humans,30 mg per 
day of β-carotene has been shown to decrease the activity of leukocyte superoxide 
dismutase and to lower levels of serum glutathione peroxidase, two important components 
of antioxidant defence (McGill, Green et al. 2003). Additionally, in the HIV context high 
vitamin A supplementation has been related to increased mother-to-child transmission, 
explained by an increased viral shedding in breast milk and the vagina (Villamor, Koulinska et 
al. 2010). 
Highly concentrated micronutrient preparations can have a wide range of effects. It is known 
that the same micronutrients can act synergistically at moderate doses and antagonistically 
at high doses. Zinc, for example, is immunosuppressive at high doses but an essential 
mineral for the immune system (Chandra 1984). A statistic modelling found that at a high 
concentration, antioxidative supplements can have adverse effects, whereas at a moderate 
concentration, temporal supplementation can boost uninfected CD4 cells (van Gaalen and 
Wahl 2009). Vitamin C at high doses showed steady-state pharmacokinetics of the protease 
inhibitor indinavir in healthy volunteers (Slain, Amsden et al. 2005). Nonetheless in 2011, 
supplementation and implementation of enriched food have to be surveyed on HAART 
pharmacokinetics (Raiten 2011). Currently, a review of micronutrient supplementation 
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concluded that one should strictly follow the WHO 2003 recommendation, which endorses 
an intake at the recommended dietary allowance amounts (Forrester and Sztam 2011). 
Iron supplements are the subject of large debates and special recommendations among 
regions in Africa. Iron plays a central role in the metabolism of protozoa, especially 
Plasmodium spp. (Wilson and Britigan 1998). The role of iron in the specific case of infection 
makes an iron supplement questionable (Clark and Semba 2001). Iron supplements have 
been shown to increase the incidence and morbidity of malaria in endemic areas (Prentice, 
Ghattas et al. 2007; Weinberg and Moon 2009). The international health agency refers to the 
dilemma of iron deficiency in malaria-endemic regions as a major public health problem 
(WHO 2007). The current recommendation is an iron supplement as a cure for identified iron 
anaemia. It warns against supplementation as prevention in malaria-endemic regions 
(Raiten, Namaste et al. 2011). The role of iron in humans and its interaction with infections, 
as is especially the case for HIV women in malaria-endemic regions, has increased attention 
on providing iron from natural products. The effect of natural products such as Asp could 
prevent patients from incurring an aggravation of iron deficiency and preserve them from an 
enhanced risk of malaria crises. Even if the study showed that a supplementation with Asp 
has no curative effect on anaemia status, Asp assures a minimal iron supply, which is vital for 
women at childbearing age. However, spirulina cannot replace an iron-balanced 
alimentation or iron supplementation in the case of severe anaemia. Nonetheless, Asp 
consumption could represent a sustainable solution to prevent severe iron deficiency 
anaemia without exacerbating malaria outbreaks. 
Each individual has unique knowledge about food and access to it. The current solutions are 
educational programs, food distribution, or facilitated access to food. In special cases of 
acute disease phases or emergency situations when a direct, quick impact on the symptom is 
required, a highly concentrated supplementation or therapeutic ready-to-use food can be 
implemented. In these particular cases, medical monitoring must be present and deal with 
short-term objectives. Sustainable solutions regarding cultural specificity, economic 
potential, and the social and ecological burden are still needed, with attention to individual 
health outcomes. 
Natural preparations can be implemented over longer periods of time due to their diversity 
and normal concentration of bioactive molecules. Important reasons for the study and 
implementation of herbal products are that they are mostly local, cultural, and socially non-
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discriminating, as well as ecological. It also induces an empowerment of the people to find 
their appropriate individual preparation for an acceptable price. Animal source foods have 
been promoted by Friis for being richer in essential nutrients and specific vitamins, with a 
higher bioavailability of minerals in the management of malnourished children (Michaelsen, 
Hoppe et al. 2009). Herbal products and animal food have to be part of the set of answers 
given to a lifelong infection. The focus on plants that can be cultivated and prepared by 
PLWHA can represent a milestone in the achievement of a sustainable answer to the 
pandemic. 
Each proposed solution has to answer the challenges of HIV nutrition intervention in a 
limited country setting. Those were summarized well by De Pee and Semba (De Pee and 
Semba 2010): 
-Weight loss can be due to many factors. Its treatment and prevention have to address 
different factors simultaneously and take the specific circumstances of the individual patient 
into account. 
-Management of weight and nutritional status becomes more and more complex as HIV 
infection progresses. Therefore, nutrition interventions should start as early as possible and 
should include nutrition assessment, education, and counselling, augmented with 
supplements and pharmaceutical preparations when required. 
-HAART reduces the risk of weight loss and may increase appetite, but it also has side effects 
and long-term metabolic effects (dyslipidaemia, insulin resistance, and obesity) that require 
dietary management. 
-Common sense dictates that a balanced diet containing all nutrients in the recommended 
amounts, including micronutrients, should be consumed, particularly by people who are 
vulnerable such as HIV-infected patients in order to support the body and immune system. 
In areas where micronutrient deficiencies are widely prevalent, HIV-infected people may 
need an intake somewhat above the RDA in order to correct these deficiencies in addition to 
meeting normal bodily needs. 
-Products for vulnerable patients have to be chosen according to the following criteria: 
The composition of the food variety, quality, and relative proportions of macro- and 
micronutrients; (higher energy density and lower content of a nutrients) and the use (less 
likely to be shared with other family members because it is ready to eat and more easily 
accepted as being a therapeutic food to be consumed exclusively by the patient). 
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4.4 Conclusion 
The present research documented a supplementation of ten caps per day of Arthrospira 
platensis, a locally available food rich in nutrients that supposedly has effects on the immune 
system and antiretroviral activities among HIV patients. Even if the chosen product for the 
study was not a locally grown alga, due to standardization and purity requirements, the 
implementation of spirulina products is a current topic for Cameroon. 
The study described an implementation of the natural product on a sensitive target 
population consisting of women between 18 and 49 years, not under HAART, presenting a 
low immunity, and it excluded patients with pregnancy, lactation, overweight, or currently 
suffering from a chronic disease. The exclusion criteria were required to keep a homogenous 
study population. The following conclusions are restricted to this defined urban female 
population, present in the health care units of Yaoundé, and on the amount and form of the 
product tested. The trial had two research objectives covering the therapeutic aspect versus 
a protein and energy equivalent placebo, and the nutritional aspect related to an HIV 
infection. 
The Asp supplementation of five grams per day of dry powder had the same effect as the 
placebo on CD4 cells and the viral load among pre-HAART infected women over the duration 
of three months. A long-term action of Asp on the CD4 and VL stabilization cannot be 
excluded, as in the present study the long-term effects observed seem to be more related to 
the fact that involvement in the six-month intervention meant that no treatment had been 
started, which represents a selection of healthy patients. 
Even if the immune marker measurement over the three-month RCT could not figure out 
whether Asp had a direct effect on the infection course, the start of therapy and the 
concomitant events frequency showed differences between the supplementation products. 
A main outcome of the RCT intervention was a non-significantly higher proportion of 
patients starting with HAART in the placebo versus the Asp group, ten against five patients, 
respectively, combined with a higher incidence of concomitant events, 70% in the placebo 
group versus 43% in the Asp group. These observations could not be deepened further but 
are useful for future studies that assess the properties of spirulina in relation to the time 
elapsed from seroconversion to initiation of HAART. 
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The nutritional aspect documented a positive effect of both intervention products on 
weight. No severe weight losses were observed, and most patients stabilized or increased 
their weight. 
A main significant effect of spirulina intake among HAART-naïve HIV patients was 
documented by the increase in antioxidative capacity. This effect was stronger for patients 
with a poor antioxidative index at baseline, a rehabilitation effect could be proposed. 
A further important outcome of the study is the decreasing effect on total cholesterol 
present among all study groups; however, it tended to be higher among Asp groups. This 
outcome confirms the cholesterol-lowering effect of spirulina documented in former studies. 
Lipid regulation, especially the TC-lowering effect has to be investigated for people receiving 
HAART. 
In the current study, the active components of Asp did not seem to act as a curative 
element. Ingestion in other forms such as enriched Asp extracts or in larger amounts of raw 
powder mixed with already cooked food may be a more appropriate way to enhance the 
beneficial effect of Asp intake. Recommendations based on the present study could be to 
consider natural Asp as a nutrient with proven antioxidative potential and rich protein 
content. Natural products of Asp should not promise antiretroviral or immunotherapeutic 
activities. Furthermore, a stigmatization of the product with a special use for PLWHA has to 
be avoided. Therefore, Asp at a dose of five grams per day can only be recommended as 
support to antioxidative status. 
4.5 Outlook 
Clinical pilot studies with algae and spirulina suggested a stabilization or improvement for 
some patients in their HIV/AIDS outcomes (Teas and Irhimeh 2012). Dose-dependent studies 
with a sufficient sample size and with active extracts have to be carried out in order to 
provide a more detailed description of the long-term effects of Asp consumption. The 
measurement of the time lapse from seroconversion to the start of HAART could answer the 
question of whether spirulina has the benefit of enlarging the asymptomatic time lapse. A 
future study may assess the properties of spirulina by focusing on the time elapsed from 
seroconversion to HAART among HIV patients. One focus should be on the pharmacopeia 
effects of Asp on HAART. A result that needs to be looked into is the creatinine increase 
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related to the consumption of Asp. It has to be studied dose dependently in order to 
determine the burden of daily Asp consumption on the kidneys. 
The research focuses on various molecules present in algae and, particularly in spirulina, 
sulphated polysaccharide, phlorotannins, lectins, and bioactive peptides, which could be key 
active molecules in the presumed antiviral activity (Vo and Kim 2010). The reviews of 
previous essays have attributed various nutritional and medicinal potencies to metabolites 
from spirulina (Nuhu 2013). 
 
Table 4.2 Arthrospira active components promoting health 
Molecule Function 
Phycocyanin 
Antioxidant 
Lipid preoxidation inhibitor 
Hepatoprotection 
Anti-inflammation 
Anti-cancer 
Induce haematopoiesis 
Immunomodulation 
Antiviral 
β-carotene 
Source of vitamin A 
Anti-carcinogenic 
Antioxidant scavenging 
Calcium-spirulina 
(sulphatedpolysaccharides) 
Anti-viral (shielding off the positively 
charged amino acids in the V3 loops of 
the enlv glycoprotein gp120-->inhibition 
of the virus-cell binding ) 
Anti-cancer 
Immunomodulation 
GLA 
Antioxidant 
Prostaglandin precursor 
Immolina Immunomodulation 
 
Oral consumption of spirulina-polysaccharide can enhance components of the mucosal and 
systemic immune system (Balachandran, Pugh et al. 2006). Lectins, carbohydrate binding 
agents such as cyanovirin-N, could prevent transmission from infected cells to non-infected 
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cells (Huskens and Schols 2012). Immolina extracts from Asp, a braun-type lipoprotein, 
activate the immune system (Nielsen, Balachandran et al. 2010). A further substance-like 
phycocyanin presents a highly active antioxidant potential. The functions of major active 
molecules are described in the table below. The mechanisms of these molecules have to be 
described in relation to their action in the gut, and on the bioavailability of drugs and 
nutrients. Metabolism and their assimilation into the human body are key pieces of 
information that need to be collected. 
Additionally the culture and transforming conditions have to be examined in terms of the 
enrichment of secondary metabolites such as phycocyanin, calcium polysaccharide, and 
lipids. For example, there are possibilities to enforce Asp with selenium and to combine it 
with a formula of ready-to-use food. As a microorganism, the growing conditions have to be 
studied in relation to the metabolite and their accumulation. 
The quality and purity of products based on spirulina have to be controlled well. 
Furthermore, the origin of the supplement has to be clearly defined. The culture of Asp can 
be artisanal, semi-industrial and industrial, or naturally harvested. The growing conditions, 
quality of water, and correct drying are major factors influencing the safety of the product 
and its nutrient content. Spirulina is a cyanobacterium related to species producing 
cyanotoxine, therefore the purity of the product has to be guaranteed as well as good 
transformation of the product after harvesting wherever putrefaction can occur. 
This study had the purpose of encouraging further research in the application field of 
Arthrospira platensis and supporting accurate monitoring of natural local products in their 
implement on patients suffering from chronic infection and diseases. 
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5 Abstract 
Background: Supplements are often used to improve the nutritional status of people living 
with HIV. Arthrospira platensis (Asp) is an alga rich in proteins, minerals, and antioxidants. So 
far, there has been a paucity of data describing the immune-modulating activity and 
nutritional properties of Asp. This study describes the influence of Asp supplementation on 
the immune and nutritional status of HIV patients. 
Objective: The focus of the study was on a sensitive population of pre-highly active anti-
retroviral therapy (HAART) status and gender-oriented towards women. It aimed to assess 
the effects of a five-gram Asp supplementation on immune regulators and nutritional status. 
Methods: The nutritional intervention was a pilot randomized placebo-controlled study 
(RCT) of three months, followed by a three-month open intervention with Asp. The use of a 
placebo mixture with the same protein calorie potential focused the observed effect on the 
micronutrient and secondary phytonutrient composition of the microorganism. An 
additional group of women undergoing a stable antiretroviral therapy was recruited. 73 
HAART-naïve and 35 HIV-infected adult women under HAART with CD4 T cell count between 
350 and 600 cells/mm3 and a BMI ≤ 26 were recruited in Yaoundé between June and 
September 2010. The RCT groups were compared to each other. The six-month intervention 
groups were discussed separately as well as the Asp intervention on HAART patients. The 
disease predictors were CD4 cells, viral load, the immune activation marker CD38 
expression, and concomitant events. Furthermore, common nutritional markers and the 
antioxidant marker total antioxidant status on the serum were measured. Statistical analyses 
were performed with non-parametric tests, and the effect size of each interaction was 
calculated to assure an adequate analysis of group variance and comparison. 
Results: There were no significant differences in the immune inflammatory virological 
markers set during the RCT. In the placebo group, 21 of 30 patients (70%) developed 
concomitant events, while in the Asp group, only 12 of 28 patients (43%) did. The nutritional 
markers showed a beneficial aspect for the lipid profile, with a significant decrease in 
cholesterol of -0.14 (-0.47– -0.04) g/l, p<.004 and a slightly non-significant increase of 
triglyceride of 0.05 (-0.18– 0.20) g/l. Haemoglobinand erythrocytec ounts were not 
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significantly stimulated by Asp. Serum antioxidant capacities increased by 56 (1– 98) µM and 
were significantly different from the placebo p<.001 with a large effect size of r=.51. 
Creatinine showed a significant increase of 0.1 (0.0– 0.2) g/l, p=.002 with a large effect 
magnitude of r=.59 for the Asp group. The long-term exposure confirmed the tendency of 
the RCT. The HAART group showed a decrease in cholesterol but no other related effects. 
Conclusions and Recommendations: The lack of an effect from a supplementation of ten 
pills per day on immune markers can be considered a lack of therapeutic activity of natural 
spirulina powder on HIV. However, the intervention seemed to reduce the incidence of 
concomitant events. The increase in antioxidant capacities could lead to a long-term effect. 
Furthermore, the decline in cholesterol especially for HAART patients should be the focus of 
additional research. The enhancing effect of Asp on creatinine should be investigated in a 
dose-dependent intervention. Moreover, further research on natural local products in terms 
of nutritional RCT intervention, during early HIV stages, and for patients under HAART on a 
larger population can be recommend, focusing on both urban and rural settings. 
6 Zusammenfassung 
Die Welt Gesundheitsorganisation schlug in ihrem Bericht von 2011 bereits vor, dass die 
bestehenden HIV Maßnahmen für Notsituationen durch längerfristige Maßnahmen für die 
Patientenfürsorge ersetzt werden müssen (WHO 2011).  
Ein Problem stellen Nahrungsergänzungsmitteln in Bezug auf Vermarktung, Zugang und 
Gesundheitlichen Stellenwert dar. Die Gesundheitsministerien und internationalen 
Agenturen wurden bereits auf die Problematik aufmerksam und forderten 2005, Forschung, 
Ernährung und HIV in Afrika zu einem Schwerpunkt zu machen. Das Statement lautet wie 
folgt:  “there is a proliferation in the marketplace of unproven diets and dietary therapies, 
with exploitation of fears, raising of false hopes and further impoverishment of those infected 
and affected by HIV and AIDS” (WHO 2005). 
Am Beispiel von Arthrospira platensis, im allgemeinen Sprachgebrauch auch unter dem 
Namen Spirulina bekannt, wo aktuelle Forschungen auf der Basis von Zellkulturen und 
Tierversuchen gezeigt haben, dass das Cyanobakterium ein immunmodulatorische 
Funktionen (Hayashi, Katoh et al. 1994; Qureshi, Garlich et al. 1996; Mao, J et al. 2000) und 
antiretrovirale Wirkungen aufweist (Hayashi, Hayashi et al. 1996; Ayehunie, Belay et al. 
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1998; Rechter, Konig et al. 2006). Dieses Lebensmittel wird seit Jahrhunderten um den 
Tschad See von der Bevölkerungsgruppe der Kanembu konsumiert(FAO 2008). Obgleich 
aktuelle in vitro Forschungsergebnisse eine antiretrovirale Wirkung gezeigt haben, fehlen 
derzeit ausreichende Ergebnisse aus Humanstudien. 
Die hier vorliegenden Studie untersucht die Wirkung von Spirulina bei Menschen die mit HIV 
Leben. Diese Studie ist eine Pilot-Studie, um Tendenzen in den Bereichen Immunologie, 
Virologie und Ernährung zu dokumentieren. 
Die pilot-Studie ist eine klinische mit randomisiertem, Placebo kontrolliertem, doppel-
blinden Studiendesign. Die Studie wurde am Zentralen Krankenhaus in Yaoundé, Kamerun 
im Zeitraum von 15.08.2010 bis 15.05.2011 durchgeführt. 73 Frauen die mit HIV leben und 
keine HAART bekommen, haben drei Monate lang täglich zehn Kapseln a 0,5 Gramm 
bekommen. Zu Beginn und am Ende der Intervention wurden venöse Blutproben 
entnommen T-CD4 und die Anzahl an viralen Partikel im Blutwurden gemessen. 
Blutparameter Eisen, Albumin, Kreatinin und Harnstoff wurden biochemisch bestimmt. Als 
Marker für Anämie wurden die Anzahl an Erythrozyten sowie die Hämoglobin Konzentration 
bestimmt. Außerdem wurde der Total Anti-Oxidant Status gemessen. Die Gruppen wurden 
wegen deren geringen Anzahl an probaten mittels robusten nicht parametrischen Test, 
Mann-Whitney und Wilcoxon rang Test auf signifikante Unterschiede getestet (p<0,05). Der 
Effekt Ausmaß würde für alle statistischen Test mittels der Effekt Größe, r ausgerechnet. 
Resultate: Die Studie hat gezeigt, dass eine Anwendung von natürlicher Spirulina in Höhe 
von 5 gram pro Tag über drei Monate keine Auswirkung auf die hier untersuchten 
Infektionsmarker hat. Der immunologische und virologische Infektionsverlauf haben sich im 
Vergleich zu Kontrollgruppe nicht signifikant unterschieden. Die Zunahme und Stabilisierung 
des Gewichtes aller Patienten hat hingegen gezeigt, dass eine Zugabe an Protein und Energie 
einen positiven Effekt aufweist. Des Weiteren steht die Einnahme von Spirulina mit einer 
Erhöhung der antioxidativen Kapazität und der Blut Kreatinin-Spiegel in Verbindung.  
Die vorliegend Studie ist hier ein Schritt in der direkten Beurteilung eines bereits 
verwendeten natürlichen Präparates bei gängiger Dose von einem hochwertigen reinen 
Produkt im Humanen Kontext. Die Ergebnisse haben gezeigt dass es keine direkte 
Auswirkung auf dem Infektionsverlauf gibt. Ein kurzfristiges einsetzen bei gängiger dose hat 
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keine Antiretrovirale oder immun verstärkende Wirkung. Die hier geführt Untersuchung lässt 
auf eine Langzeit Verstärkung über den Erhalt des Redox Gleichgewicht im Körper vermuten. 
Die Vorliegenden Ergebnisse müssen weitergeführt werden um eine bessere Einschätzung 
des Produkts auf verschiedene Populationen und Infektion Stadien zu dokumentieren. 
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10 Appendix 
 Study Time 
The climatic conditions during the sampling periods, temperature and humidity, were taken 
at the airport in Yaoundé (see table 10.1). 
TABLE 10.1 SAMPLING PERIOD IN RELATION TO THE CLIMATIC CONDITION 
Sampling period Temperature 
in°C 
Mean rainfall 
in mm 
June-September 2010 19.3 to 27.7 293 
October-December 2010 19.5 to 28.5 19 
March 2011 20.3 to 30.4 124 
www.Worldweather.int 
 Exclusion Data 
TABLE 10.2 DROPOUT REASONS WITHIN THE GROUPS OVER THE INTERVENTION 
 HAART 
Start 
Co-
medication 
Withdrawal 
Lost to 
follow-up 
Pregnancy Total 
Group Count % Count % Count % Count % Count % Count % 
 
Placebo-
Asp* 
0/10/1 48 0/0/0 0 0/4/0 17 5/1/1 30 1/0/0 4 6/15/2=23 100 
Asp-
Asp* 
3/2/2 36.8 0/1/2 15.8 2/1/0 15.8 4/2/0 31.6 0/0/0 0 9/6/4=19 100 
*For the pre-HAART groups, the patients were divided into three time periods: during three months, 
continuing for six months, during six months. 
 
II 
 
TABLE 10.3 EXCLUSION REASONS PER PERIOD 
 RCT 
n=15/73 (20%) 
Between 
RCT and OLI 
n=22/58 (38%) 
OLI 
n=6/36 (20%) 
 
Reasons 
Frequency 
(Patient) 
Percent 
(%) 
Frequency 
(Patient) 
Percent 
(%) 
Frequency 
(Patient) 
Percent 
(%) 
 
HAART Start 3 20 12 55 3 -  
Relevant co-
medication 
- - 1 5 2 -  
Withdrawal of consent 2 13 5 25 - -  
Lost to follow-up 9 60 3 15 1 -  
Pregnant 1 7 - - - -  
Total 15 100 22 100 6 *  
*Below 10 patients no percentage 
indication 
      
 
 Compliance 
TABLE 10.4 INTERVENTION VARIABLES BETWEEN EXCLUDED AND COMPLIANT TO THE INTERVENTION IN THE PRE-
HAART POPULATION 
 
Excluded n=43 Compliant n=30 
Variable at Baseline 
Median 
(IQR) 
Min-Max 
 
Median 
(IQR) 
Min-Max 
Age (year) 30 (26– 36) 18– 48 
 
28 (24– 35) 19– 43 
BMI (kg/m2) 21 (20– 23) 17– 27 
 
23 (21– 24) 18– 26 
CD4 (cells/mm3) 449 (364– 542) 139– 781 
 
446 (427– 559) 321– 815 
CD8-CD38(%) 24(16– 30) 7– 49 
 
23 (16– 40) 11– 58 
CRP (mg/l) 1.2 (0.4– 4.7) 0.2– 54.0 
 
0.8 (0.4– 2.6) 0.2– 90.8 
TAOS (µM) 357 (296– 400) 95– 533 
 
365 (304– 424) 193– 509 
Albumin (g/l) 49 (47– 52) 39– 55 
 
50 (47– 52) 42– 58 
III 
Iron (mg/l)) 0.8(0.7–1.0) 0.4– 1.4 
 
0.9 (0.7– 1.0) 0.3– 1.2 
Haemoglobin 
(g/dl) 
11.8 (10.2– 12.5)* 5.7– 13.2 
 
12.1 (11.0– 13.5)* 8.9– 14.8 
Erythrocytes (tera/l) 4.4 (4.0– 5.0)* 2.5– 5.8 
 
4.6 (4.4– 5.1)* 3.6– 6.4 
Triglycerides 
(g/l) 
0.87  
(0.63– 1.14) 
0.44– 5.05 
 
0.76  
(0.60– 0.96) 
0.30– 1.35 
Cholesterol 
(g/l) 
1.65 (1.41– 1.88) 1.0– 2.70 
 
1.54 (1.29– 1.72) 0.96– 2.18 
Creatinine 
(mg/l) 
7 (6– 7) 4–9 
 
7 (6– 8) 3–16 
Urea (g/l) 0.19 (0.15– 0.22) 0.11–0.30 
 
0.18 (0.15– 0.22) 0.10–0.41 
eGFR 57.5 (50.8– 66.8) 35.7– 109.3 
 
57.6 (50.3– 69.0) 22.3– 143.2 
* p<.05 
 Data from the RCT 
o CD4 Lymphocytes 
TABLE 10.5 LYMPHOCYTE CD4 DURING THE RCT 
 
Placebo n=30 Arthrospiran=28 
 
CD4 
(Cells/mm3) 
Mean(SD) Median(IQR) 
Min-
Max 
Mean(SD) Median(IQR) 
Min-
Max 
U- 
test(p=) 
Baseline 467.0 (132.2) 
462 
(413–558) 
139– 
815 
469.7 (95.9) 
440  
(415– 550) 
324– 
781 
.7 
After 
12 weeks 
401.8 (106.2) 
417 
(311– 486) 
184– 
595 
414.0 
(132.1) 
406  
(320– 499) 
227– 
887 
.9 
Difference -65.2 (86.2) 
-52  
(-112– -16) 
-293– 
120 
-55.7 (71.4) 
-66  
(-111– -20) 
-153– 
106 
.9 
Wilcoxon 
(p=) 
 <.001*   <.001*   
*p<.05 
IV 
 
o Viral Load 
TABLE 10.6 VIRAL LOAD DURING THE RCT 
 Placebo n=30 Arthrospiran=28  
Viral load  
(Log10) 
Mean(SD) 
Median 
(IQR) 
Min-
Max 
Mean(SD) Median(IQR) Min-Max 
U-
test(p
=) 
Baseline 5.3 (1.2) 5.6 (5.1–6) 1.4– 6.9 5.1 (1.3) 5.3(4.3–5.8) 1.4– 7.4 .2 
After 12 
weeks 
5.0 (1.5) 5.5(4.7– 5.9) 1.4– 6.8 5.0 (1.3) 5.3(4.5–5.9) 1.4– 6.8 .7 
Difference -0.3 (1.1) 0.0(-0.4– 0.2) -4.4– 1 -0.1 (1.2) 0.0(-0.2–0.4) -5.3– 2.2 .2 
Wilcoxon 
(p=) 
 .3   .5   
 
o LymphocyteCD8-CD38 
 
TABLE 10.7 T LYMPHOCYTECD8-CD38 DURING THE RCT 
 Placebo n=30 Arthrospiran=28  
CD8-CD38  
(%) 
Mean(SD) Median (IQR) Min-Max Mean(SD) Median (IQR) Min-Max 
U-
test 
(p=) 
Baseline 27.6 (13.3) 25.2(17.1– 37.1) 7– 58 24.6 (9.8) 22.4(16.2– 30.5) 11.5– 46.9 .5 
After 12 
weeks 
26.1 (13.4) 21.2(15.5– 36.3) 3– 61.4 24.6 (11.3) 24.5(14.5– 29.9) 8.6– 52.4 .7 
Difference -1.5 (8.3) -0.9(-4.17– 1.56) -21.5– 22.5 0.1 (8.7) -1.3(-5.8– 2.0) -13.5– 28.7 .8 
Wilcoxon 
(p=) 
 .18 
 
 .32 
 
 
 
V 
 
o C-Reactive Protein 
TABLE 10.8 C-REACTIVE PROTEIN ABSOLUTE VALUE DURING THE RCT 
 Placebo n=30 Arthrospira n=28  
C-Reactive Protein 
(mg/l) 
Median 
(IQR) 
Min-Max 
Median 
(IQR) 
Min-Max 
U-test 
(p=) 
Baseline 1.50 (0.40– 2.80) 0.20– 90.80 0.80 (0.17– 3.90) 0.20– 42.60 .5 
After 12 weeks 1.15 (0.40– 3.40) 0.20– 64.70 0.35 (0.25– 0.85) 0.20– 20.10 .7 
Difference 0.19 (-0.85– 2.40) -90.4– 62.8 0.20 (-0.30– 0.77) -42.50 - 19.30 .7 
Wilcoxon (p=) .32  .37   
 
o Concomitant Events during the RCT 
 
TABLE 10.9 CONCOMITANT EVENTS DURING THE RCT 
 Placebo n=30 Arthrospira n=28 Total n=58 
Events n 
Percent 
(%) 
n 
Percent 
(%) 
n 
Percent 
(%) 
Headache 3 14 1 8 4 12 
Fatigue 2 10 1 8 3 9 
Malaria 6 29 4 33 10 30 
Gastrointestinal 
symptoms 
3 14 3 25 6 18 
Diarrhoea 1 5 1 8 2 6 
Opportunistic 
infections 
3 14 - - 3 9 
Respiratory disease 1 5 1 8 2 6 
Injuries 2 10 1 8 3 9 
Total events 
occurred  
21 70 12 43 33  57 
 
o Body Weight 
VI 
TABLE 10.10 BODY WEIGHT DURING THE RCT 
*p<.05 
 
o Total Antioxidant Status 
TABLE 10.11 TOTAL ANTIOXIDANT STATUS DURING THE RCT 
 Placebo n=30 Arthrospiran=28 
TAOS (µM) Mean(SD) 
Median 
(IQR) 
Min-Max Mean(SD) 
Median 
(IQR) 
Min-Max 
U-test 
(p=) 
Baseline 351 (101) 357(298– 424) 160– 509 331 (82) 330(275– 384) 95– 505 .2 
After 12 
weeks 
315 (113) 336(275– 373) 7–498 379 (92) 387(320– 430) 165– 533 .02* 
Difference -36 (73) -22(-64– 19) -185– 153 48 (85) 56(1– 98) -124–251 <.001* 
Wilcoxon (p=)  .008*   .007*   
*p<.05 
 
o Albumin 
 
TABLE 10.12 ALBUMIN 
 Placebo n=30 Arthrospiran=28  
Albumin  
(g/l) 
Mean(SD) Median (IQR) Min- Max Mean(SD) Median (IQR) Min- Max 
U- test 
 (p=) 
Baseline 48.9 (4.0) 49.5(47– 52) 39 – 58 48.7 (3.7) 49 (47– 51) 40 – 54 .9 
After 12 weeks 47.0 (4.1) 47.5(46 – 49) 39 – 55 47.1 (3.5) 47(44.5– 50) 40 – 53 .8 
Difference -1.9 (4.9) -1.5(-4.0– 1.0) -14 – 10 -1.5 (4.1) -3.0(-4.0– 0.0) -10 – 9 .6 
Wilcoxon (p=)  .034*   .026*   
*p<.05 
 Placebo n=30 Arthrospira n=28 
Body Weight 
(kg) 
Mean(SD) 
Median 
(IQR) 
Min-Max Mean(SD) 
Median 
(IQR) 
Min-Max 
U-test 
(p=) 
Baseline 57 (6.5) 56.8(54.1 - 61.7) 45.9–69.7 57.9 (6.5) 57.3(53.2–62.3) 48.3–73.3 .9 
After 12 weeks 58.4 (6.6) 58.4(54.9–63.1) 45.6–69.6 58.1 (6.5) 57.8(52.9–62.5) 46.6–72.1 .7 
Difference 1.4 (2.2) 0.6(-0.1–2.9) -3.4–5.8 0.2 (2.1) 0.5(-0.4–1.7) -4.4–3.7 .1 
Wilcoxon (p=)  .005*   .51   
VII 
 
o Erythrocyte Count 
TABLE 10.13 ERYTHROCYTE COUNT 
 Placebo n=30 Arthrospira n=28  
RBC 
(tetra/l) 
Mean(SD) 
Median 
(IQR) 
Min-Max Mean(SD) 
Median 
(IQR) 
Min-Max 
U-test 
(p=) 
Baseline 4.6 (0.7) 4.5(4.2– 5.1) 2.5 – 6.4 4.5 (0.5) 4.5(4.1– 5.0) 3.4 – 5.4 .8 
After 12 
weeks 
4.2 (0.6) 4.2(3.8– 4.7) 2.9 – 5.5 4.3 (0.5) 4.3(4.0 – 4.7) 3.2 – 5.2 .7 
Difference -0.3 (0.4) 
-0.4(-0.5 - -
0.2) 
-1.5 – 1.1 -0.2 (0.5) -0.3(-0.4–0.0) -1.9 – 1.1 .1 
Wilcoxon 
(p=) 
 <.001*   <.002*   
*p<.05 
 
o Iron 
 
TABLE 10.14 PLASMA IRON 
 Placebo n=30 Arthrospiran=28  
Iron (mg/l) Mean(SD) Median (IQR) 
Min-
Max 
Mean(SD) Median (IQR) 
Min-
Max 
U-
test(p=) 
Baseline 0.8 (0.2) 0.9 (0.6– 1.0) 0.4– 1.2 0.8 (0.2) 0.8 (0.7– 1.0) 0.3– 1.4 .8 
After 12 
weeks 
0.8 (0.3) 0.7 (0.6– 1.0) 0.3–1.4 0.8 (0.2) 0.8 (0.7– -0.9) 0.57 - 1.4 .4 
Difference -0.05 (0.36) -0.1 (-0.3– 0.2) -0.9– 1 0.01 (0.27) -0.1 (-0.15– 0.2) -0.5– 0.6 .4 
Wilcoxon(p=)  .48   .95   
 
o  
VIII 
 
o Haematocrit 
TABLE 10.15  HAEMATOCRIT 
 Placebo n=30 Spirulinan=28  
Haematocrit 
(%) 
Mean(SD) 
Median 
(IQR) 
Min-
Max 
Mean(SD) 
Median 
(IQR) 
Min-
Max 
U-
test 
(p=) 
Baseline 33.4 (4.5) 
34.0  
(31.5– 36.0) 
20.0 – 
41.0 
34.5 (3.6) 
34.5  
(32.0– 37.0) 
28.0 – 
43.0 
.304 
After 12 
weeks 
32.6 (3.9) 
33.0  
(30.0– 35.0) 
24.0 – 
40.0 
35.0 (3.6) 
35.0  
(32.0– 37.0) 
30.0 – 
43.0 
.028* 
Difference -0.8 (2.9) 
-1.5 
(-2.0– 0.0) 
-6.0 – 
10.0 
0.2 (3.1) 
-0.0 
(-1.0– 2.0) 
-10.0 – 
8.0 
.039* 
Wilcoxon 
(p=) 
 <.039*   <.645   
 
Baseline U-test (z=-1.027; r= .18; p=.304); U-test after 12 weeks (z=-2.200; r=.33; p=.028), 
Diff.U-test (z=-2.061; r=.31; p=.039); Placebo (z=-2.062; r=.31; p=.039); Asp (z=-0.461; r=.11; 
p=.645) 
o Cholesterol 
TABLE 10.16 CHOLESTEROL 
 Placebo n=30 Arthrospiran=28  
Cholesterol 
(g/l) 
Mean(SD) Median (IQR) Min-Max Mean(SD) Median (IQR) Min-Max 
U-test 
(p=) 
Baseline 1.58 (0.32) 1.57(1.41 – 1.84) 1.00 – 2.18 1.58 (0.39) 1.53(1.34 – 1.8) 0.96 – 2.7 .7 
After 12 
weeks 
1.50 (0.29) 1.50(1.30 – 1.66) 1.04 – 2.11 1.38 (0.32) 1.35(1.20 – 1.53) 0.83 – 2.27 .1 
Difference -0.08 (0.30) -0.07(-0.20– 0.06) -0.68 – 0.65 -0.20 (0.36) -0.14(-0.47- -0.04) -0.80 – 0.79 .1 
Wilcoxon 
(p=) 
 .113   .004*   
*p<.05 
 
IX 
 
o Triglyceride 
TABLE 10.17 TRIGLYCERIDE DURING RCT 
 Placebo n=30 Arthrospiran=28  
Triglyceride 
(g/l) 
Mean(SD) 
Median 
(IQR) 
Min-Max Mean(SD) 
Median 
(IQR) 
Min-Max 
U-test 
(p=) 
Baseline 1.0 (0.8) 0.8(0.6 – 1.1) 0.4 – 5.1 0.8 (0.3) 0.8(0.6 – 1.0) 0.3 – 1.7 .7 
After 12 weeks 1.1 (0.8) 0.8(0.7 – 1.4) 0.4 – 4.0 0.87 (0.33) 0.7(0.6 – 1) 0.5 – 1.6 .3 
Difference 0.1 (0.5) 0.1(-0.2 – 0.5) -1.1– 1.2 0.0 (0.4) 0.0(-0.2 – 0.2) -2.1– 1.0 .7 
Wilcoxon (p=)  .188   .407   
 
o Creatinine 
TABLE 10.18 CREATININE DURING RCT 
*p<.05 
 
o Urea 
TABLE 10.19 UREA 
 Placebo n=30  Arthrospiran=28   
Urea (g/l) Mean(SD) Median (IQR) Min-Max Mean(SD) Median (IQR) Min-Max 
U-test 
(p=) 
Baseline 0.20(0.05) 0.19(0.16– 0.22) 0.10–0.30 0.19 (0.07) 0.17(0.13– 0.20) 0.10– 0.41 .1 
After 12 
weeks 
0.20(0.06) 0.18(0.15– 0.22) 0.12– 0.37 0.18 (0.06) 0.18(0.12– 0.22) 0.09– 0.28 .3 
Difference 0.00(0.05) 0.00(-0.3 - 0.04) -0.12 - 0.09 -0.01 (0.06) 0.00(-0.35– 0.03) -0.19 - 0.07 .8 
Wilcoxon   .905   .861   
 Placebo n=30 Arthrospiran=28  
Creatinine 
(g/dl) 
Mean(SD) 
Median  
(IQR) 
Min-
Max 
Mean(SD
) 
Median 
(IQR) 
Min-
Max 
U-test 
(p=) 
Baseline 0.7 (0.2) 0.7(0.6 – 0.8) 0.5 – 1.6 0.66 (0.2) 0.7(0.6 – 0.7) 0.3 – 0.1 .5 
After 12 weeks 0.7 (0.2) 0.7(0.6 – 0.8) 0.4 – 1.4 0.8 (0.2) 0.8(0.6 – 0.9) 0.5 – 1.1 .09 
Difference -0.02 (0.14) 0.0(-0.1 –0.1) -0.3 – 0.2 0.09 (0.14) 0.1(0.0 – 0.2) -1 – 4 .008* 
Wilcoxon (p=)  .51   .002*   
X 
 
o eGFR 
TABLE 10.20 EGFR 
 Placebo n=30  Arthrospira n=28  
eGFR 
ml/min 
Mean(SD) Median (IQR) 
Min-
Max 
Mean(SD) Median (IQR) Min-Max 
U-test 
(p=) 
Baseline 57.7 (13.0) 57.7(50.5– 61.1) 22.3– 88.8 64.7 (23.2) 59.8(51.2– 72) 38.2 - 143.2 .35 
After 12 
weeks 
59.3 (16.0) 56.6(48.7– 70.5) 26.9 -103.1 55.2 (15.0) 51.3(43.0- 67.1) 34.0– 89.5 .25 
Difference 1.6 (13.8) 0.0(-6.7– 4.6) -18.1– 42.0 -9.5 (15.4) -7.3(-17.2– 0.9) -53.7– 14.4 .01* 
Wilcoxon 
(p=) 
 .99   .004*   
*p<.05 
 
 Open-Label Intervention 
TABLE 10.21 CONSTANT VARIABLES OF OPEN-LABEL INTERVENTION POPULATIONS 
 Crossover n=13 Long-Term n=17 
Variables Median(IQR) Min-Max Median(IQR) Min-Max 
Age (year) 34 (26–36) 19– 41  25 (23– 30) 19– 43 
IDDS 5 (4– 6) 2– 8  6 (5– 6) 3– 8 
Height (m) 
1.63  
(1.60– 1.66) 
1.47– 1.68  
1.63  
(1.59–1.67) 
1.53–1.73 
Weight (kg) 58 (56– 62) 50–68  59 (53–64) 48–73 
BMI 
(kg/m2) 
22 (21– 23) 18– 26  23 (21–24) 18–26 
 
XI 
 
TABLE 10.22CONCOMITANT EVENTS DURING THE OLI 
 
Crossover n=13* 
Long-Term 
n=17* 
Events 
Frequency 
(Patient) 
Percent 
(%) 
Frequency 
(Patient) 
Percent 
(%) 
Headache 1 / 2 7/13 4 / - 19/- 
Fatigue 1 / 2 7/13 1 / 1 5 /5 
Malaria 2 / 5 13 /33 5 / 2 24/10 
Gastrointestinal 
symptoms 
1 / 1 7/7 5 / 3 24/14 
Diarrhoea 1 / 1 7/7 2 / 4 10/19 
Opportunistic 
infections 
2 / 1 13/7 1 / - 5/- 
Respiratory disease 1 / 2 7/13 3 / 1 14/5 
Other injuries  1 / 2 7/13 - / 1 -/5 
Total  11/ 16 68/106 21/12 101/58 
The incidence rate of concomitant events was lower in the crossover group compared to the 
long-term group. However, the long-term group showed a decrease in the incidence rate in 
the second three-month period. The main concomitant event was malaria with a roughly 
20% clinical manifestation. 
 
 
XII 
 Long Term 
o Variable of the Long-Term Intervention 
 
FIG 10.1 BOX PLOT REPRESENTING THE CD4 T LYMPHOCYTE COUNTS IN THE LONG-TERM INTERVENTION PER 
SAMPLING 
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XIII 
 
FIG  10.2 BOX PLOT REPRESENTING THE IMMUNE ACTIVATION MARKER CD38-CD8 IN THE LONG-TERM 
INTERVENTION PER SAMPLING 
The CD8 lymphocytes expressing the CD38 antigen are presented at the three sampling 
points over the 24-week intervention. 
TABLE 10.23 PRESENTING BODY WEIGHT, TAOS, AND ALBUMIN FOR THE LONG-TERM INTERVENTION 
 
Body Weight (kg) TAOS (µM) Albumin (g/l) 
Long-Term 
n=17 
Median (IQR) Min-Max Median (IQR) Min-Max 
Median 
(IQR) 
Min-
Max 
Baseline 59.2 (53.4– 63.7) 48.3– 73.3 325(276– 383) 256– 505 50 (48– 52) 42– 54 
12 weeks  60.4 (54.5– 63.7) 49.5– 72.1 412*(363 - 484) 165– 533 49 (46– 50) 40– 52 
24 weeks 62.3 (53.5– 65.2) 49.1– 71.2 503*(464 - 545) 409– 721 44 (41– 47) 39– 53 
*p<.05 
 
 
C
D
38
-C
D
8
  
(%
) 
  
XIV 
Albumin 
 
FIG 10.3 BOX PLOT REPRESENTING ALBUMIN IN THE LONG-TERM INTERVENTION PER SAMPLING 
 
TABLE 10.24HAEMOGLOBIN, RED BLOOD CELL COUNT, AND IRON FOR THE LONG-TERM INTERVENTION 
 
Haemoglobin (g/dl) RBC (tera/l) Iron (mg/l) 
Long-Term 
n=17 
Median 
(IQR) 
Min-Max 
Median 
(IQR) 
Min-Max 
Median 
(IQR) 
Min-Max 
Baseline 12.0 (11.4– 13.7) 8.9– 14.8 4.9 (4.4– 5.1) 3.6– 5.4 0.7 (0.7– 1) 0.3–1.2 
After 12 weeks 12.0 (10.7– 12.7) 9.1– 14.8 4.5 (4.1– 4.7)* 3.2– 5.2 0.8 (0.7 – 1) 0.5–1.4 
After 24 weeks 11.6 (10.4– 12.6)* 6.9– 14.9 4.5 (4.0– 4.7) 2.6– 5.2 0.9 (0.7– 1.1) 0.5– 1.5 
*p<.05 
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FIG C 10.4 BOX PLOT REPRESENTINGHB IN THE LONG-TERM INTERVENTION PER SAMPLING 
 
 
FIG 10.5 BOX PLOT REPRESENTING RBC COUNT IN THE LONG-TERM INTERVENTION PER SAMPLING 
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FIG 10.6 BOX PLOT REPRESENTING IRON IN THE LONG-TERM INTERVENTION PER SAMPLING 
TABLE 10.25 PRESENTING TOTAL CHOLESTEROL AND TRIGLYCERIDES DURING THE LONG-TERM INTERVENTION 
 
Cholesterol (g/l) Triglycerides (g/l) 
Long-Term 
n=17 
Median 
(IQR) 
Min-Max 
Median 
(IQR) 
Min-Max 
Baseline 1.46 (1.32– 1.56) 0.96– 1.97 0.72 (0.61–0.92) 0.3–1.08 
After 12 Weeks 1.25 (1.10– 1.53) 0.83– 2.27 0.73 (0.60–1.0) 0.46–1.64 
After 24 Weeks 1.28 (1.21– 1.54) 0.80– 2.25 0.61 (0.51–0.71) 0.4–1.24 
*p<.05 
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FIG10.7 BOX PLOT REPRESENTING CHOLESTEROL IN THE LONG-TERM INTERVENTION PER SAMPLING 
 
FIG 108 BOX PLOT REPRESENTING TRIGLYCERIDE IN THE LONG-TERM INTERVENTION PER SAMPLING 
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TABLE 10.26 RENAL FUNCTION DURING LONG TERM 
 
Creatinine (g/dl) Urea (g/l) eGFR (ml/min) 
Long-Term 
n=17 
Median 
(IQR) 
Min-
Max 
Median 
(IQR) 
Min-Max 
Median 
(IQR) 
Min-Max 
Baseline 0.7 (0.6– 0.7) 0.3 - 1.0 0.18 (0.14 - 0.22) 0.1– 0.47 59.9 (51.5– 75.1) 38.2– 143.2 
After 12 weeks 0.8 (0.6– 0.9) 0.5 - 1.1 0.20 (0.16 - 0.23) 0.09 - 0.28 48.4 (40.5– 67.8) 34.0– 89.5 
After 24 weeks 0.8 (0.7– 1.0)* 0.6 - 1.1 0.17 (0.15 - 0.22) 0.11 - 0.33 47.2 (35.1– 59.1) 30.8– 69.2 
*p<.05 
 
 
FIG 10.9 BOX PLOT REPRESENTING CREATININE IN THE LONG-TERM INTERVENTION PER SAMPLING 
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FIG .10.10 BOX PLOT REPRESENTING EGFR IN THE LONG-TERM INTERVENTION PER SAMPLING 
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 Cross over Intervention 
 
TABLE 10.27 IMMUNO-VIRAL OUTCOMES OF THE CROSSOVER INTERVENTION 
 
CD4 (cells/mm3)  Viral Load (log10) CD38-CD8 (%) 
Crossover 
n=13 
Median 
(IQR) 
Min-Max 
Median 
(IQR) 
Min-Max 
Median 
(IQR) 
Min-Max 
Baseline 469(435–558) 321– 815 5.9 (5.6– 6.2) 3.1–6.7 26.6(23.3 -44.8) 15.5–58 
Placebo Period -33 (-87– 14) -252 - 120 0.0 (-0.4 - 0.2) -1.0–0.6 -2.4(-11.3– 0.4) -21.5–16.6 
Asp Period -14(-71–131) 296– 176 -0.2(-0.4 - 0.1) -1.4–0.6 0.0(-11.2– 3.5) -23.9–4.7 
 
Viral load 
 
FIG. 10.11 BOX PLOT REPRESENTING THE VL DIFFERENCE OCCURRING IN THE VL IN THE CROSSOVER POPULATION 
DURING THE TWO PERIODS, PLACEBO AND UNDER ASP 
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TABLE 10.28 BODY WEIGHT, TAOS, AND ALBUMIN VARIABLES 
 
Weight (kg) TAOS (µM) Albumin (g/l) 
Crossover n=13 Median (IQR) 
Min-
Max 
Median (IQR) Min-Max 
Median 
(IQR) 
Min-
Max 
Baseline 57.9 (55.8– 62.3) 49.7– 68 408 (361– 460) 193– 509 50 (47– 51) 43– 58 
Placebo Period  0.4 (0.2– 2.5) -3.4– 5.8 -54 (-103– -00)* -154– 153 -2 (-5– 0) -12– 5 
AspPeriod  -1.1 (-2.0– 0.2) -6.1– 3.6 67 (44– 243)* 2– 345 0 (-4– 1) -7– 5.2 
*p<.05 
 
 
TABLE 10.29 HAEMOGLOBIN, RED BLOOD CELLS, AND IRON 
 
Haemoglobin (g/dl) RBC (tera/l) Iron (mg/l) 
Crossover 
n=13 
Median 
(IQR) 
Min-Max 
Median 
(IQR) 
Min-Max 
Median 
(IQR) 
Min-Max 
Baseline 12.5 (10.7– 12.8) 9– 14.6 4.5 (4.4– 4.9) 4.1– 6.4 1 (0.9–1.1) 0.4–1.2 
Placebo Period 
-1.1 (-1.3– -0.5)* -2.2– 2.5 -0.4 (-0.5– -0.3)* -1.5– -0.1 0.0 (-0.3–0.3) -0.9–1.0 
Asp Period 
0.2 ( -0.7– 1.0)* -1.7– 3.4 0.3 (-0.2– 0.4)* -0.3– 0.9 0.1 (-0.1– 0.2) -0.6–0.4 
*p<.05 
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Haemoglobin 
 
FIG. 10.12 BOX PLOT REPRESENTING THE HB DIFFERENCE OCCURRING IN THE CROSSOVER POPULATION DURING 
THE TWO PERIODS, PLACEBO AND UNDER ASP 
 
 
FIG. 10.13 BOX PLOT REPRESENTING THE RBC DIFFERENCE OCCURRING IN THE CROSSOVER POPULATION DURING 
THE TWO PERIODS, PLACEBO AND UNDER ASP 
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Iron 
 
FIG. 10.14 BOX PLOT REPRESENTING THE IRON DIFFERENCE OCCURRING IN THE CROSSOVER POPULATION DURING 
THE TWO PERIODS, PLACEBO AND UNDER ASP 
 
TABLE 10.30 TOTAL CHOLESTEROL AND TRIGLYCERIDES IN THE CROSSOVER GROUP 
 
Cholesterol (g/l) Triglycerides (g/l) 
Crossover 
n=13 
Median 
(IQR) 
Min-Max 
Median 
(IQR) 
Min-Max 
Baseline 1.70(1.29– 1.84) 1.00– 2.18 0.79(0.60–0.97) 0.39–1.35 
 Placebo Period -0.06 (-0.18– 0.03) -0.68– 0.42 0.07 (-0.16–0.57) -0.44– 1.22 
AspPeriod 0.05 (-0.15– 0.17) -0.72– 0.45 -0.24 (-0.36–-0.08) -1.10–0.26 
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TABLE 10.31 RENAL FUNCTION 
 
Creatinine (g/dl) Urea (g/l) eGFR (ml/min) 
Crossover 
n=13 
Median 
(IQR) 
Min-Max 
Median 
(IQR) 
Min-Max 
Median 
(IQR) 
Min-Max 
Baseline 0.7 (0.6– 0.8) 0.5– 1.6 0.21 (0.17– 0.24) 0.10– 0.30 51.2 (49.3– 61.1) 22.3– 77.1 
Placebo Period 0.0 (-0.2– 0.1) -0.3– 0.2 -0.02 (-0.05– 0.01) -0.12– 0.09 2.7 (-6.3– 4.6) -18.1– 42.0 
Asp Period 0.1 (0.0– 0.3) -0.1– 0.4 0.0 (-0.02– 0.07) -0.19– 0.14 -4.9 (-18.9– 0.1) -44.1– 1.6 
 
eGFR 
 
FIG. 10.15 BOX PLOT REPRESENTING THE EGFR DIFFERENCE OCCURRING IN THE CROSSOVER POPULATION DURING 
THE TWO PERIODS, PLACEBO AND UNDER ASP 
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 Arthrospira Platensis  comme supplément nutritionnel chez les adultes vivant avec le VIH/SIDA à 
Yaoundé au Cameroun 
 
 
Fiche d´information du Participant 
 
Les déficits nutritionnels sont en général un problème de santé publique dans les pays en voie de 
développement .La malnutrition ne signifie pas seulement une perte de poids, (malnutrition 
quantitative) mais aussi une carence en éléments essentiels comme les vitamines, les sels minéraux 
(malnutrition qualitative).  
La nutrition représente une composante essentielle de la prise en charge globale des personnes 
infectées par le VIH. Cependant, l’aspect nutritionnel n’est pas encore suffisamment intégré dans la 
prise en charge des personnes vivant avec le VIH/SIDA, malgré l’effet bénéfique d’une nutrition 
adéquate sur l’évolution de la maladie d’une part et sur la prévention de la transmission mère-enfant 
d’autre part. 
Prévenir la survenue des déficits nutritionnel chez les personnes vivants avec le VIH/SIDA par une 
supplémentation des repas est très important, et surtout un supplément adapté á l´alimentation 
locale et peu couteux.  
La spiruline  scientifiquement appelé « Athrospira Platensis » est une algue de la famille des 
Cyanobactérie. Elle est consommée traditionnellement depuis des décennies par les 
habitants du Kanem pourtour du lac Tchad et certaines populations en Amérique centrale.  
De nombreuses études scientifiques réalisées dans diverses universités dans le monde et 
grandes institutions internationales ont établi  que la spiruline est très riche en protéine et 
micronutriment  (les vitamines et oligo-éléments).  
Même si le nombre d’études sur l’homme reste encore insuffisant, l’effet positif sur la santé de la 
Spiruline ne fait plus aucun doute.  
Ces effets sont particulièrement intéressants dans la régulation du système immunitaire, dans la 
prévention de certains cancers, dans les infections virales et dans la réduction du taux de cholestérol.  
Ceci est d’autant plus intéressant que la culture de la Spiruline est bien maîtrisée et qu’elle a fait la 
preuve de sa parfaite innocuité. En Afrique, une étude scientifique menée au Burkina-Faso a 
introduit la spiruline avec succès dans le programme de réhabilitation des enfants malnutris vivant 
avec le VIH/SIDA Plusieurs pays africain ont commencé la production locale de la spiruline (RDC, Mali, 
Burkina-Faso, Mauritanie, etc…). 
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But de l´Etude 
Vous êtes appelé à participer volontairement á une étude qui consiste á évaluer l´impact bénéfique 
qu´un aliment á base de  spiruline peut avoir notamment chez les personnes adultes vivant avec le 
VIH/SIDA et sujette á un déficit nutritionnel.  
Plusieurs composés extraits de plantes ou d’algues possèdent un effet bactéricide et virucide. Les 
extraits totaux de plantes contiennent souvent plusieurs composants qui agissent en synergie et 
permettent d'augmenter cet effet tout en diminuant le risque de résistance. Par ailleurs, comme déjà 
mentionné plus haut, certains produits naturels ont également un effet modulateur sur le système 
immunitaire, ce qui permet d'augmenter l’effet protecteur contre les virus et bactéries. 
Les études réalisées montrent une activité antivirale de la Spiruline dans divers modèles in vitro et 
chez les animaux. La Spiruline peut donc avoir un rôle intéressant pour le patient porteur du virus 
HIV. Elle aura non seulement une action sur le virus lui-même, mais également sur les autres 
infections virales ou bactériennes présentes chez le malade porteur du virus HIV.La Spiruline permet 
d'apporter une quantité importante d'antioxydants nécessaires à notre organisme : des caroténoïdes 
comme le béta-carotène et la zeaxanthine, des enzymes comme la superoxyde-dismutase ou encore 
de la phycocyanine.  
Notre But est d´évaluer les bénéfices apporté par la spiruline, au vue de son prix dérisoire, compte 
tenue du pouvoir d´achat des Camerounais. Pour notre étude nous utiliserons une spiruline fournie 
gracieusement par une ONG…….. dont la qualité est officiellement admise selon les standards requis 
par les autorités alimentaires européennes. 
Risques et préjudices  possible. 
“Arthrospira platensis” as nutritional supplementation for adult patients infected by human 
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Il n´y n’a aucun préjudice connu associé à la participation de cette étude. Aucun dommage 
spécifique non plus n´est envisageable. La réhabilitation nutritionnelle par les aliments 
connus ne pose pas de risque particulier. La Spiruline peut être consommée sans aucun danger. 
Son innocuité en tant que nourriture a été établie par des siècles d'utilisation humaine ainsi que par 
des études toxicologiques rigoureuses. Elle reçut en 2003 de l´administration Américaine (US Food 
and Drug-administration) de sa biomasse sèche, le statut de Aliment conventionnel (GRAS generally 
regarded as Safe). 
Bienfaits possible pour le Patient 
L´établissement et la validation de l´impact bénéfique de la réhabilitation nutritionnelle des 
personnes vivant avec le VIH/SIDA pourrait constituer une amélioration des soins á cette catégorie 
de personne, avec une base de production nationale d´une source protéique(Spiruline) de haute 
qualité comme c´est déjà le cas dans certains pays de l´Afrique de l´ouest. 
Nous attendons une amélioration de la qualité de vie des patients et participant ainsi aux efforts de 
lutte contre la pauvreté á l´échelle nationale. 
Le principal bénéfice pour le patient est le suivi biologique aux normes du plan nationale de lutte 
contre le SIDA, mais financé par l´étude, pendant la durée de l’inclusion. En plus de ce qui est prévu 
dans le plan national de lutte contre le SIDA, le participant aura un complément de suivi biologique 
du point de vue de la charge virale. Evaluation scientifique complète du statut nutritionnel avec plan 
de renutrition taillé-sur –mesure pour chaque participant (habituellement très difficile dans la 
pratique quotidienne). 
Description de l´étude 
Cette étude est étalée sur une période de six mois. A trois reprises les échantillons de votre sang 
seront prélevés pour analyse des éléments nutritionnels, immunitaires et infectieux. Au début et á la 
fin de l´étude un médecin vous examinera, en dehors des rendez-vous usuels avec votre médecin-
traitant, ou avec le psychologue. Vous passerez une interview de 10 á 20 minutes. Vous aurez  à 
consommer la spiruline pendant la durée d´inclusion. 
Des séances seront organisées au fur et á mesure de l´avancement de l´étude  dans le but d´apporter 
des réponses á vos réponses éventuelles futures questions 
 Confidentialité : 
La confidentialité sera respectée. Aucune information révélant l'identité du sujet ne sera diffusée ou 
publiée sans consentement à moins d'en être astreint par la loi. En dehors de l´interview médicale et 
les examens physiques, votre identité est anonyme.  
Consentement : 
En signant ce formulaire, j´atteste que : 
- Toutes les explications m´ont été donnée concernant l´étude. 
- Toutes mes questions ont étés répondues. 
“Arthrospira platensis” as nutritional supplementation for adult patients infected by human 
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- Les préjudices et les malaises possible ainsi que les bienfaits de cette étude m´ont été 
expliqués 
- J´ai le choix de ne pas répondre á toute questions particulière. 
- Je suis libre de poser des questions, maintenant et á l´avenir concernant l´étude. 
- J´ai été informé de la confidentialité de mon information personnel 
- Aucun renseignement pouvant m´identifier ne sera diffusé ou imprimé sans mon 
consentement. 
- Je recevrai une copie signée due présent formulaire de consentement. 
Par la présente, je consens á Participer á l´étude : 
 
 
 
Nom :……………………………………………………. Age :…………………………………………Date :……………………………… 
 
 
Numéro de Téléphone :……………………………………………………………………………………………………………………… 
 
 
Etabli par :…………………………………………………… Tel.Nr…………………………………………………………………………… 
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 CPC Tube Distribution 
Marker Used Blood Blood 
fraction 
Quantite 
need 
Probe storage Mesurement Departement 
Charge viral EDTA Plasma 1ml   Viro 
Protein C  serum    Viro 
CD4+ T-Cell EDTA Whole blood  2.5 ml of Whole EDTA blood  Cytometrie Viro 
CD8+ T-Cell EDTA Whole blood  - Cytometrie Viro 
CD38/CD8+ T-
Cell 
EDTA Whole blood  - Cytometrie Viro 
total T-Cell EDTA Whole blood  - Cytometrie Viro 
CMV EDTA Whole blood  - PCR Viro 
TAOS heparin Plasma  Plasma in cup at -70°C (Hep. 
aliquot) 
Spectro, 600nm Biochemi 
Albumin heparin serum 10 µl Heparin tube 0.5 ml serum aliquot Spectro, 628nm Biochemi 
Creatinin heparin serum 100 µl - 492nm Biochemi 
Fer tube sec serum 20 µl -  Biochemi 
Ca heparin serum 20 µl - 570nm Biochemi 
Zn   20 µl -  Biochemi 
Uree tube sec, pas 
d´heparin 
serum 10 µl - 578nm Biochemi 
Protein total tube sec   -  Biochemi 
cholesterol heparin ou EDTA serum 10 µl - 500nm Biochemi 
Bilirubin heparin serum 100 µl - 546nm Biochemi 
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Fiche de Donnée : 
Étude Intervention Nutritionnelle sur des Patientes de l’Hôpital du Jours, 
Yaoundé 
 
 
Nr de la patiente dans l´étude :    
Groupe d’intervention : 
Code anonyme   
 (Nr étude, année de naissance, deux lettres du nom, lettre de group):                         ____.____.____.__ 
 
     
  Echéancier des visites prévues dans le protocole pour la patiente :  
N°
  
Echéancier RDV prévu Vu le Commentaire 
1 J0 Visite générale    
2 J30 ou S4    
3 J60 ou S8    
4 J90  ou S12 visite générale    
5 J 120 ou S16    
6 J150 ou S20    
7 J180 ou S24 visite de fin 
d’intervention 
   
8 J 210 après l’intervention    
 
 
 
 
 
Dossier contient :  
-Consentement éclaire signer du patient 
 -les fiches résultats Laboratoire du CPC (3 fiches) 
-Fiche Vérification des critères d’inclusion dans l’intervention  
-Fiche Consultation General (3 fiches) 
-Fiche Clinique  (nombre : ___) 
-Fiche Biologie (3 fiches) 
 -Fiche Consultation Suivie (4 fiches) 
-Fiche Dernière Visite 
Fiche de Donnée : Étude Intervention Nutritionnel sur des Patientes de l’Hôpital du Jours, Yaoundé 
Phase de l’Etude : ______________         Code Patient : ___.____.___.__ 
Tel. Etude: 74 37 47 87                              Page:  ___/___  
 
-Questionnaire Patient (4 questionnaires) 
-Dépliant Patient (6 dépliants) 
  VERIFICATION DES CRITERES D’INCLUSION DANS 
L’INTERVENTION 
Oui Non 
- Femme    
- Age supérieur ou égal à 18 ans, inferieur à 49 ans    
- Infection VIH documentée   
- BMI<26   
- CD4 >350 mm 3/l   
- ARV naif.   
- Absence d’infection opportuniste en cours non stabilisée ou toute pathologie grave ou évolutive   
- Patient en mesure de comprendre l’information qui lui est délivrée et de participer au protocole, 
acceptant l’intervention et le suivi pendant au moins 24 semaines et acceptant de ne prendre aucun 
Supplément nutritif associé pendant la durée de l’essai sans en aviser l’investigateur. 
  
- Test de grossesse négatif pour les femmes en âge de procréer, n'allaitant pas et acceptant une 
contraception mécanique. 
  
- Critères Clinique en pré-inclusion. 
. Diabètes  ……………………………………………..……………… 
. Cirrhose du foie ..…………………………………………………………… 
. Fumeuse active  ….…………………………………………………………. 
. dysfonctionnement rénal  ……………………………………………..……………… 
.Diarrhée persistante ……………………………………………………………… 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signature du consentement éclairé : Date de signature |__|__| |__|__| |__|__|   
COMMENTAIRES concernant les critères d’éligibilité ? 
…………………………………………………………………………………………………………………… 
En conclusion :     patiente non éligible Raison : …………………………………………………… 
                patiente éligible                          Stade OMS : …………………... 
  Date prévue pour l’inclusion (J0) : |___|___| |___|___| |___|___| 
Je certifie l’exactitude des critères d’inclusion ci-dessus 
Nom investigateur : 
 ……………………… Date de recueil : ______________ 
Signature : 
Fiche de Donnée : Étude Intervention Nutritionnel sur des Patientes de l’Hôpital du Jours, Yaoundé 
Phase de l’Etude : ______________         Code Patient : ___.____.___.__ 
Tel. Etude: 74 37 47 87                              Page:  ___/___  
 
La patiente est-il venu en consultation ? Oui 
  DATE DE LA CONSULTATION PREVU …………………………………. 
 Non     Raison : ………………………………………………………………………………. 
Consultation General N° 
Nom : Nationalité :  
Age date de naissance: Religion :  
Quartier à Yaoundé :  
Tel.  de la Patiente :   
Tel. 2 :  
Tel. 3 :  
Nr de la patiente dans l´étude :     
Groupe d’intervention :  
Code anonyme   
 (Nr dans l’étude, deux derniers chiffres de l’année de naissance, deux dernières lettres du nom, lettre de group):                                                                           
____.____.____.__ 
 
Donnée Clinique : 
 Poids :___________ g Taille :_________cm IMC :____________g/cm  
 Température : ________,___°C  
 Pression artérielle, systolique/diastolique : _____/_____mm.Hg  (après 10 minutes de repos allongé)  
 Tour de taille  ________ cm ; Tour de hanche  ________ cm ; Tour de cuisse ________ cm 
 
 
Test de grosse : 
 Test sanguin β hCG Oui       Non      Fait le : ________________  Résultat :___________  
Historique des CD4 et charges virales :  
Année de Test :_______________ Année d´infection :___________ 
Sérologie VIH (ci-connu) : VIH Type _____________ 
Valeur Virologique : 
  Prélèvement le : _____________         
 CD4                                                 / mm 3   
 CD8                                                 / mm 3   
 CV                                            Cp/ ml    
(à l’endroit le plus large des hanches) (debout, à l’endroit le plus étroit à mi-distance 
de la dernière côte et de la crête iliaque) 
   (à 15 cm du bord supérieur de la rotule) 
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FICHE CLINIQUE N° 
Antécédents Clinique :  
Noter les antécédents cliniques importants portés à votre connaissance (maladie chronique, cardio-vasculaire, diabète, allergie,  etc...). et les évènements cliniques que 
présente le patient actuellement. 
 
 
Nature de l’événement 
(diagnostic si possible,  
sinon symptômes) 
classement 
OMS 
D
e
gr
é
  (
a)
 
Date 
de début 
Date 
de fin 
D
e
gr
é
 m
ax
 (
a)
 
A
ct
io
n
 (
b
) 
 
O
u
i 
N
o
n
 
           
           
           
           
           
           
           
           
           
(a) Degré ou degré max : 1 = Léger 2 = Modéré 3 = Sévère 4 = Menace vitale  
(b) Action : 0 = Aucune  1 = Traitement ou chirurgie  2 = Traitement ou chirurgie avec Hospitalisation   
 
Traitements associes :  
Noter les traitements ayant été pris en prophylaxie ou les traitements pris actuellement 
 
Traitement 
Posologie 
dose/j 
mg ou cp 
P
ro
p
h
yl
ax
ie
 
C
u
ra
ti
f 
Indication 
 (cf. évènements 
cliniques) 
Date de 
début 
 
 
        
        
        
        
        
        
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Antécédents cliniques lies au VIH : 
 Antécédent clinique nature de l´événement, symptôme oui Degré de sévérité  
 OMS Stade 1  
 Asymptomatique  
 Adénopathies généralisées persistantes  
OMS Stade 2 
 Chéilite angulaire (perlèches)  
 Dermite séborrhéique  
 Eruption papulaire prurigineuse (prurigo)  
 Zona  
 Infections des voies aériennes supérieures récurrentes  
 Mycose unguéale  
 Perte de poids inexpliquée < 10%   
 Ulcérations orales récurrentes   
OMS Stade 3 
 Anémie (<8g/dl) ou neutropénie (<500/mm3) ou thrombocytopénie (<50 000/mm3) inexpliquée 
 Candidose persistante orale  
 Diarrhée inexpliquée > 1 mois  
 Fièvre constante ou intermittente inexpliquée >1 mois  
 Infections bactériennes sévères (pneumonie inclue)   
 Leucoplasie orale chevelue  
 Perte de poids > 10 %, inexpliquée   
 Stomatite/gingivite/desmodontite ulcérative aigue nécrosante  
 Tuberculose pulmonaire  
OMS Stade 4 
 Candidose de l’oesophage, trachéobronchique ou pulmonaire  
 Carcinome cervical invasif  
 Cardiomyopathie liée au VIH  
 Cryptococcose extra-pulmonaire (méningite incluse)  
 Cryptosporidiose avec diarrhée > 1 mois  
 Cytomégalovirus, infection  
 Encéphalopathie liée au VIH  
 Herpes cutanéo-muqueux > 1 mois ou viscéral  
 Isosporose avec diarrhée > 1 mois  
 Leishmaniose viscérale   
 Leucoencéphalopathie multifocale progressive  
 Lymphome cérébral ou non-Hodgkinien à cellules B  
 Mycobactériose atypique disséminée  
 Mycose disséminée (e.g. histoplasmose, penicilliose, coccidioïdomycose) 
 Néphropathie liée au VIH  
 Pneumonie bactérienne récurrente  
 Pneumonie à Pneumocystis carinii  
 Sarcome de Kaposi  
 Septicémie récurrente à salmonelle non-typhique  
 Syndrome cachectique lié au VIH(perte de poids >10% et soit >1 mois diarrhée ou >1 mois fièvre)  
 Tuberculose extra-pulmonaire ou disséminée (eg Tuberculose ganglionnaire abdominale) 
 Toxoplasmose cérébrale 
 
 
  
 *) 1 = Leger ; 2 = Modéré ; 3 = sévère ; 4 =menace vitale 
 
Classification de l’infection VIH aujourd’hui : T=______ OMS 
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Fiche Biologie N° 
 
Bilans biologique : 
(Voire résultat fiche CPC, reporter dans le tableau ci-dessus) 
 Test Valeur  
 NFS   
 Hémoglobine     
 Leucocytes     
 Polynucléaires    
       neutrophiles    |__|__|, |__| 10
9
/l   
       éosinophiles    |__|__|, |__| 10
9
/l   
       basophiles    |__|__|, |__| 10
9
/l   
 Lymphocytes     
 Monocytes   
 VGM   
 Plaquette   
 Biochimie   
 Albumine    
 Bilirubine   
 Cholestérol   
 Créatinine   
 Urée   
 Fer   
 Marqueur antioxydant   
 TAOS   
 MDA   
    
    
Test malaria : 
 Goutte épaisse   
Commentaire :………………………………………………………………………………………………………………………………………………………………
…………………………………………………………..………………………………………………………… ……………………………………………………………
………………………………………………………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………… 
Date /signature : 
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La patiente est-il venu en consultation ? Oui   DATE DE LA CONSULTATION PREVU …………………………… 
 Non     Raison :…………………………………………………………………………. 
Consultation de suivie N°  
 Date de consultation 
Effectuer 
  
 Code Patiente   
 Nouveau Tel.   
    
 
Bonne réception du dépliant Patiente :   Oui  Non  
 La patiente présente t´il de nouveau évènement clinique et/ou évolution d´événement déjà 
rapporté ?    Oui      Non  
 
 Ci oui, (pour des symptômes et traitement nouveau remplir une fiche Clinique) 
 
 
 
Donnée Clinique : 
 Poids :___________ g Taille :_________cm IMC :____________g/cm  
 Température : ________,___°C  
 Pression artérielles, systolique/diastolique : _____/_____mm.Hg  (après 10 minutes de repos allongé)  
 Tour de taille  ________ cm ; Tour de hanche  ________ cm ; Tour de cuisse ________ cm 
 
 
Date/ Signature :  
 
 
(à l’endroit le plus large des hanches) (debout, à l’endroit le plus étroit à mi-distance 
de la dernière côte et de la crête iliaque) 
   (à 15 cm du bord supérieur de la rotule) 
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DERNIERE VISITE DE LA PATIENTE DANS LE PROTOCOLE 
  Date du suivi : _____________________     
RAISON DE FIN D’ESSAI 
Indiquer la raison principale : 
        Fin conforme au protocole 
        Patiente sous ARV 
        Date de début de traitement : _____________ 
        Abandon avec retrait du consentement 
      Date du retrait : ________________________ 
        Patiente perdu de vue  
      Date du dernier contact : _________________ 
Commentaires : .............................................................................................................................................................. ………… 
  
 Patiente décédé  
 Date du décès :_______________________ 
Cause :............... ............................................................................................................................................................. ………… 
                                                           Autre (préciser) :  .................................................................................. ………… 
  .............................................................................................................................................................................. 
COMMENTAIRES 
  .............................................................................................................................................................................. 
  .............................................................................................................................................................................. 
  .............................................................................................................................................................................. 
Date / Signature :  
  
 
Consentement éclairé pour le patient 
Le médecin m´a fourni les explications orales 
et les informations écrites sur l´objet de 
l´étude, l´intervention, les effets attendus, 
avantages  et inconvénients éventuels. 
Par ma participation, je confirme avoir été 
bien informé du déroulement de l´étude et je 
m´engage á fournir les informations correcte. 
 
Je peux retirer á tout moment mon 
consentement á participer à l´étude sans avoir 
á fournir de raison et sans que mes soins 
médicaux futurs soient affectés. 
 Etude clinique sur l´effet 
d´un supplément 
alimentaire chez les P. plus 
à Yaoundé 
 
 
Nous nous engageons á vous donner toutes les 
informations sur votre état de santé dans le cadre 
de cette étude. Ainsi qu´une fiche patient 
documentant de votre poids (BMI), proportion de 
gras et statut immunitaire. 
Vous vous engagez á prendre 5 gr. de supplément 
par jour soit 10 capsules. Ceci pendant les heures 
de repas. 
Vous vous engagez á nous informer de tout 
changement vous concernent pendant la durée de 
l´étude (adresse, santé..), ainsi que de remplir le 
tableau au verso. 
Nous sommes á votre disposition 7jours/7 á tout 
moment. Sous le numéro de téléphone: 
Dr : 
 
 
Vous vous engagez á vous présenter á la visite mensuelle. 
ICI, votre boite de capsule ainsi que ce dépliant avec le 
tableau dument remplie, vous seront remplacés par un 
nouveau dépliant ainsi que les capsules pour un mois. 
Votre prochaine visite est prévu pour  
le :    A : 
 
 
 
 
 
Quels sont les buts de l´étude? 
Notre étude vise á évaluer l´impacte qu´une 
supplémentation á base de Arthrospira platensis peut 
avoir chez les P + et sujette á un déficit alimentaire 
Cercle vicieux Maladie et Malnutrition 
Les P + ont un besoin accrus en nutriment. Cet 
apport est dû à l´activité permanente du system 
immunitaire. En plus l´augmentation de l´apport en 
nutriment devra compenser les pertes dues aux 
perturbations lors de l`assimilation de ces même 
nutriment dans le corps. Le supplément nutritif est 
censé compléter votre alimentation ordinaire 
(Vitamines, sels minéraux, acides gras etc..). 
 
Quel bénéfice pour les Personnes ?   
Suivi personnalisé aux normes du plan de lutte. Le 
 patient recevra un complément de suivi biologique, á 
chaque visite une fiche sur son poids, sont statut 
immunitaire, ainsi qu´une évaluation scientifique 
complète du statut nutritionnel avec plan de 
renutrition á la fin de l´étude. Il lui est garantie de 
recevoir au cours de l´étude un supplément nutritif 
 
  Nom et prénoms du Patient :_______________________________________________ Nr de téléphone :_____________________ Prochain Rendez-vous :________ Heure :___________ 
Remplir le Tableau á l´aide des nombres, 1=pas du tout ; 2= un petit peu ; 3= moyennement ; 4= beaucoup ;  5= énormément.  
*lundi=Lu,  Mardi=Ma,  Mercredi=Me,  Jeudi=Je,  Vendredi=Ve,  Samedi=Sa,  Dimanche=Di.  
 
Remarque :_____________________________________________________________________________________________________________________________________________________________
_______________________________________________________________________________________________________________________________________________________________________
_______________________________________________________________________________________________________________________________________________________________________
_______________________________________________________________________________________________________________________________________________________________________
_______________________________________________________________________________________________________________________________________________________________________
_______________________________________________________________________________________________________________________________________________________ 
Date Semaine Nr ._____ du_______/_______ Semaine Nr.____ _du_______/______ Semaine Nr ._____du________ /_______ Semaine Nr ._____du________ /_______ 
Jours de la semaine* Lu Ma Me Je Ve Sa Di Lu Ma Me Je Ve Sa Di Lu Ma Me Je Ve Sa Di Lu Ma Me Je Ve Sa Di 
Prise des 10 Capsules ; 
Oui/Non = O/N 
                             
Documentez votre santé 
le soir pour la journee 
passée 
Remplir le Tableau á l´aide des nombres, 1=pas du tout ; 2= un petit peu ; 3= moyennement ; 4= beaucoup ; 5= énormément 
Appétit                              
Fatigue                             
Nausée/Vomissement                             
Toux 
Sèche                             
Crachat                             
Douleurs abdominales                             
Selles 
Diarrhée                             
Constipation                             
Jours de la semaine*                             
 
Tableau de suivie journalier; Prise du Supplément et des petits malaises rencontrés. 
